

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 10-K**

---

(Mark One)

- ☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the fiscal year ended December 31, 2022
- or
- ☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number 001-32559  
Commission file number 333-177186

**Medical Properties Trust, Inc.  
MPT Operating Partnership, L.P.**  
(Exact Name of Registrant as Specified in Its Charter)

Maryland  
Delaware  
(State or Other Jurisdiction of  
Incorporation or Organization)  
1000 Urban Center Drive, Suite 501  
Birmingham, AL  
(Address of Principal Executive Offices)

20-0191742  
20-0242069  
(IRS Employer  
Identification No.)

35242  
(Zip Code)

(205) 969-3755

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value \$0.001 per share, of Medical Properties Trust, Inc.	MPW	The New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:  
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Medical Properties Trust, Inc. Yes ☒ No ☐ MPT Operating Partnership, L.P. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Medical Properties Trust, Inc. Yes ☐ No ☒ MPT Operating Partnership, L.P. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Medical Properties Trust, Inc. Yes ☒ No ☐ MPT Operating Partnership, L.P. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Medical Properties Trust, Inc. Yes ☒ No ☐ MPT Operating Partnership, L.P. Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Medical Properties Trust, Inc.

Large accelerated filer ☒

Non-accelerated filer ☐

Accelerated filer ☐

Smaller reporting company ☐

Emerging growth company ☐

MPT Operating Partnership, L.P.

Large accelerated filer ☐

Non-accelerated filer ☒

Accelerated filer ☐

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Act).

Medical Properties Trust, Inc. Yes ☐ No ☒ MPT Operating Partnership, L.P. Yes ☐ No ☒

As of June 30, 2022, the aggregate market value of the 592.9 million shares of common stock, par value \$0.001 per share ("Common Stock"), held by non-affiliates of Medical Properties Trust, Inc. was \$9.1 billion based upon the last reported sale price of \$15.27 on the New York Stock Exchange on that date. For purposes of the foregoing calculation only, all directors and executive officers of Medical Properties Trust, Inc. have been deemed affiliates.

As of February 17, 2023, 598.3 million shares of Common Stock were outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of the definitive Proxy Statement of Medical Properties Trust, Inc. for the Annual Meeting of Stockholders to be held on May 25, 2023 are incorporated by reference into Items 10 through 14 of Part III, of this Annual Report on Form 10-K.

## **EXPLANATORY NOTE**

This report combines the Annual Reports on Form 10-K for the year ended December 31, 2022, of Medical Properties Trust, Inc., a Maryland corporation, and MPT Operating Partnership, L.P., a Delaware limited partnership, through which Medical Properties Trust, Inc. conducts substantially all of its operations. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” “Medical Properties,” “MPT,” or “company” refer to Medical Properties Trust, Inc. together with its consolidated subsidiaries, including MPT Operating Partnership, L.P. Unless otherwise indicated or unless the context requires otherwise, all references to “operating partnership” refer to MPT Operating Partnership, L.P. together with its consolidated subsidiaries.

## TABLE OF CONTENTS

A WARNING ABOUT FORWARD LOOKING STATEMENTS .....	4
PART I	
ITEM 1. Business .....	6
ITEM 1A. Risk Factors .....	24
ITEM 1B. Unresolved Staff Comments .....	43
ITEM 2. Properties .....	44
ITEM 3. Legal Proceedings .....	46
ITEM 4. Mine Safety Disclosures .....	46
PART II	
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities .....	47
ITEM 6. Reserved .....	48
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations .....	49
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk .....	67
ITEM 8. Financial Statements and Supplementary Data .....	69
ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure .....	119
ITEM 9A. Controls and Procedures .....	119
ITEM 9B. Other Information .....	120
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections .....	120
PART III	
ITEM 10. Directors, Executive Officers and Corporate Governance .....	121
ITEM 11. Executive Compensation .....	121
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters .....	121
ITEM 13. Certain Relationships and Related Transactions, and Director Independence .....	121
ITEM 14. Principal Accountant Fees and Services .....	121
PART IV	
ITEM 15. Exhibits and Financial Statement Schedules .....	122
ITEM 16. Form 10-K Summary .....	130
SIGNATURES .....	131

## A WARNING ABOUT FORWARD LOOKING STATEMENTS

We make forward-looking statements in this Annual Report on Form 10-K that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans, and objectives. Statements regarding the following subjects, among others, are forward-looking by their nature:

- our business strategy;
- our projected operating results;
- our ability to close on any pending transactions or complete current development projects on the time schedule or terms described or at all;
- our ability to acquire, develop, and/or manage additional facilities in the United States (“U.S.”), Europe, Australia, South America, or other foreign locations;
- availability of suitable facilities to acquire or develop;
- our ability to enter into, and the terms of, our prospective leases and loans;
- our ability to raise additional funds through offerings of debt and equity securities, joint venture arrangements, and/or property disposals;
- our ability to obtain future financing arrangements (including refinancing of existing financing arrangements);
- estimates relating to, and our ability to pay, future distributions;
- our ability to service our debt and comply with all of our debt covenants;
- our ability to compete in the marketplace;
- lease rates and interest rates;
- market trends;
- projected capital expenditures; and
- the impact of technology on our facilities, operations, and business.

Forward-looking statements are based on our beliefs, assumptions, and expectations of our future performance, taking into account information currently available to us. These beliefs, assumptions, and expectations can change as a result of many possible events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, and results of operations may vary materially from those expressed in our forward-looking statements. You should carefully consider these risks before you make an investment decision with respect to our common stock and other securities, along with, among others, the following factors that could cause actual results to vary from our forward-looking statements:

- the factors referenced in this Annual Report on Form 10-K, including those set forth under the sections captioned “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Business;”
- the political, economic, business, real estate, and other market conditions in the U.S. (both national and local), Europe (in particular the United Kingdom, Germany, Switzerland, Spain, Italy, Finland, and Portugal), Australia, South America (in particular Colombia), and other foreign jurisdictions where we may own healthcare facilities or transact business, which may have a negative effect on the following, among other things:
  - the financial condition of our tenants, our lenders, or institutions that hold our cash balances or are counterparties to certain hedge agreements, which may expose us to increased risks of default by these parties;

- our ability to obtain equity or debt financing on attractive terms or at all, which may adversely impact our ability to pursue acquisition and development opportunities, refinance existing debt, and our future interest expense; and
- the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain debt financing secured by our real estate assets or on an unsecured basis;
- the impact of factors that may affect our business, our joint ventures or the business of our tenants/borrowers that are beyond our control, including natural disasters, health crises, or pandemics (such as the coronavirus (“COVID-19”)) and subsequent government actions in reaction to such matters;
- the risk that a condition to closing under the agreements governing any or all of our pending transactions (including the transactions described in the notes to Item 8 of this Annual Report on Form 10-K) that have not closed as of the date hereof may not be satisfied;
- the possibility that the anticipated benefits from any or all of the transactions we have entered into or will enter into may take longer to realize than expected or will not be realized at all;
- the competitive environment in which we operate;
- the execution of our business plan;
- financing risks, including due to rising inflation and interest rates;
- acquisition and development risks;
- potential environmental contingencies and other liabilities;
- adverse developments affecting the financial health of one or more of our tenants, including insolvency;
- other factors affecting the real estate industry generally or the healthcare real estate industry in particular;
- our ability to maintain our status as a real estate investment trust (“REIT”) for U.S. federal and state income tax purposes;
- our ability to attract and retain qualified personnel;
- changes in foreign currency exchange rates;
- changes in federal, state, or local tax laws in the U.S., Europe, Australia, South America, or other jurisdictions in which we may own healthcare facilities or transact business;
- healthcare and other regulatory requirements of the U.S., Europe, Australia, South America, and other foreign countries; and
- the accuracy of our methodologies and estimates regarding environmental, social, and governance (“ESG”) metrics and targets, tenant willingness and ability to collaborate towards reporting ESG metrics and meeting ESG goals and targets, and the impact of governmental regulation on our and our tenants’ ESG efforts.

When we use the words “believe,” “expect,” “may,” “potential,” “anticipate,” “estimate,” “plan,” “will,” “could,” “intend,” or similar expressions, we are identifying forward-looking statements. You should not place undue reliance on these forward-looking statements. Except as required by law, we disclaim any obligation to update such statements or to publicly announce the result of any revisions to any of the forward-looking statements contained in this Annual Report on Form 10-K.

## PART I

### ITEM 1. *Business*

#### Overview

We are a self-advised REIT formed in 2003 to acquire and develop net-leased healthcare facilities. At December 31, 2022, we had investments in 444 facilities and approximately 44,000 licensed beds in 31 states in the U.S., in seven countries in Europe, across Australia, and in Colombia in South America. We have operated as a REIT since April 6, 2004, and accordingly, elected REIT status upon the filing of our calendar year 2004 federal income tax return. Medical Properties Trust, Inc. was incorporated under Maryland law on August 27, 2003, and MPT Operating Partnership, L.P. was formed under Delaware law on September 10, 2003. We conduct substantially all of our business through MPT Operating Partnership, L.P.

Our primary business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear most of the costs associated with the property. The majority of our leased assets are owned 100%; however, we do own some leased assets through joint ventures with other partners that share our view that healthcare facilities are part of the infrastructure of any community, which we refer to as investments in unconsolidated real estate joint ventures. We also may make mortgage loans to healthcare operators collateralized by their real estate assets. In addition, we may make loans to certain of our operators through our taxable REIT subsidiaries (“TRS”), the proceeds of which are typically used for working capital and other purposes. From time-to-time, we may make noncontrolling investments in our tenants, which we refer to as investments in unconsolidated operating entities. These investments are typically made in conjunction with larger real estate transactions with the tenant that give us a right to a share in such tenant’s profits and losses and provide for certain minority rights and protections. Our business model facilitates acquisitions and recapitalizations, and allows operators of healthcare facilities to serve their communities by unlocking the value of their real estate assets to fund facility improvements, technology upgrades, and other investments in operations.

Our investments in healthcare real estate, other loans, and any investments in our tenants are considered a single reportable segment as further discussed in Note 1 of Item 8 of this Annual Report on Form 10-K.

#### *Assets*

At December 31, 2022 and 2021, our total assets were made up of the following (dollars in thousands):

	<u>2022</u>		<u>2021</u>	
Real estate assets — at cost . . . . .	\$15,917,839	81.0%	\$17,425,765	84.9%
Accumulated real estate depreciation and amortization . . . . .	(1,193,312)	-6.1%	(993,100)	-4.8%
Cash and cash equivalents . . . . .	235,668	1.2%	459,227	2.2%
Investments in unconsolidated real estate joint ventures . . . . .	1,497,903	7.6%	1,152,927	5.6%
Investments in unconsolidated operating entities . . .	1,444,872	7.4%	1,289,434	6.3%
Other . . . . .	1,755,030	8.9%	1,185,548	5.8%
Total assets(1) . . . . .	<u>\$19,658,000</u>	<u>100.0%</u>	<u>\$20,519,801</u>	<u>100.0%</u>

- (1) At December 31, 2022 and 2021, respectively, our total adjusted gross assets were \$21 billion and \$22 billion, which represents total assets plus accumulated depreciation and amortization adjusted for our investments in unconsolidated real estate joint ventures and assumes material transaction commitments as described in Note 8 and Note 13 of Item 8 of this Annual Report on Form 10-K are completed at December 31, 2022 — see section titled “Non-GAAP Financial Measures” in “Management’s Discussion

and Analysis of Financial Condition and Results of Operations” in Item 7 of this Annual Report on Form 10-K.

### **Revenues**

The following is a breakdown of our revenues for the years ended December 31 (dollars in thousands):

	<u>2022</u>		<u>2021</u>	
Rent billed . . . . .	\$ 968,874	62.8%	\$ 931,942	60.4%
Straight-line rent . . . . .	204,159	13.2%	241,433	15.6%
Income from financing leases . . . . .	203,580	13.2%	202,599	13.1%
Interest and other income . . . . .	166,238	10.8%	168,695	10.9%
Total revenues(1) . . . . .	<u>\$1,542,851</u>	<u>100.0%</u>	<u>\$1,544,669</u>	<u>100.0%</u>

- (1) For 2022 and 2021, our adjusted revenues were \$1.7 billion, which adjusts actual total revenues to include our pro rata portion of similar revenues in our unconsolidated real estate joint venture arrangements. See section titled “Non-GAAP Financial Measures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of this Annual Report on Form 10-K.

See “Overview” in Item 7 of this Annual Report on Form 10-K for details of transaction activity for 2022 and 2021.

### **Portfolio of Properties**

As of February 17, 2023, our portfolio consisted of 444 properties: 427 facilities are leased to 55 tenants, seven are under development, five are in the form of mortgage loans, and five properties, representing less than 1% of total assets, are not currently leased to a tenant, as discussed in Note 3 to Item 8 of this Annual Report on Form 10-K. Of our portfolio of properties, 106 facilities are owned by way of our five unconsolidated real estate joint venture arrangements in which we share control with our joint venture partners. Our facilities consist of 202 general acute care hospitals, 67 behavioral health facilities, 112 inpatient rehabilitation hospitals (“IRFs”), 20 long-term acute care hospitals (“LTACHs”), and 43 freestanding ER/urgent care facilities (“FSERs”).

See Item 2 of this Annual Report on Form 10-K for further information about our properties.

### **Outlook and Strategy**

Our strategy is to lease the facilities that we acquire or develop to experienced healthcare operators pursuant to long-term net leases. In addition, we may selectively structure certain of our investments as long-term, interest-only mortgage loans to healthcare operators. Our mortgage loans are typically structured such that we obtain annual cash returns similar to our net leases. In addition, we have obtained and may continue to obtain profits or other interests in certain of our tenants’ operations. These noncontrolling investments in our tenants are typically made in conjunction with larger real estate transactions, provide for certain minority rights and protections, and typically give us a right to participate in future real estate transactions and enhance our overall return. However, none of the investments in our tenants require us to provide additional capital funding.


The market for healthcare real estate is extensive and includes real estate owned by a variety of healthcare operators. For example, according to the 2022 American Hospital Association hospital statistics report, there were approximately 5,000 community hospitals in 2020, as well as an estimated \$500-\$750 billion of operator-owned hospital real estate facilities in the U.S. alone (according to industry reports). We typically focus on acquiring and developing net-leased facilities that are specifically designed to reflect the latest trends in

healthcare delivery methods and that focus on the most critical components of healthcare. We typically invest in facilities that have the highest intensity of care including:


- General acute care hospitals — provide inpatient care for the treatment of acute conditions and manifestations of chronic conditions. This type of facility also provides ambulatory care through onsite emergency rooms.
- Behavioral health facilities — specialty facilities focused on the treatment of mental, social, and even physical illnesses, while promoting the health and well-being of the body, mind, and spirit. Behavioral health services range in acuity of care from outpatient therapy and drug and alcohol rehabilitation services to secured, inpatient mental health hospital care.
- IRFs — provide rehabilitation to patients with various neurological, musculoskeletal orthopedic, and other medical conditions following stabilization of their acute medical issues.
- LTACHs — specialty-care hospitals designed for patients with serious medical problems that require intense, specialized treatment for an extended period of time, sometimes requiring a hospital stay averaging in excess of three weeks.
- FSERs — provide emergency medical services comparable to most hospital emergency rooms, while not physically attached to a hospital campus. Urgent care centers operate similarly, but generally provide care for non-emergent injuries and illnesses.

On a property type basis, our total assets at December 31, 2022 and total revenues for the 2022 year are as follows:

**TOTAL ASSETS BY ASSET TYPE**



**TOTAL REVENUES BY ASSET TYPE**




### ***Diversification***

A fundamental component of our business plan is the continued diversification of our portfolio. We monitor diversification in several ways, including concentration in any one facility. We believe facility level diversification is important because if an individual facility is needed in the community and has support from local physicians and others in the community, its operations will generally be successful regardless of who the operator is (see “Underwriting/Asset Management” section below for performance indicators we look for at the facility level). Other ways we monitor diversification include our tenant relationships, the types of hospitals we own, and the geographic areas in which we invest.




At December 31, 2022, no single property accounted for more than 3% of our total assets, similar to the prior year. From a tenant relationship perspective, see section titled “Significant Tenants” below for detail. See sections titled “Portfolio of Properties” and “Outlook and Strategy” above for information on the diversification of our hospital types. From a geographical perspective, we have investments across the U.S. and in Europe, Australia, and South America. See below for investment concentration in the U.S. and our global concentration at December 31, 2022 as a percentage of total assets, along with our concentration of revenues for the year ended December 31, 2022:


**TOTAL ASSETS BY COUNTRY**




**TOTAL REVENUES BY COUNTRY**



**ASSETS BY U.S. STATE**



**REVENUES BY U.S. STATE**



For geographic concentration, certain of our loan and equity investments in operators are allocated in proportion to our real estate investments at the end of each reporting period. Such allocations are subject to change from period-to-period.

### ***Underwriting/Asset Management***

Revenues from rents we earn pursuant to lease agreements with our tenants make up approximately 90% of our total revenues with the remainder of our income coming from interest income from loans to our tenants and other facility owners and from profits or equity interests in certain of our tenants’ operations. Our tenants operate in the healthcare industry, generally providing medical, surgical, rehabilitative, and behavioral health care to patients. The capacity of our tenants to pay our rents and interest is dependent upon their ability to conduct their operations at profitable levels. We believe that the business environment of the industry segments in which our

tenants operate is generally positive for efficient operators. However, our tenants' operations are impacted by economic, regulatory, healthcare, and market conditions (along with the possibility of natural disasters, health crises, or pandemics, like COVID-19) that may affect their profitability, which could impact our results. Accordingly, we monitor certain key performance indicators that we believe provides us with early indications of conditions that could affect the level of risk in our portfolio.

Key factors that we may consider in underwriting prospective deals and in our ongoing monitoring of our tenants' (and guarantors') performance, as well as the condition of our properties, include, but are not limited to, the following:

- the scope and breadth of clinical services and programs, including utilization trends (both inpatient and outpatient) by service type;
- the size and composition of medical staff and physician leadership at our facilities, including specialty, tenure, and number of procedures performed and/or referrals;
- an evaluation of our operators' administrative team, as applicable, including background and tenure within the healthcare industry;
- staffing trends, including ratios, turnover metrics, recruitment and retention strategies at corporate and individual facility levels;
- facility operating performance measured by current, historical, and prospective operating margins (measured by a tenant's earnings before interest, taxes, depreciation, amortization, management fees, and facility rent) of each tenant and at each facility;
- the ratio of our tenants' operating earnings to facility rent and to other fixed costs, including debt costs;
- changes in revenue sources of our tenants, including the relative mix of public payors (including Medicare, Medicaid/MediCal, and managed care in the U.S., as well as equivalent payors in Europe, Australia, and South America) and private payors (including commercial insurance and private pay patients);
- historical support (financial or otherwise) from governments and/or other public payor systems during major economic downturns/depressions;
- trends in tenants' cash collections, including comparison to recorded net patient service revenues, knowing and assessing current revenue cycle management systems and potential future planned upgrades or replacements;
- tenants' free cash flow;
- the potential impact of healthcare pandemics/epidemics, legislation, and other regulations (including changes in reimbursement) on our tenants', borrowers', and guarantors' profitability and liquidity;
- the potential impact of any legal, regulatory, or compliance proceedings with our tenants (including at the facility level);
- the potential impact of supply chain and inflation-related challenges as they relate to new developments or capital addition projects;
- an ongoing assessment of the operating environment of our tenants, including demographics, competition, market position, status of compliance, accreditation, quality performance, and health outcomes as measured by The Centers for Medicare and Medicaid Services ("CMS"), Joint Commission, and other governmental bodies in which our tenants operate;
- the level of investment in the hospital infrastructure and health IT systems; and
- physical real estate due diligence, typically including property condition and Phase 1 environmental assessments, along with annual property inspections thereafter.

In addition to the key factors above, we may analyze the physician relationships with the hospital and study admissions to understand how broad such referrals are to the hospital. Finally, we typically address two primary questions when underwriting an investment — 1) is this hospital truly needed in the market? and 2) would the community suffer were the hospital not there? We believe answers to these two questions can usually provide significant insight on whether or not to move forward with a particular investment.

## **Healthcare Industry**

The delivery of healthcare services, whether in the U.S. or elsewhere, requires real estate. The global outbreak of COVID-19 further validated this, as hospitals during the pandemic were proven invaluable. As a consequence, healthcare providers depend on real estate to maintain and grow their businesses. We believe that the healthcare real estate market provides investment opportunities due to the:

- compelling demographics driving the demand for health services;
- specialized nature of healthcare real estate investing; and
- consolidation of the fragmented healthcare real estate sector.

As noted previously, we have investments in 10 different countries across four continents. Although there are regulatory, cultural, and other differences between these countries, the importance of healthcare and its impact on the economy is a consistent theme. See below for details of the healthcare industry in each of the countries in which we currently do business (according to government sources and healthcare industry reports):

### *United States (population — approximately 330 million)*

- U.S. citizens receive healthcare primarily through private (via insurance carried by the individual or its employer) or public (Medicare/Medicaid) payors.
- U.S. currently ranks highest in overall health expenditure in the world with \$4.3 trillion in 2021, or \$12,914 per person. U.S. health expenditures as a percentage of Gross Domestic Product (“GDP”) were 18.3% in 2021.
- The largest share of total health spending was paid by the federal government at 34%, with individual pay at 27%, private business funding 17%, state and local governments making up 15%, and other private sources accounting for 7%.
- Medicare spending grew 8.4% to \$900.8 billion in 2021, or 21% of total National Health Expenditures (“NHE”).
- Medicaid spending grew 9.2% to \$734.0 billion in 2021, or 17% of total NHE.
- Hospital expenditures grew 4.4% to \$1.3 trillion in 2021.
- Out-of-pocket spending grew 10.4% to \$433.2 billion in 2021, or 10% of total NHE.

### *United Kingdom (population — approximately 68 million)*

- All English residents are entitled to public healthcare through the National Health Service (“NHS”), including hospital, physician, and mental health care.
- Overall health expenditures grew to £276.6 billion in 2021, up from £257.5 billion in 2020.
- Health expenditures accounted for 11.9% of GDP in 2021.
- Government-financed healthcare expenditure made up 83% of healthcare spending in 2021.
- The main provider type of government-financed healthcare was hospitals, making up 47% of government healthcare expenditure in 2020.

- Private household out-of-pocket and voluntary health insurance spending totaled £30 billion in 2020, down from £40 billion in 2019.

*Switzerland (population — approximately 9 million)*

- Switzerland operates a universal healthcare system which is highly decentralized, with the cantons playing a key role in its operation.
- Health expenditures accounted for 11.8% of GDP in 2020.
- Overall health expenditures were CHF83.3 billion in 2020, which was a 1.0% increase from 2019.
- In 2019, hospital care represented 37% of total health expenditures.

*Germany (population — approximately 84 million)*

- Health insurance in Germany is compulsory and consequently offers almost universal coverage.
- Health expenditures were approximately 13% of GDP in 2020.
- Health expenditures were €440.6 billion in 2020, or €5,298 per person, which was a 7.3% increase from 2019.
- In 2020, private health insurance accounted for 8.0% of total health expenditures.
- Hospital expenditures totaled €114.2 billion in 2020, up from €103.4 billion in 2019.

*Australia (population — approximately 25 million)*

- Australia has a regionally administered, universal public health insurance program that is financed through general tax revenue and a government levy.
- In 2020, health expenditures accounted for 10.6% of GDP.
- Overall health expenditures were A\$202.5 billion in 2020, a 3.7% increase from 2019.
- The federal and local government funded approximately 70% of health spending in 2020.
- In 2020-2021, Australia spent \$89.7 billion of health expenditure on hospitals, which was an increase of 4.9% compared with the previous year.

*Spain (population — approximately 47 million)*

- Spain has a public healthcare system, mainly financed by taxes, which allows residents to have access to free or very low-cost healthcare.
- In 2020, health expenditures accounted for 10.7% of GDP.
- Overall health expenditures were €122.9 billion in 2020, a 6.4% increase from 2019.
- In 2020, hospital care represented approximately 62% of the overall public healthcare expenditure.
- Public spending accounted for 74% of all health spending in 2020.
- Out-of-pocket payments were 19.6% in 2020.

*Italy (population — approximately 60 million)*

- Italy's healthcare system provides universal coverage for all citizens and legal foreign residents and is funded by corporate and value-added tax revenues collected by the central government.

- In 2021, total health expenditures were €169 billion, or 9.5% of GDP.
- In 2021, public spending on healthcare was €128 billion and private funding was €41 billion.
- In 2021, hospital care represented approximately 42% of the overall healthcare expenditure.
- In 2021, 22% of total health spending was paid out-of-pocket.

*Finland (population — approximately 6 million)*

- Finland's healthcare system provides public healthcare services that all residents are entitled to, which is funded by taxes and social security payments.
- In 2019, total health expenditures were €22 billion, or €3,983 per person, an increase of 3% from the prior year.
- In 2020, health expenditures accounted for 9.2% of GDP.
- In 2019, public spending on healthcare accounted for 77% of the overall healthcare expenditure.
- Finland invested €8.2 billion in hospitals in 2019, an increase of 2% from the prior year.

*Portugal (population — approximately 10 million)*

- Portugal provides universal health coverage to its citizens through its National Health Service, which is financed through taxation.
- Health spending in Portugal accounted for 11.2% of GDP in 2021, up from 10.1% in 2020.
- Overall health expenditures were €211 billion in 2020, or €2,050 per person.
- Public spending accounted for 67% of all health spending in 2020.
- In 2019, Portugal invested €8.6 billion in hospitals, an increase of 7% from the prior year.
- In 2020, 28% of total health spending was paid out-of-pocket.

*Colombia (population — approximately 51 million)*

- Colombia provides universal public and private coverage available for purchase through private companies where all citizens are entitled to a comprehensive health benefit package.
- In 2020, health expenditures were 9% of GDP.
- In 2020, overall health expenditures were \$22.6 billion and are projected to grow to \$27.8 billion in 2023.
- Out-of-pocket payments were \$3.7 billion in 2019, a decrease of 4% from the prior year.

## **Our Leases and Loans**

The leases of our facilities are generally “triple-net” leases with terms requiring the tenant to pay all ongoing operating expenses of the facility, including property, casualty, general liability, and other insurance coverages; utilities and other charges incurred in the operation of the facilities; real estate and certain other taxes; ground lease rent (if any); and the costs of repairs and maintenance (including any repairs mandated by regulatory requirements). Our tenants are also responsible for any desired capital expenditures (costs that either improve the value of the facility or extend the facility's life), subject to our approval; however, if we agree to fund such capital expenditures instead, our lease revenue will increase accordingly. Similarly, borrowers under our mortgage loan arrangements retain the responsibilities of ownership, including physical maintenance and improvements and all costs and expenses. Our leases and loans typically require our tenants to indemnify us for any past or future environmental liabilities, as well.

Our current leases and loans have a weighted-average remaining initial term of 17.6 years (see Item 2 for more information on remaining lease and loan terms) and most include renewal options at the election of our tenants. Based on current monthly revenue, over 99% of our leases provide annual rent escalations based on increases in the Consumer Price Index (“CPI”), or similar indexes for properties outside the U.S. and/or fixed minimum annual rent escalations.

### Significant Tenants

Our top five tenants, on a total asset basis, were as follows (dollars in thousands):

#### *Total Assets by Operator*

	As of December 31, 2022		As of December 31, 2021	
	Total Assets	Percentage of Total Assets	Total Assets	Percentage of Total Assets
<b>Operators</b>				
Steward				
Florida market . . . . .	\$ 1,324,555	6.7%	\$ 1,279,633	6.2%
Utah market . . . . .	1,192,384	6.1%	1,224,666	6.0%
Texas/Arkansas/Louisiana market . .	1,073,425	5.5%	863,992	4.2%
Massachusetts market . . . . .	756,818	3.8%	1,376,289	6.7%
Arizona market . . . . .	298,486	1.5%	279,956	1.4%
Ohio/Pennsylvania market . . . . .	117,005	0.6%	119,365	0.6%
Circle . . . . .	2,062,474	10.5%	2,371,038	11.6%
Prospect . . . . .	1,483,599	7.5%	1,631,691	8.0%
Priory . . . . .	1,290,213	6.6%	1,000,009	4.9%
Springstone . . . . .	985,959	5.0%	993,446	4.8%
Other operators . . . . .	7,461,923	38.0%	7,802,257	38.0%
Other assets . . . . .	1,611,159	8.2%	1,577,459	7.7%
Total . . . . .	<u>\$19,658,000</u>	<u>100.0%</u>	<u>\$20,519,801</u>	<u>100.0%</u>

On a total adjusted gross asset basis after adjusting for binding commitments and transactions closed after December 31, 2022 as described in Note 8 and Note 13 to Item 8 of this Annual Report on Form 10-K, our top five tenants were Steward Health Care System LLC (“Steward”) (19.8%), Circle Health Ltd. (“Circle”) (10.4%), Lifepoint Health, Inc. (“Lifepoint”) (6.6%), Swiss Medical Network (6.4%), and Priory Group (“Priory”) (6.2%). See section titled “Non-GAAP Financial Measures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of this Annual Report on Form 10-K.

#### *Steward*

Affiliates of Steward lease 41 facilities across six different markets pursuant to two master lease agreements (one of which covers the eight properties that are part of the joint venture with Macquarie Asset Management (“MAM”), as further described in Note 3 to Item 8 of this Annual Report on Form 10-K). The master leases are basically identical and have a fixed term ending October 2041 with one remaining five-year extension option, plus annual inflation-based escalators. At December 31, 2022, these facilities had an average remaining fixed lease term of 18.8 years. The remaining five-year extension option must include all leased properties within the respective master lease, if exercised. The master leases include a right of first refusal for the repurchase of the leased properties.

In addition to the master leases, we hold a promissory note totaling approximately \$220 million, which consists of five tranches with varying terms. On January 8, 2021, we made a \$335 million loan to affiliates of Steward, the terms of which provide us opportunities for participation in the value of Steward’s growth. All of the proceeds from this loan were paid to Steward’s former private equity sponsor to redeem a similarly sized convertible loan. Finally, we hold a 9.9% equity investment in Steward totaling approximately \$126 million.

### *Circle*

Affiliates of Circle lease 36 facilities pursuant to separate lease agreements. Of these leases, 31 are cross-defaulted individual leases guaranteed by Circle and have initial fixed terms ending in 2050, with two five-year extension options plus annual inflation-based escalators. The remaining five facilities are leased pursuant to four separate leases with a weighted-average remaining initial fixed term of 13.6 years along with annual inflation-based escalators and extension options.

### *Prospect*

Affiliates of Prospect Medical Holdings, Inc. (collectively, “Prospect”) lease 13 facilities pursuant to two master lease agreements. Both master leases had initial fixed terms of 15 years (ending in August 2034) and contain two extension options of five years and one extension option of four years and nine months, plus annual inflation-based escalators. In addition to these master leases, we hold a \$151 million mortgage loan secured by a first mortgage on an acute care hospital and a \$112 million term loan. The master leases, mortgage loan, and term loan are all cross-defaulted and cross-collateralized.

See Note 3 and Note 8 to Item 8 of this Annual Report on Form 10-K for activity in 2022 and expected activity in 2023 involving Prospect.

### *Priory Group*

Affiliates of Priory lease 32 facilities pursuant to separate lease agreements. Of these properties, 26 are cross-defaulted individual leases guaranteed by Priory and have initial fixed terms ending in 2046, with two ten-year extension options plus annual inflation-based escalators. The remaining six facilities are cross-defaulted individual leases guaranteed by Priory and have initial fixed terms ending in 2044, with annual inflation-based escalators.

On February 16, 2022, we agreed to participate in an existing syndicated term loan with a term of six years originated on behalf of Priory, of which we funded £96.5 million towards a £100 million participation level in the variable rate loan, which as of December 31, 2022 paid an effective rate of 8.3%. See Note 3 to Item 8 of this Annual Report on Form 10-K for more information regarding this transaction.

### *Springstone*

Affiliates of Springstone Health Opco, LLC (“Springstone”) lease 18 facilities pursuant to one master lease agreement. The master lease had an initial fixed term of 20 years (ending in October 2041), and contains two extension options of five years plus inflation-based escalators. In addition to the master lease, we hold a mortgage loan secured by a first mortgage on a behavioral health hospital. The master lease and mortgage loan are all cross-defaulted and cross-collateralized. Finally, we have an acquisition loan and a 49% interest in Springstone at December 31, 2022.

On February 7, 2023, a subsidiary of Lifepoint acquired a majority interest in Springstone and paid off the approximately \$190 million acquisition loan, plus accrued interest. In addition, our mortgage loan was converted to fee simple ownership of the same property in connection with this transaction. See Note 13 to Item 8 of this Annual Report on Form 10-K for more information regarding this transaction.

No other tenant accounted for more than 5% of our total assets at December 31, 2022.

## **Tax Structure**

We have operated as a real estate investment trust (“REIT”) under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended, (the “Code”) since 2004. Accordingly, we are generally not subject to U.S.

federal corporate income tax on our REIT taxable income, provided that we continue to qualify as a REIT and our distributions to our stockholders equal or exceed such taxable income. This treatment substantially eliminates the “double taxation” that ordinarily results from investment in a “C” corporation.

The Code defines a REIT as a corporation that: (a) is managed by one or more directors; (b) would be taxable as a domestic corporation if not for Sections 856 through 860 of the Code; (c) is beneficially owned by 100 or more persons; (d) does not have five or fewer individuals owning more than 50% in value of the outstanding stock; and (e) meets certain asset, income, and distributions tests.

We believe that we are organized and have operated in a manner that is in line with the Code’s definition of a REIT since 2004, and we intend to operate in this manner for the foreseeable future. However, see our “Tax Risks” section in Item 1A of this Annual Report on Form 10-K for further information including the potential impact to us if we were to lose our REIT status.

Certain non-real estate activities (such as working capital loans or investments in unconsolidated operating entities) we undertake are conducted by entities which we elected to be treated as a TRS. Our TRS entities are subject to both U.S. federal and state income taxes. In the case of domestic investments in unconsolidated operating entities, these investments typically fall under a structure permitted by the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”). Under the provisions of RIDEA, a REIT may lease “qualified health care properties” on an arm’s length basis to a TRS that owns healthcare operations so long as the property is operated by an entity that qualifies as an “eligible independent contractor.”

For our properties located outside the U.S., we are subject to the local taxes of the jurisdictions where our properties reside and/or legal entities are domiciled; however, we do not expect to incur additional taxes, of a significant nature, in the U.S. from foreign-based income as the majority of such income flows through our REIT.

## **Environmental Matters**

Under various U.S. federal, state, and local environmental laws and regulations and similar international laws, a current or previous owner, operator, or tenant of real estate may be required to remediate hazardous or toxic substance releases or threats of releases. There may also be certain obligations and liabilities on property owners with respect to asbestos containing materials. Investigation, remediation, and monitoring costs may be substantial. The confirmed presence of contamination or the failure to properly remediate contamination on a property may adversely affect our ability to sell or rent that property or to borrow funds using such property as collateral and may adversely impact our investment in that property. Generally, prior to completing an acquisition or closing a mortgage loan, we obtain Phase I environmental assessments (or similar studies outside the U.S.) in order to attempt to identify potential environmental concerns at the facilities. These assessments are carried out in accordance with an appropriate level of due diligence and generally include a physical site inspection, a review of relevant environmental and health agency database records, one or more interviews with appropriate site-related personnel, review of the property’s chain of title, and review of historic aerial photographs and other information on past uses of the property. We may also conduct limited subsurface investigations and test for substances of concern where the results of the Phase I environmental assessments or other information indicates possible contamination or where our consultants recommend such procedures. Upon closing and for the remainder of the lease or loan term, our transaction documents typically require our tenants to repair and remediate environmental issues at the applicable facility, and to comply in full with all environmental laws and regulations.

## **Seismic Standards**

### California Seismic Standards

The Alfred E. Alquist Hospital Facilities Seismic Safety Act of 1983 (“Alquist Act”), establishes, under the jurisdiction of the Office of Statewide Health Planning and Development (“OSHPD”), a program of seismic



safety building standards for certain hospitals constructed on and after March 7, 1973. The law requires the California Building Standards Commission to adopt earthquake performance categories, seismic evaluation procedures, standards and timeframes for upgrading certain facilities, and seismic retrofit building standards. This legislation was adopted to avoid the loss of life and the disruption of operations and the provision of emergency medical services that may result from structural damage sustained to hospitals resulting from an earthquake. A violation of any provision of the act is a misdemeanor.

Under the Alquist Act and related rules and regulations, all general acute care hospital buildings in California are assigned a structural performance category (“SPC”). SPC ratings range from 1 to 5 with SPC-1 assigned to buildings that may be at risk of collapse during a strong earthquake and SPC-5 assigned to buildings reasonably capable of providing services to the public following a strong earthquake. Pursuant to the Alquist Act, state law initially required all SPC-1 buildings to be removed from providing general acute care services by 2020 and all SPC-2 buildings to be removed from providing general acute care services by 2030. However, in 2017, OSHPD adopted a new performance category that allowed hospitals to explore the possibilities of upgrading nonconforming buildings to a new performance level that is not as rigorous. Under SPC-4D, buildings undergoing a retrofit to this level can continue functioning indefinitely beyond 2030. In addition, California AB 2190 bill required OSHPD to grant an additional extension of time to an owner who was subject to the January 1, 2020, deadline if specified conditions were met. The bill authorized the additional extension to be until July 1, 2022, if the compliance plan was based upon replacement or retrofit, or up to five years if the compliance plan was for a rebuild.

As of December 31, 2022, we have 20 licensed hospitals in California totaling investments of approximately \$1.5 billion. Exclusive of one hospital granted an OSHPD extension to October 10, 2024 (representing less than 0.6% of our total assets), under California AB 2190, all of our California hospitals are seismically compliant through 2030 as determined by OSHPD. We expect full compliance by the end of 2024 for the one remaining hospital.

#### Colombia Seismic Standards

Similar to California, the design, construction, and technical supervision of buildings in Colombia must meet certain minimum seismic standards. Such standards divide the country into seismic hazard zones: low threat, intermediate threat, and high threat. Two of our facilities are located in Bogotá, an intermediate threat zone, while the other two facilities (representing less than 1% of our total assets) are located in a high threat zone.

In addition, all buildings are classified into use groups. Clinical hospitals and health centers fall into Group IV, which are deemed indispensable buildings and are held to a higher standard of earthquake resistant construction. Buildings in Group IV are considered essential for the recovery of the community after the occurrence of an emergency, including an earthquake, and the additional structural requirements are in place to ensure that they can remain operational.

As of December 31, 2022, we estimate that our four facilities need approximately \$15 million of seismic upgrades to become compliant under Colombian law. The deadline for making such upgrades is December 2024, which we fully expect to meet.

Under our current lease and loan agreements, our tenants (or borrowers) are responsible for capital expenditures in connection with seismic laws. We do not currently expect California or Colombia seismic standards to have a negative impact on our financial condition or cash flows. We also do not currently expect compliance with seismic standards to materially impact the financial condition of our tenants.

## **Competition**

We compete in acquiring and developing facilities with financial institutions, other lenders, real estate developers, healthcare operators, other REITs, other public and private real estate companies, and private real estate investors. Among the factors that may adversely affect our ability to compete are the following:

- we may have less knowledge than our competitors of certain markets in which we seek to invest in or develop facilities;
- some of our competitors may have greater financial and operational resources than we have;
- some of our competitors may have lower costs of capital than we do;
- some of our competitors may pursue a transaction more quickly than we do;
- our competitors or other entities may pursue a strategy similar to ours; and
- some of our competitors may have existing relationships with our potential tenants/operators.

To the extent that we experience vacancies in our facilities, we will also face competition in leasing those facilities to prospective tenants. The actual competition for tenants varies depending on the characteristics of each local market. Virtually all of our facilities operate in highly competitive environments, and patients and referral sources, including physicians, may change their preferences for healthcare facilities from time-to-time. The operators of our properties compete on a local and regional basis with operators of properties that provide comparable services. Operators compete for patients based on a number of factors, including quality of care, reputation, physical appearance of a facility, location, services offered, physicians, staff, and price. We also face competition from other healthcare facilities for tenants, such as physicians and other healthcare providers that provide comparable facilities and services.

For additional information, see “Risk Factors” in Item 1A of this Annual Report on Form 10-K.

## **Insurance**

We obtain various types of insurance to mitigate the impact of property, business interruption, liability, flood, earthquake, fire, wind, and other environmental losses. We attempt to obtain the appropriate policy terms, conditions, limits, and deductibles considering the relative risk of loss and cost of coverage. However, there are certain types of extraordinary losses that may be either uninsurable or not economically insurable.

We maintain or require in our leases and mortgage loans that our tenants maintain applicable types of insurance on our facilities and their operations. In addition, we have a comprehensive insurance program to further protect our interests. At December 31, 2022, we believe that the policy specifications and insured limits of our tenant’s policies and our own policies are appropriate given the relative risk of loss, the cost of the coverage, and standard industry practice. However, no assurances can be given that we will not incur losses that are uninsured or that exceed our insurance coverage.

## **Healthcare Regulatory Matters**

The following discussion describes certain material federal healthcare laws and regulations that may affect our operations and those of our tenants. The discussion, however, does not address all applicable federal healthcare laws, and does not address state healthcare laws and regulations, except as otherwise indicated. These state laws and regulations, like the federal healthcare laws and regulations, could affect the operations of our tenants and, accordingly, our operations. In addition, in some instances we own a minority interest in our tenants’ operations and, in addition to the effect on our tenant’s ability to meet its financial obligations to us, our ownership and investment returns may also be negatively impacted by such laws and regulations. Moreover, the discussion relating to reimbursement for healthcare services addresses matters that are subject to frequent review

and revision by Congress and the agencies responsible for administering federal payment programs. Consequently, predicting future reimbursement trends or changes, along with the potential impact to us, is inherently difficult and imprecise. Finally, though we have not included a comprehensive discussion of applicable foreign laws or regulations, our tenants in Europe, Australia, and South America are subject to similar laws and regulations governing the ownership or operation of healthcare facilities including, without limitation, laws governing patient care and safety, reimbursement, licensure, and data protection.

Ownership and operation of hospitals and other healthcare facilities are subject, directly and indirectly, to substantial U.S. federal, state, and local government healthcare laws, rules, and regulations. Our tenants' failure to comply with these laws and regulations could adversely affect their ability to meet their obligations to us. Physician investment in our facilities or in real estate joint ventures is also subject to such laws and regulations. Although we are not a healthcare provider or in a position to influence the referral of patients or ordering of items and services reimbursable by the federal government, to the extent that a healthcare provider engages in transactions with our tenants, such as sublease or other financial arrangements, the Anti-Kickback Statute and the Stark Law (both discussed in this section), and any state counterparts thereto, could be implicated.

As in the U.S. under HIPAA, our tenants in foreign jurisdictions are typically subject to strict laws and regulations governing data protection (such as the European Union's General Data Protection Regulation ("GDPR")), generally, and the protection of a patient's personal health information, specifically. Tenants may also be subject to laws and regulations addressing billing and reimbursement for healthcare items and services. Furthermore, in certain cases, as with certificate of need laws in the U.S., government approval in foreign jurisdictions may also be required prior to the transfer of a healthcare facility or prior to the establishment of new or replacement facilities, the addition of beds, the addition or expansion of services, and certain capital expenditures.

Our leases and loan documents typically require our tenants, both domestic and foreign, to comply with all applicable laws, including healthcare laws. We intend for all of our business activities and operations (including that of our tenants/borrowers) in such jurisdictions to conform in all material respects with all applicable healthcare laws, rules, and regulations.

#### ***Applicable Laws (not intended to be a complete list)***

***Anti-Kickback Statute.*** The federal Anti-Kickback Statute (codified at 42 U.S.C. § 1320a-7b(b)) prohibits, among other things, the offer, payment, solicitation, or acceptance of remuneration, directly or indirectly, in return for referring an individual to a provider of items or services for which payment may be made in whole, or in part, under a federal healthcare program, including the Medicare or Medicaid programs. Violation of the Anti-Kickback Statute is a crime, punishable by fines of up to \$100,000 per violation, ten years imprisonment, or both. Violations may also result in civil sanctions, including civil monetary penalties of up to \$50,000 per violation, exclusion from participation in federal healthcare programs, including Medicare and Medicaid, and additional monetary penalties in amounts treble to the underlying remuneration. The Anti-Kickback Statute is an intent based statute, and has been broadly interpreted. As an example, courts have held that there is a violation of the Anti-Kickback Statute if just one purpose of an arrangement is to generate referrals despite the fact that there may be one or more other lawful purposes to the arrangement at issue.

The Office of Inspector General of the Department of Health and Human Services ("OIG") has issued "Safe Harbor Regulations" that describe practices that will not be considered violations of the Anti-Kickback Statute. Nonetheless, the fact that a particular arrangement does not meet safe harbor requirements does not also mean that the arrangement violates the Anti-Kickback Statute. Rather, the safe harbor regulations simply provide a guaranty that qualifying arrangements will not be prosecuted under the Anti-Kickback Statute. We intend to use commercially reasonable efforts to structure our arrangements with tenants so as to satisfy, or meet as closely as possible, all safe harbor conditions. We also require our tenants, under our lease or loan agreements, to comply with applicable laws which would include structuring their arrangements with third parties in a manner that

complies with the Anti-Kickback Statute. We cannot assure you, however, that we or our tenants will meet all the conditions for an applicable safe harbor.

*Physician Self-Referral Statute (“Stark Law”).* Unless subject to an exception, the Ethics in Patient Referrals Act of 1989, or the Stark Law (codified at 42 U.S.C. § 1395nn) prohibits a physician from making a referral to an “entity” furnishing “designated health services” (which would include, without limitation, certain inpatient and outpatient hospital services) paid by Medicare or Medicaid if the physician or a member of his immediate family has a “financial relationship” with that entity. The prohibition further bars the entity from billing Medicare or Medicaid for any services furnished pursuant to a prohibited referral. Sanctions for violating the Stark Law include denial of payment, refunding amounts received for services provided pursuant to prohibited referrals, civil monetary penalties of up to \$15,000 per prohibited service provided, and exclusion from the participation in federal healthcare programs. The statute also provides for a penalty of up to \$100,000 for a circumvention scheme.

There are exceptions to the self-referral prohibition for many of the customary financial arrangements between physicians and providers, including, without limitation, employment contracts, rental of office space or equipment, personal services agreements and recruitment agreements. Unlike safe harbors under the Anti-Kickback Statute, the Stark Law imposes strict liability on the parties to an arrangement, and an arrangement must comply with every requirement of a Stark Law exception or the arrangement is in violation of the Stark Law.

CMS has issued multiple phases of final regulations implementing the Stark Law and continues to make changes to these regulations. Although our lease and loan agreements require lessees and borrowers to comply with the Stark Law and we intend for them to comply with the Stark Law, we cannot offer assurance that the arrangements entered into by us, our facilities, or our tenants and borrowers will be found to be in compliance with the Stark Law, as it ultimately may be implemented or interpreted. In addition, changes to the Stark Law could require our tenants to restructure certain arrangements with physicians, which could impact the business of our tenants.

*False Claims Act.* The federal False Claims Act prohibits the making or presenting of any false claim for payment to the federal government. It is the civil equivalent to federal criminal provisions prohibiting the submission of false claims to federally funded programs. Additionally, *qui tam*, or whistleblower, provisions of the federal False Claims Act allow private individuals to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government. Whistleblowers may collect a portion of the federal government’s recovery — an incentive for private parties to bring such actions. A successful federal False Claims Act case may result in a penalty of three times the actual damages, plus additional civil penalties payable to the government, plus reimbursement of the fees of counsel for the whistleblower. Many states have enacted similar statutes preventing the presentation of a false claim to a state government.

*The Civil Monetary Penalties Law.* The Civil Monetary Penalties Law (“CMPL”) is a comprehensive statute that covers an array of fraudulent and abusive activities and is very similar to the False Claims Act. Among other things, the CMPL prohibits the knowing presentation of a claim for certain healthcare services that is false or fraudulent, the presentation of false or misleading information in connection with claims for payment, and other acts involving fraudulent conduct. Violation of the CMPL may result in penalties ranging from \$20,000 to in excess of \$100,000 (penalties are periodically adjusted). Notably, such penalties apply to each instance of prohibited conduct, including each item or service not provided as claimed and each provision of false information or each false record. In addition, violators of the CMPL may be penalized up to three times the amount unlawfully claimed and may be excluded from participation in federal healthcare programs.

*Licensure.* Our tenants are subject to extensive federal, state, and local licensure, certification, and inspection laws and regulations including, in some cases, certificate of need laws. Further, various licenses and permits are required to dispense narcotics, operate pharmacies, handle radioactive materials, and operate

equipment. Failure to comply with any of these laws could result in loss of licensure, certification or accreditation, denial of reimbursement, imposition of fines, and suspension or decertification from federal and state healthcare programs.

*EMTALA.* Our tenants that provide emergency care in the U.S. are subject to the Emergency Medical Treatment and Active Labor Act (“EMTALA”). Regardless of an individual’s ability to pay, this federal law requires such healthcare facilities to conduct an appropriate medical screening examination of every individual who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. Liability for violations of EMTALA are severe and include, among other things, civil monetary penalties and exclusion from participation in federal healthcare programs. Our lease and mortgage loan agreements require our tenants to comply with EMTALA, and we believe our tenants conduct business in substantial compliance with EMTALA.

### *Other Healthcare Matters*

*Reimbursement Pressures.* Healthcare facility operating margins have faced significant pressure due to the deterioration in pricing flexibility and payor mix, a continued shift toward alternative payment models, increases in operating expenses, reductions in levels of Medicaid funding due to state budget shortfalls, and other similar cost pressures on our tenants. More specifically, certain facilities and departments such as IRFs, LTACHs, and Hospital Outpatient Departments (“HOPDs”) continue to face reimbursement pressures because of legislative and regulatory restrictions and limitations on reimbursement. Finally, the outbreak of the COVID-19 pandemic materially adversely affected our tenants and their operations, as well as the global economy and financial markets. For example, as a result of the COVID-19 pandemic, elective surgery volumes at our tenants’ facilities declined and routine physician office visits were down due to stay-at-home orders and general reluctance on the part of patients to visit facilities for non-emergent health services. We cannot predict how and to what extent pandemics like COVID-19 or other health crises may impact the business of our tenants or whether our business will be adversely impacted.

*Healthcare Reform.* The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) has expanded health insurance coverage through tax subsidies and federal health insurance programs, individual and employer mandates for health insurance coverage, and health insurance exchanges. A number of reforms stem from the ACA, and federal agencies, including CMS, continue to propose and implement policies founded in the ACA. These include various cost containment initiatives, quality improvement efforts, pay-for-performance criteria, and value-based purchasing programs, among others. Health information technology standards for healthcare providers also continue to be implemented as a means of improving quality and reducing costs. We cannot predict the impact of how any new initiatives, if adopted, will affect our business, as some aspects may benefit the operations of our tenants, while other aspects may present challenges.

### **Environmental, Social, and Governance**

Environmental, social, and governance (“ESG”) initiatives are an important part of our overall corporate activities, and we intend to further our sustainability efforts in each of the three ESG pillars. Our approach to sustainability is overseen by our board, executive management team, and our Environmental and Social Committee, which was formed to continuously improve programs, policies, and practices relating to environmental, social, and governance initiatives across all aspects of our business. In addition, we have an Ethics, Nominating and Governance Committee with responsibility for developing and recommending corporate governance guidelines and policies. We also have established an employee-led “Green Team” with responsibility for driving further environmental performance improvements across all aspects of our business.

In early 2022, we completed and published our inaugural Corporate Responsibility Report, which describes how our approach to ESG issues enables us to support our employees, to build strong tenant relationships, and

positions us for sustainable success. Our environmental sustainability initiatives focus on environmental improvements to our corporate operations and hospital facilities.

For additional information regarding our ESG initiatives and to view our Corporate Responsibility Report, please visit our website at [www.medicalpropertytrust.com](http://www.medicalpropertytrust.com).

## **Human Capital**

Our employees are our most valuable asset. Led by our founding executives, including Emmett McLean who has announced his retirement effective September 1, 2023, we have a total of 119 employees as of February 17, 2023, located in the U.S., Luxembourg, United Kingdom, and Australia. As we grow, we expect our head count to increase as well. However, we do not believe that any year-over-year adjustments to the number of employees will have a material effect on our operations or to general and administrative expense as a percent of revenues. None of our employees are subject to a collective bargaining agreement.

We believe that our relations with our employees are good, and we are committed to providing a dynamic and supportive workplace for our employees that encourages both personal and professional growth through significant training and continuing education opportunities. We offer employees the opportunity to attend continuing education courses in order to maintain their professional certifications, participate in seminars and workshops on topics related to their job responsibilities, and build upon their leadership abilities through management development programs. In addition, we provide regular training for all employees on topics such as personal safety, cybersecurity, and data security awareness, and we have established company-wide human rights, and health and safety policies.


We offer a competitive benefits package that has recently included annual performance-based bonuses and stock compensation, a 401(k) plan, leading healthcare and insurance benefits, paid time off, health and wellness reimbursement programs, etc. designed to help recruit and retain high-quality, motivated employees, and to contribute to their health and security. We routinely evaluate and benchmark the competitiveness of our compensation and benefit programs to ensure that we are rewarding our employees and supporting their needs.

In 2022, we conducted an employee satisfaction survey to measure the level of satisfaction of each employee and gain insight into the health of our company. The responses and comments we received were overwhelmingly positive. As a result, MPT earned a 95% overall engagement score, high levels for employee satisfaction and confidence in executive management, and was selected as one of Modern Healthcare's Best Places to Work in healthcare for 2022.

Given the value placed on our employees and their interests, we believe it is important to improve the communities in which they live. We do this by providing financial support for private and public non-profit programs aimed at improving community public health and supporting the diverse interests of our employees. In addition, we encourage each of our employees to get involved in their communities to make a positive difference, and we provide time off to do so.

We are firmly committed to providing equal opportunity in all aspects of employment. We forbid discrimination against any person or harassment, intimidation, or hostility of any kind, including on the basis of race, religion, color, sex, sexual orientation, sexual or gender identity, age, disability, national origin, military or veteran status, retaliation or any other characteristic or conduct that may be protected by applicable local, state, or federal law. Our hiring process includes a robust search for the best available candidate and each candidate is properly vetted through interviews with numerous MPT employees. The company also retains the services of an experienced independent industrial psychologist to ensure a strong fit exists between the company and the candidate and that the candidate meets the standards for the specific job and the needs of the company. We

provide regular training on anti-harassment policies. Our commitment to a diverse and inclusive workplace is demonstrated by the following:



#### Available Information

Our website address is [www.medicalpropertytrust.com](http://www.medicalpropertytrust.com) and provides access in the “Investor Relations” section, free of charge, to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, including exhibits, and all amendments to these reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (“SEC”). We use, and intend to continue to use, the “Investor Relations” section of our website as a means of disclosing material nonpublic information and of complying with our disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the “Investor Relations” section, in addition to following our press releases, SEC filings, public conference calls, presentations, and webcasts. Also available on our website, free of charge, are our Corporate Governance Guidelines, the charters of our Ethics, Nominating, and Corporate Governance, Audit and Compensation Committees and our Code of Ethics and Business Conduct. If you are not able to access our website, the information is available in print free of charge to any stockholder who should request the information directly from us at (205) 969-3755. Information on or connected to our website is neither part of nor incorporated by reference into this Annual Report on Form 10-K or any other SEC filings.

## **ITEM 1A. Risk Factors**

*The risks and uncertainties described herein are not the only ones facing us and there may be additional risks that we do not presently know of or that we currently consider not likely to have a significant impact on us. All of these risks could adversely affect our business, results of operations, financial condition, and our ability to service our debt and make distributions to our stockholders. Some statements in this report including statements in the following risk factors constitute forward-looking statements. Please refer to the section entitled “A Warning About Forward Looking Statements” at the beginning of this Annual Report.*

### **RISKS RELATED TO OUR BUSINESS AND GROWTH STRATEGY**

***Adverse U.S. and global market, economic and political conditions, health crises and other events beyond our control could have a material adverse effect on our business, results of operations, and financial condition.***

Another economic or financial crisis, significant concerns over energy costs and inflation, rising interest rates, geopolitical issues, the availability and cost of credit, or a declining real estate market in the U.S. or abroad can contribute to increased volatility, diminished expectations for the economy and the markets, shortage of available healthcare workers and related increased labor costs, and high levels of unemployment by historical standards. As was the case from 2008 through 2010, as well as most of 2022, these factors, combined with volatile oil prices and fluctuating business and consumer confidence, can precipitate a steep economic decline.

Adverse U.S. and global market, economic and political conditions, including dislocations and volatility in the credit markets, rising inflation and interest rates, and general global economic uncertainty, could have a material adverse effect on our business, results of operations, and financial condition as a result of the following potential consequences, among others:

- reduced values of our properties may limit our ability to dispose of assets at attractive prices, or at all, or to obtain debt financing secured by our properties and may reduce the availability of unsecured loans; and
- our ability to obtain financing on terms and conditions that we find acceptable, or at all, may be limited, which could reduce our ability to pursue acquisition and redevelopment opportunities and refinance existing debt, reduce our returns from our acquisition and redevelopment activities and increase our future interest expense.

Public health crises, pandemics and epidemics, such as those caused by new strains of viruses such as H5N1 (avian flu), severe acute respiratory syndrome (SARS) and, most recently, COVID-19, could adversely impact our and our tenants’ business by disrupting supply chains and transactional activities, and negatively impacting local, national, or global economies.

***Our revenues are dependent upon our relationships with and success of our tenants, particularly our largest tenants, like Steward, Circle, Prospect, Priory, and Springstone.***

Our tenants’ financial performance and resulting ability to satisfy their lease and loan obligations to us are material to our financial results and our ability to service our debt and make distributions to our stockholders. We are dependent upon the ability of our tenants to make rent and loan payments to us, and any failure to meet these obligations could have a material adverse effect on our financial condition and results of operations.

As of December 31, 2022, our largest tenants — Steward, Circle, Prospect, Priory, and Springstone — represented 24.2%, 10.5%, 7.5%, 6.6%, and 5.0%, respectively, of our total assets.

Our tenants operate in the healthcare industry, which is highly regulated by U.S. federal, state, and local laws along with laws in Europe, Australia, and South America and changes in regulations may temporarily



impact our tenants' operations until they are able to make the appropriate adjustments to their business. In addition, our tenants experience operational challenges from time-to-time, and this can be even more of a risk for those tenants that grow (or have grown) via acquisitions in a short time frame, like Steward, Circle, and others. The ability of our tenants and operators to integrate newly acquired businesses into their existing operational, financial reporting, and collection systems is critical towards ensuring their continued success. If such integration is not successfully implemented in a timely manner, operators can be negatively impacted in the form of write-offs of uncollectible accounts receivable, higher expenses, or even insolvency in certain extreme cases.

Any adverse result to our tenants (particularly Steward, Circle, Prospect, Priory, and Springstone) in regulatory proceedings or financial or operational setbacks may have a material adverse effect on the relevant tenant's operations and on its ability to make required lease and loan payments to us. If any one of these tenants were to file for bankruptcy protection, we may not be able to collect any pre-filing amounts owed to us by such tenant. In a bankruptcy proceeding, such tenant may terminate our lease(s), in which case we would have a general unsecured claim that would likely be for less than the full amount owed to us. Any secured claims we have against such tenant may only be paid to the extent of the value of the collateral, which may not cover all or any of our losses. The protections that we have in our leases, which can include letters of credit, cross default provisions, parent guarantees, repair reserves, and the right to exercise remedies including the termination of the lease and replacement of the operator, may prove to be insufficient, in whole or in part, or may entail further delays. In instances where we have an equity investment in our tenant's operations, in addition to the effect on these tenants' ability to meet their financial obligation to us, our ownership and investment interests may also be negatively impacted.

***We have experienced rapid growth over the years, from adding new tenants to expanding our global footprint, and our failure to effectively manage our growth may adversely impact our financial condition and cash flows, which could negatively affect our ability to service our debt and make distributions.***

We have experienced growth through investments in healthcare properties and expansion into ten countries and four continents. We continually evaluate property acquisition and development opportunities as they arise, and we typically have a number of potential acquisition and development transactions under active consideration.

There is no assurance that we will be able to adapt our management, administrative, accounting, and operational systems, or hire and retain sufficient operational staff, to manage the facilities we have acquired over the years across ten countries and those that we may acquire or develop in the future. Additionally, investing in real estate located in foreign countries creates risks associated with the uncertainty of foreign laws, economies, and markets, and exposes us to local economic downturns and adverse market developments.

Our failure to manage such growth effectively may adversely impact our financial condition and cash flows, which could negatively affect our ability to service our debt and make distributions to our stockholders. Our rapid growth could also increase our capital requirements, which may require us to issue potentially dilutive equity securities and/or incur additional debt.

***It may be costly to replace defaulting tenants and we may not find suitable replacements on suitable terms.***

Failure on the part of a tenant to comply materially with the terms of a lease could give us the right to terminate the lease, repossess the facility, cross default certain other leases and loans with that tenant, and enforce the payment obligations under the lease. The process of terminating a lease with a defaulting tenant and repossessing the applicable facility may be costly and require a disproportionate amount of management's attention. In addition, defaulting tenants may initiate litigation in connection with a lease termination or repossession against us. If a tenant-operator defaults and we choose to terminate the lease, we would then be required to find another tenant-operator or to sell the facility. The transfer of healthcare facilities is highly regulated, which may result in delays and increased costs in locating a suitable replacement tenant. The lease of these properties to non-healthcare operators may be difficult due to the added cost and time of refitting the

properties. If we are unable to re-let the properties, we may be forced to sell the properties at a loss. There can be no assurance that we would be able to find another tenant in a timely fashion, or at all, or that, if another tenant were found, we would be able to enter into a new lease on favorable terms. Defaults by our tenants under our leases may adversely affect our results of operations, financial condition, and our ability to service our debt and make distributions to our stockholders. Defaults by our significant tenants under master leases (like Steward, Circle, and Prospect) will have an even greater effect.

***It may be costly to find new tenants when lease terms end, and we may not be able to replace such tenants with suitable replacements on suitable terms.***

Failure on the part of a tenant to renew or extend the lease at the end of its fixed term could result in us having to search for, negotiate with, and execute new lease agreements. The process of finding and negotiating with a new tenant, along with costs (such as maintenance, property taxes, utilities, ground lease expenses, etc.) that we will incur while the facility is untenanted, may be costly and require a disproportionate amount of our management's attention. There can be no assurance that we would be able to find another tenant in a timely fashion, or at all, or that, if another tenant were found, we would be able to enter into a new lease on favorable terms. If we are unable to re-let the properties to healthcare operators, we may be forced to sell the properties at a loss due to the repositioning expenses likely to be incurred by non-healthcare purchasers. Alternatively, we may be required to spend substantial amounts to adapt the facility to other uses. Thus, the non-renewal or extension of leases may adversely affect our results of operations, financial condition, and our ability to service our debt and make distributions to our stockholders. This risk is even greater for those properties under master leases (like Steward, Circle, and Prospect) because several properties have the same lease ending dates. See Item 2 for our lease and loan maturity schedule.

***We have made investments in certain operators of our healthcare facilities and the cash flows (and related returns) from these investments are subject to more volatility than our properties with the traditional net leasing structure.***

At December 31, 2022, we have approximately \$1.4 billion of investments in unconsolidated operating entities, including \$0.5 billion of investments in Steward, our largest tenant. These investments include loans but also equity investments that generate returns dependent upon the operator's performance. As a result, the cash flow and returns from these investments may be more volatile than that of our traditional triple-net leasing structure. Our results of operations and financial condition may be adversely affected if the related operators fail to successfully operate the facilities efficiently and in a manner that is in our best interest.

***We have less experience with healthcare facilities located outside the U.S.***

At December 31, 2022, we had approximately 39% of our total assets located in nine different countries outside the U.S. We have less experience investing in healthcare properties or other real estate-related assets located outside the U.S. Investing in real estate located in foreign countries creates risks associated with the uncertainty of foreign laws and markets including, without limitation, laws respecting foreign ownership, the enforceability of loan and lease documents, and foreclosure laws. Foreign real estate and tax laws are complex and subject to change, and we cannot assure you we will always be in compliance with those laws or that compliance will not expose us to additional expense. The properties we have acquired internationally will face risks in connection with unexpected changes in regulatory requirements, political and economic instability, potential imposition of adverse or confiscatory taxes, possible challenges to the anticipated tax treatment of the structures that allow us to acquire and hold investments, possible currency transfer restrictions, the difficulty in enforcing obligations in other countries, the impact from Brexit and future developments in the European Union, and the burden of complying with a wide variety of foreign laws. In addition, to qualify as a REIT, we generally will be required to operate any non-U.S. investments in accordance with the rules applicable to U.S. REITs, which may be inconsistent with local practices. We may also be subject to fluctuations in local real estate values or markets or the economy as a whole, which may adversely affect our investments.

In addition, the revenues and expenses incurred internationally are denominated in either euros, British pounds, Swiss francs, Australian dollars, or Colombian pesos, which could expose us to losses resulting from fluctuations in exchange rates to the extent we have not hedged our position, which in turn could adversely affect our revenues, operating margins, and dividends, and may also affect the book value of our assets and the amount of stockholders' equity. While we may hedge some of our foreign currency risk, we may not be able to do so successfully and may incur losses on our investments as a result of exchange rate fluctuations. Furthermore, we are subject to laws and regulations, such as the Foreign Corrupt Practices Act and similar local anti-bribery laws, which generally prohibit companies and their employees, agents, and contractors from making improper payments to governmental officials for the purpose of obtaining or retaining business. Failure to comply with these laws could subject us to civil and criminal penalties that could materially and adversely affect our results of operations, the value of our international investments, and our ability to service our debt and make distributions to our stockholders.

***We and our tenants have exposure to contingent rent escalators, which could impact profitability.***

We receive a significant portion of our revenues by leasing assets under long-term net leases that generally provide for fixed rental rates subject to annual escalations. These annual escalations may be contingent on changes in CPI (or a similar index internationally), typically with specified caps and floors. If, as a result of weak economic conditions or other factors, the CPI does not increase, our growth and profitability may be hindered by these leases. In addition, if strong economic conditions or higher than normal inflation results in significant increases in CPI (like has been the case in 2022), but the escalations under our leases are capped, our growth and profitability may be limited.

On the flip side, higher than normal increases in CPI could negatively impact our tenants' profitability, particularly if reimbursement revenues from governmental programs, like Medicare, do not keep pace. Even if these governmental programs eventually increase reimbursement rates in line with CPI, there could be interim shortfall for our tenants, which may adversely impact our ability to collect rent/interest on a timely basis.

***The bankruptcy or insolvency of our tenants or investees could harm our operating results and financial condition.***

Some of our tenants may be newly organized, have limited or no operating history, or may be thinly capitalized such that they may need loans from us for working capital purposes from time-to-time. Any bankruptcy filings by one of our tenants could bar us from collecting pre-bankruptcy debts from that tenant or their property, unless we receive an order permitting us to do so from the bankruptcy court. A tenant bankruptcy can be expected to delay our efforts to collect past due balances under our leases and loans, and could ultimately preclude collection of these sums. If a lease is assumed by a tenant in bankruptcy (like it was in the case of Pipeline Health System, LLC ("Pipeline") in 2022), we expect that all pre-bankruptcy balances due under the lease would be paid to us in full. However, if a lease is rejected by a tenant in bankruptcy, we would have only a general unsecured claim for damages. Any secured claims we have against our tenants may only be paid to the extent of the value of the collateral, which may not cover any or all of our losses. Any unsecured claim (such as our equity interests in our tenants) we hold against a bankrupt entity may be paid only to the extent that funds are available and only in the same percentage as is paid to all other holders of unsecured claims. We may recover none or substantially less than the full value of any unsecured claims, which would harm our financial condition.

***Our business is highly competitive, and we may be unable to compete successfully.***

We compete for development opportunities and opportunities to purchase healthcare facilities with, among others: private investors, including large private equity funds; healthcare providers, including physicians; other REITs; real estate developers; government-sponsored and/or not-for-profit agencies; financial institutions; and other lenders. Some of these competitors may have substantially greater financial resources than we have and may have better relationships with lenders and sellers. Competition for healthcare facilities from competitors

may adversely affect our ability to acquire or develop healthcare facilities and the prices we pay for those facilities. If we are unable to acquire or develop facilities or if we pay too much for facilities, our revenue, earnings growth, and financial return could be materially adversely affected. Certain of our facilities, or facilities we may acquire or develop in the future, will face competition from other nearby facilities that provide services comparable to those offered at our facilities. Some of those facilities are owned by governmental agencies and supported by tax revenues, and others are owned by tax-exempt corporations and may be supported to a large extent by endowments and charitable contributions. Those types of support are not generally available to our facilities. In addition, competing healthcare facilities located in the areas served by our facilities may provide healthcare services that are not available at our facilities. From time-to-time, referral sources, including physicians and managed care organizations, may change the healthcare facilities to which they refer patients, which could adversely affect our tenants and indirectly our results of operations, financial condition, and ability to service our debt and make distributions.

***Many of our tenants have an option to purchase the facilities we lease to them, which could disrupt our operations.***

Many of our tenants have the option to purchase the facilities we lease to them. There is no assurance that the formulas we have developed for setting the purchase price will yield a fair market value purchase price. In the event our tenants decide to purchase the facilities at the end of the lease term, we may not be able to re-invest the capital on as favorable terms, or at all. Our inability to effectively manage the turnover of our facilities could materially adversely affect our ability to execute our business plan and our results of operations.

We have 114 leased properties that are subject to purchase options as of December 31, 2022. For 93 of these properties, the purchase option generally allows the lessee to purchase the real estate at the end of the lease term, assuming not currently in default, at a price equivalent to the greater of (i) fair market value or (ii) our original purchase price (increased, in some cases, by a certain annual rate of return from the lease commencement date). The lease agreements generally provide for an appraisal process to determine fair market value. For 13 of these properties, the purchase option generally allows the lessee to purchase the real estate at the end of the lease term, assuming not currently in default, at our purchase price (increased, in some cases, by a certain annual rate of return from lease commencement date). For the remaining eight leases, the purchase options approximate fair value.

In certain circumstances, a prospective purchaser of our hospital real estate may be deemed to be subject to Anti-Kickback and Stark statutes, which are described in the “Healthcare Regulatory Matters” section in Item 1 of this Annual Report on Form 10-K. In such event, it may not be practicable for us to sell a property to such prospective purchaser at a price other than fair market value.

***Merger and acquisition activity or consolidation in the healthcare industry may result in a change of control of, or a competitor’s investment in, one or more of our tenants or operators, which could have a material adverse effect on us.***

The healthcare industry continues to experience consolidation, including among owners of real estate and healthcare providers. We compete with other healthcare REITs, healthcare providers, healthcare lenders, real estate partnerships, banks, insurance companies, private equity firms, and other investors that pursue a variety of investments, which may include investments in our tenants. We have historically developed strong, long-term relationships with many of our tenants. A competitor’s investment in one of our tenants, any change of control of a tenant, or a change in the tenant’s management team could enable our competitor to influence or control that tenant’s business and strategy. This influence could have a material adverse effect on us by impairing our relationship with the tenant, negatively affecting our interest, or impacting the tenant’s financial and operational performance, including their ability to pay us rent or interest. Depending on our contractual agreements and the specific facts and circumstances, we may have consent rights, termination rights, remedies upon default, or other rights and remedies related to a competitor’s investment in, a change of control of, or other transactions

impacting a tenant. In deciding whether to exercise our rights and remedies, including termination rights or remedies upon default, we assess numerous factors, including legal, contractual, regulatory, business, and other relevant considerations.

***Our investments in joint ventures could be adversely affected by our lack of control, our partners' failure to meet their obligations, and disputes with our partners.***

We have investments in five unconsolidated real estate joint ventures with independent parties that total approximately \$1.5 billion at December 31, 2022. Joint venture arrangements involve risks including the possibility that the other party may refuse or not be able to make capital contributions if needed, that our partner might have economic or other interests that are inconsistent with the joint venture's interests, or that we may become engaged in a dispute with our partner. If any of these events occur, we may need to provide additional funding to the joint ventures to meet its obligations, incur additional expenses to resolve disputes, or be forced to buy out the partner's interest or to sell our interests at a time that is not advantageous to us. Any loss of income, cash flow, or disruption of management's time could have a negative impact on the rest of our business.

***Increased scrutiny and changing expectations from investors, employees, and other stakeholders regarding our ESG practices and reporting could cause us to incur additional costs, devote additional resources, and expose us to additional risks, which could adversely impact our reputation, tenant and employee acquisition and retention, and access to capital.***

Companies across all industries are facing increased scrutiny related to their ESG practices and reporting. Investors, employees, and other stakeholders have begun to focus on ESG practices and to place greater importance on the implications and social cost of their investments and business decisions. For example, an increasing number of investment funds focus on positive ESG practices and sustainability scores when making an investment decision. In addition, investors, particularly institutional investors, use ESG practices and scores to benchmark companies against their peers and if a company is perceived as lagging, such investors may engage with a company to improve ESG disclosure or performance and may also make voting decisions on this basis. Given this increased focus and demand, public reporting regarding ESG practices is becoming more broadly expected. If our ESG practices and reporting regarding, among others, corporate governance, environmental compliance, human capital management, and workforce inclusion and diversity do not meet investor, employee, and other stakeholder expectations, our reputation may be negatively impacted. We could also incur additional costs and devote additional resources to monitoring, reporting, and implementing various ESG practices. Our failure, or perceived failure, to meet the goals and objectives we set in our sustainability disclosure or the expectations of our various stakeholders, could negatively impact our reputation, tenant and employee retention, and access to capital.

## **RISKS RELATED TO FINANCING OUR BUSINESS**

***Limited access to capital may restrict our growth.***

Our business plan contemplates growth through acquisitions and development of facilities. As a REIT, we are required to make cash distributions, which reduce our ability to fund acquisitions and developments with retained earnings. Thus, access to the capital markets, bank borrowings, and other financing vehicles are important to fund new opportunistic investments. Due to market or other conditions, we may not be able to obtain additional equity or debt capital or dispose of assets on favorable terms, if at all, at the time we need additional capital to acquire healthcare properties, which could have a material adverse effect on our results of operations and our ability to service our debt and make distributions to our stockholders.

***Our indebtedness could adversely affect our financial condition and may otherwise adversely impact our business operations and our ability to make distributions to stockholders.***

As of February 17, 2023, we had approximately \$10.3 billion of debt outstanding. Our indebtedness could have significant effects on our business. For example, it could require us to use a substantial portion (or all) of

our cash flow from operations to service our indebtedness, which would reduce the available cash flow to fund working capital, development projects, and other general corporate purposes and reduce cash for distributions; force us to dispose of one or more of our properties, possibly on disadvantageous terms, to make payments on our debt; increase our vulnerability to general adverse economic and industry conditions; limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; restrict us from making strategic acquisitions or exploiting other business opportunities; and place us at a competitive disadvantage compared to our competitors that have less debt.

Our future borrowings under our loan facilities may bear interest at variable rates in addition to the \$1.1 billion in variable interest rate debt that we had outstanding as of February 17, 2023 (excluding the variable rate debt that we have fixed through interest rate swaps). If interest rates increase significantly, our operating results would decline along with the cash available for distributions to our stockholders.

In addition, most of our current debt is, and we anticipate that much of our future debt will be, non-amortizing and payable in balloon payments. Therefore, we will likely need to refinance at least a portion of that debt as it matures. There is a risk that we may not be able to refinance debt maturing in 2023 and future years or that the terms of any refinancing will not be as favorable as the terms of the then-existing debt. If principal payments due at maturity cannot be refinanced, extended, or repaid with proceeds from other sources, such as new equity capital, joint venture proceeds, or sales of facilities, our cash flow may not be sufficient to repay all maturing debt in years when significant balloon payments come due. See Item 7 of Part II of this Annual Report on Form 10-K for further information on our current debt maturities.

***Covenants in our debt instruments limit our operational flexibility, and a breach of these covenants could materially affect our financial condition and results of operations.***

The terms of our unsecured credit facility (“Credit Facility”) and the indentures governing our outstanding unsecured senior notes and other debt instruments that we may enter into in the future are subject to customary financial and operational covenants. For example, our Credit Facility imposes certain restrictions on us, including restrictions on our ability to: incur debts; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem, or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate; and change our business. In addition, our Credit Facility and senior unsecured notes limit the amount of dividends we can pay. Finally, senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness. From time-to-time, the lenders of our Credit Facility may adjust certain covenants to give us more flexibility to complete a transaction; however, such modified covenants are temporary, and we must be in a position to meet the lowered reset covenants in the future. Our continued ability to incur debt and operate our business is subject to compliance with the covenants in our debt instruments, which limit operational flexibility. Breaches of these covenants could result in defaults under applicable debt instruments and other debt instruments due to cross-default provisions, even if payment obligations are satisfied. Financial and other covenants that limit our operational flexibility, as well as defaults resulting from a breach of any of these covenants in our debt instruments, could have a material adverse effect on our financial condition and results of operations.

***Failure to hedge effectively against interest rate changes may adversely affect our results of operations and our ability to make distributions to our stockholders.***

As of February 17, 2023, we had approximately \$2.8 billion in variable interest rate debt along with €655 million and approximately \$900 million in our joint venture arrangements with Primotop Holdings S.à.r.l. (“Primotop”) and MAM, respectively. This variable rate debt subjects us to interest rate volatility. To manage this interest rate volatility, we have entered into interest rate swaps to fix the interest rate on all but \$1.1 billion of this debt and have an interest rate cap in place on another \$900 million. However, even these hedging arrangements involve risk, including the risk that counterparties may fail to honor their obligations, that these

arrangements may not be effective in reducing our exposure to interest rate changes, and that these arrangements may result in higher interest rates than we would otherwise have (in the case of our interest rate swaps). Moreover, no hedging activity can completely insulate us from the risks associated with changes in interest rates. Failure to hedge effectively against interest rate changes may materially adversely affect our results of operations and our ability to service our debt and make distributions to our stockholders.

***The market price and trading volume of our common stock may be volatile and may decline regardless of our operating performance, and you may lose all or part of your investment.***

As can be seen in 2022, the market price of our common stock may be highly volatile and be subject to wide fluctuations. In addition, the trading volume in our common stock may fluctuate and cause significant price variations to occur. A variety of factors may cause significant price variations, including the amount and status of short interest in our securities and any coordinated trading activities or large derivative positions in our common stock. For example, the potential for a short squeeze whereby a number of investors take a short position in a stock and have to buy the borrowed securities to close out the position at a time that other short sellers of the same security also want to close out their positions, may result in volatility in our stock price. If the market price of our common stock declines significantly, you may be unable to sell your shares at or above your purchase price.

We cannot assure you that the market price of our common stock will not fluctuate or decline significantly in the future. Although not a comprehensive list, some possible factors that could negatively affect our share price or result in fluctuations in the price or trading volume of our common stock include:

- actual or anticipated variations in our quarterly operating results or distributions;
- changes in our earnings estimates, or publications of research, news, or other reports about us or the real estate industry;
- changes in market valuations of similar companies;
- changes in the market value of our facilities;
- adverse market reaction to any increased indebtedness we incur in the future;
- additions or departures of key management personnel;
- actions by institutional stockholders;
- an oversupply of, or a reduction in demand for, general acute care hospitals, behavioral health facilities, IRFs, LTACHs, or freestanding ER/urgent care facilities;
- speculation in the press or investment community;
- short-selling activity;
- the financial performance and health of our tenants; and
- general market and economic conditions, including inflation and rising interest rates.

***Future sales of common stock may have adverse effects on our stock price.***

We cannot predict the effect, if any, of future sales of common stock on the market price of our common stock. Sales of substantial amounts of common stock, or the perception that these sales could occur, may adversely affect prevailing market prices for our common stock. If the market price of our common stock declines significantly, you may be unable to sell your shares at or above your purchase price. In addition, such a share price decline could impair our ability to raise future capital through a sale of additional equity securities.

***Downgrades in our credit ratings could have a material adverse effect on our cost and availability of capital.***

As of February 17, 2023, our issue-level rating on our unsecured notes remained at BBB-, while our corporate credit rating from S&P remained at BB+ and our corporate family rating from Moody's Investors Service was Ba1. On December 22, 2022, all of our ratings with S&P were placed on negative credit watch. There can be no assurance that we will be able to maintain our current credit ratings. Any downgrades in terms of ratings or outlook by any or all of the rating agencies could have a material adverse effect on our cost and availability of capital, which could in turn have a material adverse effect on our financial condition and results of operations.

***An increase in market interest rates may have an adverse effect on the market price of our securities.***

One of the factors that investors may consider in deciding whether to buy or sell our securities is our dividend rate as a percentage of our price per share of common stock, relative to market interest rates. If market interest rates continue to increase, prospective investors may desire a higher distribution on our securities or seek securities paying higher distributions. The market price of our common stock likely will be based primarily on the earnings that we derive from rental and interest income with respect to our facilities and our related distributions to stockholders, and not from the underlying appraised value of the facilities themselves. As a result, interest rate fluctuations and capital market conditions can affect the market price of our common stock. In addition, rising interest rates would result in increased interest expense on our variable-rate debt, thereby adversely affecting cash flow and our ability to service our indebtedness and make distributions.

## **RISKS RELATING TO REAL ESTATE INVESTMENTS**

***Our investments are and are expected to continue to be concentrated in a single industry segment, making us more vulnerable economically than if our investments were more diversified.***

We acquire, develop, and make investments in healthcare real estate. In addition, we selectively make investments in healthcare operators. We are subject to risks inherent in concentrating investments in real estate. The risks resulting from a lack of diversification become even greater as a result of our business strategy to invest solely in healthcare facilities. A downturn in the real estate industry could materially adversely affect the value of our facilities. A downturn in the healthcare industry could negatively affect our tenants' ability to make lease or loan payments to us as well as our return on our equity investments. Consequently, our ability to meet debt service obligations or make distributions to our stockholders is dependent on the real estate and healthcare industries.

***Our facilities may not have efficient alternative uses, which could impede our ability to find replacement tenants in the event of termination or default under our leases.***

Primarily all of the facilities in our current portfolio are net-leased healthcare facilities. If we, or our tenants, terminate the leases for these facilities, or if these tenants lose their regulatory authority to operate these facilities, we may not be able to locate suitable replacement tenants to lease the facilities for their specialized uses. Alternatively, we may be required to spend substantial amounts to adapt the facilities to other uses. Any loss of revenues or additional capital expenditures occurring as a result could have a material adverse effect on our financial condition and results of operations and could hinder our ability to meet debt service obligations or make distributions to our stockholders.

***Illiquidity of real estate investments could significantly impede our ability to respond to adverse changes in the performance of our facilities and harm our financial condition.***

Real estate investments are relatively illiquid. Additionally, the real estate market is affected by many factors beyond our control, including adverse changes in global, national, and local economic and market



conditions and the availability, costs, and terms of financing. Our ability to quickly sell or exchange any of our facilities in response to changes in economic and other conditions will be limited. No assurances can be given that we will recognize full value for any facility that we are required to sell for liquidity reasons. Our inability to respond rapidly to changes in the performance of our investments could adversely affect our financial condition and results of operations.

***Development and construction risks could adversely affect our ability to service debt and make distributions.***

We have developed and constructed facilities in the past and are currently developing several facilities. Our development and related construction activities may subject us to the following risks: we may have to compete for suitable development sites; our ability to complete construction is dependent on there being no title, environmental, or other legal proceedings arising; we may be subject to delays due to weather conditions, strikes, supply chain disruptions, available labor, and other contingencies beyond our control; we may be unable to obtain, or suffer delays in obtaining necessary zoning, land-use, building, occupancy, and other required governmental permits, which could result in increased costs, delays, or our abandonment of these projects; and we may incur construction costs for a facility which exceed our original estimates due to increased costs for materials or labor or other costs that we did not anticipate.

We expect to fund our development projects over time. The time frame required for development and construction of these facilities means that we may have to wait for some time to earn significant cash returns. In addition, our tenants may not be able to obtain managed care provider contracts in a timely manner or at all. Risks associated with our development projects may reduce anticipated rental revenue, which could affect our ability to service our debt and make distributions.

***We may be subject to risks arising from future acquisitions of real estate.***

We may be subject to risks in connection with our acquisition of healthcare real estate, including:

- we may have no previous business experience with the tenants at the facilities acquired, and we may face difficulties in working with them;
- underperformance of the acquired facilities due to various factors, including unfavorable terms and conditions of any acquired lease agreements, disruptions caused by the management of our tenants, or changes in economic conditions;
- diversion of our management's attention away from other business concerns;
- exposure to any undisclosed or unknown potential liabilities (including environmental liabilities) relating to the acquired facilities (or entities acquired in a share deal); and
- potential underinsured losses on the acquired facilities.

We cannot assure you that we will be able to manage the new properties without encountering difficulties or that any such difficulties will not have a material adverse effect on us.

***Our facilities may not achieve expected results, which may harm our financial condition and operating results and our ability to service our debt and make the distributions to our stockholders required to maintain our REIT status.***

Acquisitions and developments entail risks that investments will fail to perform in accordance with expectations and that estimates of the costs of necessary improvements may prove inaccurate, as well as general investment risks associated with any new real estate investment. Newly-developed or newly-renovated facilities may not have operating histories that are helpful in making objective pricing decisions. The purchase prices of these facilities will be based in part upon projections by management as to the expected operating results of the

facilities, subjecting us to risks that these facilities may not achieve anticipated operating results or may not achieve these results within anticipated time frames. If our facilities do not achieve expected results and generate ample cash flows from operations, amounts available to service our debt or to make distributions to stockholders in order to maintain our status as a REIT could be adversely affected.

***We may suffer losses that are not covered by insurance or that are in excess of our insurance coverage limits.***

Our leases and mortgage loans generally require our tenants/borrowers to carry property, general liability, professional liability, loss of earnings, all risk, and extended coverage insurance in amounts sufficient to permit the replacement of the facility in the event of a total loss, subject to applicable deductibles. We carry general liability insurance and loss of earnings coverage on all of our properties as a contingent measure in case our tenant's coverage is not sufficient. However, there are certain types of losses, generally of a catastrophic nature, such as earthquakes, floods, hurricanes, and acts of terrorism, which may be uninsurable or not insurable at a price we or our tenants/borrowers can afford. Inflation, changes in building codes and ordinances, environmental considerations, and other factors also might make it impracticable to use insurance proceeds to replace a facility after it has been damaged or destroyed. Under such circumstances, the insurance proceeds we receive might not be adequate to restore our economic position with respect to the affected facility. If any of these or similar events occur, it may reduce our return from the facility and the value of our investment. We continually review the insurance maintained by our tenants/borrowers and believe the coverage provided to be adequate and customary for similarly situated companies in our industry. However, we cannot provide any assurances that such insurance will be available at a reasonable cost in the future. Also, we cannot assure you that material uninsured losses, or losses in excess of insurance proceeds, will not occur in the future.

***Capital expenditures for facility renovation may be greater than anticipated and may adversely impact rent payments by our tenants and our ability to service debt and make distributions to stockholders.***

Facilities, particularly those that consist of older structures, have an ongoing need for capital improvements, including periodic replacement of fixtures and fixed equipment. Although our leases generally require our tenants to be primarily responsible for the cost of such expenditures, renovation of facilities involves certain risks, including the possibility of environmental problems, regulatory requirements, construction cost overruns and delays, uncertainties as to market demand or deterioration in market demand after commencement of renovation, and the emergence of unanticipated competition from other facilities. All of these factors could adversely impact rent and loan payments by our tenants and returns on our equity investments, which in turn could have a material adverse effect on our financial condition, results of operations, and our ability to service debt and make distributions.

***All of our healthcare facilities are subject to property taxes that may increase in the future and adversely affect our business.***

Our facilities are subject to real and personal property taxes that may increase as property tax rates change and as the facilities are assessed or reassessed by taxing authorities. Our leases generally provide that the property taxes are charged to our tenants as an expense related to the facilities that they occupy. As the owner of the facilities, however, we are ultimately responsible for payment of the taxes to the government. If property taxes increase, our tenants may be unable to make the required tax payments, ultimately requiring us to pay the taxes. If we incur these tax liabilities, our ability to service our debt and make expected distributions to our stockholders could be adversely affected. In addition, if such taxes increase on properties in which we have an equity investment in the tenant, our return on investment maybe negatively affected.

***As the owner and lessor of real estate, we are subject to risks under environmental laws, the cost of compliance with which and any violation of which could materially adversely affect us.***

Various environmental laws may impose liability on the current or prior owner or operator of real property for removal or remediation of hazardous or toxic substances. Current or prior owners or operators may also be

liable for government fines and damages for injuries to persons, natural resources, and adjacent property. These environmental laws often impose liability whether or not the owner or operator knew of, or was responsible for, the presence or disposal of the hazardous or toxic substances. The cost of complying with environmental laws could materially adversely affect our ability to service our debt or make distributions to our stockholders. In addition, the presence of hazardous or toxic substances, or the failure of our tenants to properly manage, dispose of, or remediate such substances, including medical waste generated by other healthcare operators, may adversely affect our tenants or our ability to use, sell, or rent such property or to borrow using such property as collateral which, in turn, could reduce our revenue and our financing ability. We typically obtain Phase I environmental assessments (or similar studies) on facilities we acquire or develop or on which we make mortgage loans. However, even if the Phase I environmental assessment reports do not reveal any material environmental contamination, it is possible that material environmental contamination and liabilities may exist, of which we are unaware.

Although our leases and mortgage loans require our operators to comply with laws and regulations governing their operations, including the disposal of medical waste, and to indemnify us for environmental liabilities, the scope of their obligations may be limited. We cannot assure you that our tenants would be able to fulfill their indemnification obligations and, therefore, any material violation of environmental laws could have a material adverse effect on us. In addition, environmental laws are constantly evolving, and changes in laws or regulations, or changes in interpretations of the foregoing, could create liabilities where none exist today.

***Our interests in facilities through ground leases expose us to the loss of the facility upon breach or termination of the ground lease, may limit our use of the facility, and may result in additional expense to us if our tenants vacate our facility.***

We have acquired interests in 29 facilities, at least in part, by acquiring leasehold interests in the land on which the facility is located rather than an ownership interest in the property. As lessee under ground leases, we are exposed to the possibility of losing the property upon termination, or an earlier breach by us, which could be a negative impact to our financial condition. Ground leases may also restrict our use of facilities, which may limit our flexibility in renting the facility and may impede our ability to sell the property. Finally, if our facility lease expires or is terminated for whatever reason resulting in the tenant vacating the facility, we would be responsible for the ground lease payments until we found a replacement tenant, which would negatively impact our cash flows and results of operations.

## **RISKS RELATING TO THE HEALTHCARE INDUSTRY**

***The continued pressure on fee-for-service reimbursement from third-party payors and the shift towards alternative payment models, could adversely affect the profitability of our tenants and hinder their ability to make payments to us.***

Sources of revenue for our tenants may include the Medicare and Medicaid programs, private insurance carriers, and health maintenance organizations, among others. In addition to ongoing efforts to reduce healthcare costs, the failure of any of our tenants to comply with various laws and regulations could jeopardize their ability to continue participating in Medicare, Medicaid, and other government-sponsored payment programs.

The shift in our tenant payor mix away from fee-for-service payors results in an increase in the percentage of revenues attributable to alternative payment models implemented by private and government payors, which can lead to reductions in reimbursement for services provided by our tenants. There is continued focus on transitioning Medicare from its traditional fee-for-service model to models that employ one or more capitated, value-based, or bundled payment approaches, and private payors have implemented similar types of alternative payment models. Such efforts from private and government payors, in addition to general industry trends, continue to place pressures on our tenants to control healthcare costs. Furthermore, pressures to control healthcare costs and a shift away from traditional health insurance reimbursement have resulted in an increase in

the number of patients whose healthcare coverage is provided under managed care plans, such as health maintenance organizations and preferred provider organizations. These shifts place further cost pressures on our tenants. We also continue to believe that, due to the aging of the population and the expansion of governmental payor programs, there will be a marked increase in the number of patients relying on healthcare coverage provided by governmental payors. In instances where we have an equity investment in our tenants' operations, in addition to the effect on these tenants' ability to meet their financial obligations to us, our ownership and investment interests may also be negatively impacted.

The CMS regulatory restrictions on reimbursement for LTACHs and IRFs can lead to reduced reimbursement for our tenants that operate such facilities and departments. CMS continues to explore restrictions on LTACH and IRF reimbursement focused on more restrictive facility and patient level criteria.

The Reform Law enacted in 2010 represented a major shift in the U.S. healthcare industry by, among other things, allowing millions of formerly uninsured individuals to obtain health insurance coverage and by significantly expanding Medicaid.

We cannot predict with absolute precision how these changes will affect the long-term financial condition of our tenants. However, any significant negative impact to our tenants could have a material adverse effect on our financial condition and results of operations and could negatively affect our ability to service our debt and make distributions to our stockholders.

***Significant regulation and loss of licensure or certification or failure to obtain licensure or certification could negatively impact our tenants' financial condition and results of operations and affect their ability to make payments to us.***

The U.S. healthcare industry is highly regulated by federal, state, and local laws and is directly affected by federal conditions of participation, state licensing requirements, facility inspections, state and federal reimbursement policies, regulations concerning capital and other expenditures, certification requirements and other such laws, regulations, and rules. As with the U.S. healthcare industry, our tenants in Australia, the United Kingdom, South America, and other parts of Europe are also subject in some instances to comparable types of laws, regulations, and rules that affect their ownership and operation of healthcare facilities. Although our lease and mortgage loan agreements require our tenants/borrowers to comply with applicable laws, and we intend for these facilities to comply with such laws, we do not actively monitor compliance. Therefore, we cannot offer any assurance that our tenants/borrowers will be found to be in compliance with such, as the same may ultimately be implemented or interpreted.

From time-to-time, our tenants are subject to various federal and state inquiries, investigations, and other proceedings and would expect such governmental compliance and enforcement activities to be ongoing at any given time with respect to one or more of our tenants, either on a confidential or public basis. An adverse result to our tenant/borrower in one or more such governmental proceedings may have a material adverse effect on their operations and financial condition and on its ability to make required lease and/or loan payments to us. In instances where we have an equity investment in the operator, in addition to the effect on these tenants'/borrowers' ability to meet their financial obligation to us, our ownership and investment interests may be negatively impacted.

In the U.S., licensed health care facilities must comply with minimum health and safety standards and are subject to survey and inspection by state and federal agencies and their agents or affiliates, including CMS, The Joint Commission, and state departments of health. CMS develops Conditions of Participation and Conditions for Coverage that health care organizations must meet in order to begin and continue participating in the Medicare and Medicaid programs and receive payment under such programs. These minimum health and safety standards are aimed at improving quality and protecting the health and safety of beneficiaries, and there are several common criteria that exist across health entities. The failure to comply with any of these standards could

jeopardize a healthcare organization's Medicare certification and, in turn, its right to receive payment under the Medicare and Medicaid programs.

Further, many hospitals and other institutional providers in the U.S. are accredited by accrediting organizations, such as The Joint Commission. The Joint Commission was created to accredit healthcare providers, including our tenants that meet its minimum health and safety standards. A national accrediting organization, such as The Joint Commission, enforces standards that meet or exceed such requirements. Once hospitals achieve a minimum number of patients and approximately every three years thereafter, surveyors for The Joint Commission conduct on site surveys of facilities for compliance with a multitude of patient safety, treatment, and administrative requirements. Facilities may lose accreditation for failure to meet such requirements, which in turn may result in the loss of license or certification including under the Medicare and Medicaid programs, as well as inability to participate in certain managed care plans, which require the healthcare provider to be accredited.

Finally, healthcare facility reimbursement practices and quality of care issues may result in loss of license or certification, such as engaging in the practice of "upcoding," whereby services are billed for higher procedure codes, or an event involving poor quality of care, which leads to the serious injury or death of a patient. The failure of any tenant/borrower to comply with such laws, requirements, and regulations resulting in a loss of its license would affect its ability to continue its operation of the facility and would adversely affect its ability to make lease and/or loan payments to us. This, in turn, could have a material adverse effect on our financial condition and results of operations and could negatively affect our ability to service our debt and make distributions.

In addition, establishment of healthcare facilities and transfers of operations of healthcare facilities in the U.S. are typically subject to regulatory approvals, such as federal antitrust laws and state certificate of need laws in the U.S. Restrictions and delays in transferring the operations of healthcare facilities, in obtaining new third-party payor contracts, including Medicare and Medicaid provider agreements, and in receiving licensure and certification approval from appropriate state and federal agencies by new tenants, may affect our ability to terminate lease agreements, remove tenants that violate lease terms, and replace existing tenants with new tenants. Furthermore, these matters may affect a new tenant's/borrower's ability to obtain reimbursement for services rendered, which could adversely affect its ability to make lease and/or loan payments to us. In instances where we have an equity investment in the operator, in addition to the effect on these tenants'/borrowers' ability to meet their financial obligations to us, our ownership and investment interests may also be negatively impacted.

***Our tenants are subject to fraud and abuse laws, the violation of which by a tenant may jeopardize the tenant's ability to make payments to us and adversely affect their profitability.***

As noted earlier, in the U.S., the federal government and numerous state governments have passed laws and regulations that attempt to eliminate healthcare fraud and abuse by prohibiting business arrangements that induce patient referrals, the ordering of specific ancillary services, or the submission of false claims for payment. The trend towards increased investigation and enforcement activity in the areas of fraud and abuse and patient self-referrals to detect and eliminate fraud and abuse in the Medicare and Medicaid programs is likely to continue in future years. As described above, the penalties for violations of these laws can be substantial and may result in the imposition of criminal and civil penalties and possible exclusion from federal and state healthcare programs. Imposition of any of these penalties upon any of our tenants could jeopardize a tenant's ability to operate a facility or to make lease and/or loan payments, thereby potentially adversely affecting us.

In the case of an acquisition of a provider's operations, some of our tenants have accepted an assignment of the previous operator's Medicare provider agreement. Such operators that take assignment of Medicare provider agreements might be subject to liability for federal or state regulatory, civil, and criminal investigations of the previous owner's operations and claims submissions. These types of issues may not be discovered prior to purchase or after our tenants commence operations in these facilities. Adverse decisions, fines, or recoupments

might negatively impact our tenants' financial condition, and in turn their ability to make lease and/or loan payments to us.

***Certain of our lease arrangements may be subject to laws related to fraud and abuse or physician self-referrals.***

Physician investment in subsidiaries that lease our facilities could subject our leases to scrutiny under fraud and abuse and physician self-referral laws. Under the Stark Law, and its implementing regulations, if our leases do not satisfy the requirements of an applicable exception, the ability of our tenants to bill for services provided to Medicare beneficiaries pursuant to referrals from physician investors could be adversely impacted and subject our tenants to fines, which could impact our tenants' ability to make lease and/or loan payments to us. In instances where we have an equity investment in our tenants' operations, in addition to the effect on the tenants' ability to meet their financial obligations to us, our ownership and investment interests may also be negatively impacted. Therefore, in all cases, we intend to use our good faith efforts to structure our lease arrangements to comply with these laws.

***We may be required to incur substantial renovation costs to make our healthcare properties suitable for other tenants.***

Healthcare facilities are typically highly customized and subject to healthcare-specific building code requirements. The improvements generally required to conform a property to healthcare use can be costly and at times tenant-specific. A new or replacement operator may require different features in a property, depending on that operator's particular business. If a current operator is unable to pay rent and/or vacates a property, we may incur substantial expenditures to modify a property before we are able to secure another tenant. Also, if the property needs to be renovated to accommodate multiple tenants, or regulatory requirements, we may incur substantial expenditures before we are able to re-lease the space. These expenditures or renovations may have a material adverse effect on our business, results of operations, and financial condition.

***State certificate of need laws may adversely affect our development of facilities and the operations of our tenants.***

Certain healthcare facilities in which we invest may be subject to state laws in the U.S. which require regulatory approval in the form of a certificate of need prior to the transfer of a healthcare facility or prior to initiation of certain projects, including the establishment of new or replacement facilities, the addition of beds, the addition or expansion of services, and certain capital expenditures. State certificate of need laws are not uniform throughout the U.S., are subject to change, and may delay developments of facilities or acquisitions or certain other transfers of ownership of facilities. We cannot predict the impact of state certificate of need laws on any of the preceding activities or on the operations of our tenants. Certificate of need laws often materially impact the ability of competitors to enter into the marketplace of our facilities. As a result, a portion of the value of the facility may be related to the limitation on new competitors. In the event of a change in the certificate of need laws, this value may markedly change.

## **RISKS RELATING TO OUR ORGANIZATION AND STRUCTURE**

***We depend on key personnel, the loss of any one of whom may threaten our ability to operate our business successfully.***

We depend on the services of our executives and other officers to carry out our business and investment strategy. If we were to lose any of these, it may be more difficult for us to locate attractive acquisition targets, complete our acquisitions, and manage the facilities that we have acquired or developed. Additionally, as we expand, we will continue to need to attract and retain additional qualified officers and employees. The loss of the services of any of our officers, or our inability to recruit and retain qualified personnel in the future, could have a material adverse effect on our business and financial results.

***Pursuant to Maryland law, our charter and bylaws contain provisions that may have the effect of deterring changes in management and third-party acquisition proposals, which in turn could depress the price of our common stock or cause dilution.***

Our charter contains ownership limitations that may restrict business combination opportunities, inhibit change of control transactions, and reduce the value of our common stock. To qualify as a REIT under the Code, no more than 50% in value of our outstanding stock, after taking into account options to acquire stock, may be owned, directly or indirectly, by five or fewer persons during the last half of each taxable year. Our charter generally prohibits direct or indirect ownership by any person of more than 9.8% in value or in number, whichever is more restrictive, of outstanding shares of any class or series of our securities, including our common stock. Generally, our common stock owned by affiliated owners will be aggregated for purposes of the ownership limitation. The ownership limitation could have the effect of delaying, deterring, or preventing a change in control or other transaction in which holders of common stock might receive a premium for their common stock over the then-current market price or which such holders otherwise might believe to be in their best interests. The ownership limitation provisions also may make our common stock an unsuitable investment vehicle for any person seeking to obtain, either alone or with others as a group, ownership of more than 9.8% of either the value or number of the outstanding shares of our common stock.

Our charter and bylaws contain provisions that may impede third-party acquisition proposals. Our charter and bylaws also provide restrictions on replacing or removing directors. Directors may be removed by the affirmative vote of the holders of two-thirds of our common stock. Additionally, stockholders are required to give us advance notice of director nominations. Special meetings of stockholders can only be called by our president, our board of directors, or the holders of at least 25% of stock entitled to vote at the meetings. These and other charter and bylaw provisions may delay or prevent a change of control or other transaction in which holders of our common stock might receive a premium for their common stock over the then-current market price or which such holders otherwise might believe to be in their best interests.

***We rely on information technology in our operations, and any material failure, inadequacy, interruption, or security failure of our technology (or that of our third-party vendors) could harm our business.***

We rely on information technology networks and systems, including the Internet, to process, transmit, and store electronic information, and to manage or support a variety of business processes, including financial transactions and records, and maintaining personal identifying information (in accordance with GDPR law in Europe and similar laws elsewhere) along with tenant and lease data. We purchase or license some of our information technology from vendors. We rely on commercially available systems, software, tools, and monitoring to provide security for the processing, transmission, and storage of confidential data. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems' improper functioning or the improper access or disclosure of our or our tenant's information, such as in the event of cyber-attacks. Further, our failure to protect the security of our information systems and data maintained in those systems could subject us to liability under various U.S. federal and state, and foreign privacy laws and regulations.

Even well-protected information systems remain potentially vulnerable because the techniques used in security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. Accordingly, we may be unable to anticipate these techniques or to implement adequate security barriers or other preventative measures, and thus it is impossible for us to entirely mitigate this risk.

A security breach, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, or other significant disruption involving our IT networks and related systems (or that of our third-party vendors) could:

- disrupt the proper functioning of our networks and systems and therefore our operations, possibly for an extended period of time;

- result in misstated financial reports, violations of loan covenants, and/or missed reporting deadlines;
- result in our inability to properly monitor our compliance with regulations regarding our qualification as a REIT;
- result in the unauthorized access to, and destruction, loss, theft, misappropriation, or release of proprietary, confidential, sensitive, or otherwise valuable information of ours or others, which others could use to compete against us or for disruptive, destructive, or otherwise harmful purposes;
- require management attention and resources to remedy any resulting damages;
- subject us to liability claims or regulatory penalties; or
- damage our reputation among our tenants and investors generally.

Any of the foregoing could have a materially adverse effect on our business, financial condition, and results of operations.

***Unfavorable resolution of pending and future litigation or other regulatory proceedings could have a material adverse effect on our financial condition.***

From time-to-time, we may be involved in litigation and regulatory proceedings. Additionally, we may be named as defendants in lawsuits arising out of the actions of our tenants, in which such tenants have agreed to indemnify, defend, and hold us harmless from and against various claims, litigation, and liabilities. An unfavorable resolution of pending or future litigation, regulatory proceedings, or other claims may have a material adverse effect on our business, results of operations, and financial condition. Regardless of outcome, litigation and regulatory proceedings may result in substantial costs and expenses, significantly divert the attention of management, and could damage our reputation. An unfavorable outcome may result in our having to pay significant fines, judgments, or settlements, which, if not indemnifiable by our tenants, or if uninsured, or if exceeding insurance coverage, could adversely impact our financial condition, cash flows, results of operations, and the trading price of our common stock.

***Changes in accounting pronouncements could adversely affect us and the reported financial performance of our tenants.***

Uncertainties posed by various initiatives of accounting standard-setting by the Financial Accounting Standards Board (“FASB”) and the SEC, which create and interpret applicable accounting standards for U.S. companies, may change the financial accounting and reporting standards or their interpretation and application of these standards that govern the preparation of our financial statements.

These changes could have a material impact on our reported financial condition and results of operations. In some cases, we could be required to apply a new or revised standard retroactively, resulting in potentially material restatements of prior period financial statements. Similarly, these changes could have a material impact on our tenants’/borrowers’ reported financial condition or results of operations or could affect our tenants’ preferences regarding leasing real estate.

## **TAX RISKS**

***Loss of our tax status as a REIT would have significant adverse consequences to us and the value of our common stock.***

We believe that we qualify as a REIT as of December 31, 2022. In addition, we own a direct interest in two subsidiary REITs that have elected to be taxed as a REIT commencing with the 2019 and 2022 tax years, respectively. The REIT qualification requirements are extremely complex, and interpretations of the federal income tax laws governing qualification as a REIT are limited. Accordingly, there is no assurance that we will be



successful in operating so as to qualify as a REIT. At any time, new laws, regulations, interpretations, or court decisions may change the federal tax laws relating to, or the federal income tax consequences of, qualification as a REIT. It is possible that future economic, market, legal, tax, or other considerations may cause our board of directors to revoke the REIT election, which it may do without stockholder approval.

If we lose or revoke our REIT status (currently or with respect to any tax years for which the statute of limitations has not yet expired), we will face serious tax consequences that will substantially reduce the funds available for distribution because we would not be allowed a deduction for distributions to stockholders in computing our taxable income; therefore, we would be subject to federal income tax at regular corporate rates, and we might need to borrow money or sell assets in order to pay any such tax. We also could be subject to increased state and local taxes. Unless we are entitled to relief under statutory provisions, we also would be disqualified from taxation as a REIT for the four taxable years following the year during which we ceased to qualify.

As a result of all these factors, a loss or revocation of our REIT status could have a material adverse effect on our financial condition and results of operations and would adversely affect the value of our common stock.

***Failure to make required distributions as a REIT would subject us to tax.***

In order to qualify as a REIT, each year we must distribute to our stockholders at least 90% of our REIT taxable income, excluding net capital gains. To the extent that we satisfy the distribution requirement, but distribute less than 100% of our taxable income, we will be subject to federal corporate income tax on our undistributed income. In addition, we will incur a 4% nondeductible excise tax on the amount, if any, by which our distributions in any year are less than the sum of (1) 85% of our ordinary income for that year; (2) 95% of our capital gain net income for that year; and (3) 100% of our undistributed taxable income from prior years.

We may be required to make distributions to stockholders at disadvantageous times or when we do not have funds readily available for distribution. Differences in timing between the recognition of income and the related cash receipts or the effect of required debt amortization payments could require us to borrow money or sell assets to pay out enough of our taxable income to satisfy the distribution requirement and to avoid corporate income tax and the 4% excise tax in a particular year. In the future, we may borrow to pay distributions to our stockholders. Any funds that we borrow would subject us to interest rate and other market risks.

***Complying with REIT requirements may cause us to forego otherwise attractive opportunities.***

To qualify as a REIT for U.S. federal income tax purposes, we must continually satisfy tests concerning, among other things, the sources of our income, the nature and diversification of our assets, the amounts we distribute to our stockholders, and the ownership of our stock. In order to meet these tests, we may be required to forego attractive business or investment opportunities. Currently, no more than 20% of the value of our assets may consist of securities of one or more TRS and no more than 25% of the value of our assets may consist of securities that are not qualifying assets under the test requiring that 75% of a REIT's assets consist of real estate and other related assets. In addition, at least 95% of our gross income in any year must be derived from qualifying sources and at least 75% of our gross income must be generated from either rents from real estate or interest on loans secured by real estate (i.e. mortgage loans). Further, a TRS may not directly or indirectly operate or manage a healthcare facility. Compliance with current and future changes to REIT requirements may limit our flexibility in executing our business plan.

***If certain sale-leaseback transactions are not characterized by the Internal Revenue Service ("IRS") or similar tax authorities internationally as "true leases," we may be subject to adverse tax consequences.***

We have purchased certain properties and leased them back to the sellers of such properties. We intend for any such sale-leaseback transactions to be structured in a manner that the lease will be characterized as a "true

lease,” thereby allowing us to be treated as the owner of the property for income tax purposes. However, depending on the terms of any specific transaction, taxing authorities might take the position that the transaction is not a “true lease”. In the event any sale-leaseback transaction is challenged and successfully re-characterized, we might not be able to deduct depreciation expense on the real estate, resulting in potential higher income taxes.

***Transactions with TRSs may be subject to excise tax.***

We have historically entered into leases and other transactions with our TRS and its subsidiaries and expect to continue to do so in the future. Under applicable rules, transactions such as leases between our TRS and its parent REIT that are not conducted on a market terms basis may be subject to a 100% excise tax. While we believe that all of our transactions with our TRS are at arm’s length, imposition of a 100% excise tax could have a material adverse effect on our financial condition and results of operations.

***Loans to our tenants could be characterized as equity, in which case our income from that tenant might not be qualifying income under the REIT rules and we could lose our REIT status.***

Our TRS may make loans to tenants of our facilities to acquire operations or for working capital purposes. The IRS may take the position that certain loans to tenants should be treated as equity interests rather than debt, and that our interest income from such tenant should not be treated as qualifying income for purposes of the REIT gross income tests. If the IRS were to successfully treat a loan to a particular tenant as an equity interest, the tenant would be a “related party tenant” with respect to our company and the rent that we receive from the tenant would not be qualifying income for purposes of the REIT gross income tests. As a result, we could be in jeopardy of failing the 75% income test discussed above, which if we did would cause us to lose our REIT status. In addition, if the IRS were to successfully treat a particular loan as interests held by our operating partnership rather than by our TRS, we could fail the 5% asset test, and if the IRS further successfully treated the loan as other than straight debt, we could fail the 10% asset test with respect to such interest. As a result of the failure of either test, we could lose our REIT status, which would subject us to corporate level income tax and adversely affect our ability to service our debt and make distributions to our stockholders.

***Certain transfers may generate prohibited transaction income, resulting in a penalty tax on gain attributable to the transaction.***

From time-to-time, we may transfer or otherwise dispose of some of our properties, including by contributing properties as part of joint venture investments. Under the Code, any gain resulting from transfers of properties we hold as inventory or primarily for sale to customers in the ordinary course of business is treated as income from a prohibited transaction subject to a 100% penalty tax. We do not believe that our transfers or disposals of property or our contributions of properties into joint venture investments are prohibited transactions. However, whether property is held for investment purposes is a question of fact that depends on all the facts and circumstances surrounding the particular transaction. The IRS may contend that these types of transfers or dispositions are prohibited transactions. While we believe that the IRS would not prevail in any such dispute, if the IRS were to argue successfully that a transfer, disposition, or contribution of property constituted a prohibited transaction, we would be required to pay a 100% penalty tax on any gain allocable to us from the prohibited transaction. In addition, income from a prohibited transaction might adversely affect our ability to satisfy the income tests for qualification as a REIT.

***Changes in U.S. or foreign tax laws, regulations, including changes to tax rates, may adversely affect our results of operations.***

We are headquartered in the U.S. with subsidiaries and investments globally and are subject to income taxes in these jurisdictions. Significant judgment is required in determining our provision for income taxes. Although we believe that we have adequately assessed and accounted for our potential tax liabilities, and that our tax estimates are reasonable, there can be no assurance that additional taxes will not be due upon audit of our tax

returns or as a result of changes to applicable tax laws. The U.S. government, as well as the governments of many of the locations in which we operate (such as Australia, Germany, the United Kingdom, Colombia, Portugal, Spain, Finland, and Luxembourg, which is where most of our Europe entities are domiciled) are actively discussing changes to corporate taxation. Our future tax expense could be adversely affected by these changes in tax laws or their interpretation, both domestically and internationally. Potential tax reforms being considered by many countries include changes that could impact, among other things, global tax reporting, intercompany transfer pricing arrangements, the definition of taxable permanent establishments, and other legal or financial arrangements. The nature and timing of any changes to each jurisdiction's tax laws and the impact on our future tax exposure both in the U.S. and abroad cannot be predicted with any accuracy but could materially and adversely impact our results of operations and cash flows.

**ITEM 1B. *Unresolved Staff Comments***

None.

## ITEM 2. Properties

At December 31, 2022, our portfolio (including properties in our five real estate joint ventures) consisted of 444 properties (439 owned and five in the form of a first lien mortgage loan). Of these facilities, 432 properties are operated by 55 different operators, while seven properties were under construction and five facilities were vacant.

	<u>Total Properties</u>	<u>Total 2022 Revenues</u>	<u>Total Assets(A)</u>
(Dollars in thousands)			
<b>United States:</b>			
Alabama .....	2	\$ 791	\$ 6,946
Arizona .....	18	65,468	563,324
Arkansas .....	2	10,593	80,627
California .....	20	147,281	1,450,112 (B)
Colorado .....	14	18,423	162,142
Connecticut .....	3	46,917	457,826
Florida .....	9	101,947	1,324,555
Idaho .....	6	34,236	253,858
Indiana .....	5	3,884	64,994
Iowa .....	1	4,912	50,701
Kansas .....	11	25,682	291,141 (C)
Kentucky .....	1	23,904	264,535
Louisiana .....	6	15,182	127,562
Massachusetts .....	10	53,114	761,694 (F)
Michigan .....	2	3,588	21,342
Missouri .....	4	16,693	129,738
Montana .....	1	1,830	18,494
Nevada .....	—	7,333	—
New Jersey .....	6	34,320	270,552
New Mexico .....	2	5,071	47,405
North Carolina .....	1	3,026	32,760
Ohio .....	9	45,763	354,922
Oklahoma .....	2	6,964	74,565
Oregon .....	1	11,453	89,682
Pennsylvania .....	9	78,513	573,420
South Carolina .....	8	13,830	131,977 (B)
Texas .....	52	157,550	1,967,948 (D)
Utah .....	7	139,204	1,224,484
Virginia .....	2	3,085	20,140
Washington .....	2	3,454	37,741
Wisconsin .....	1	3,348	23,007
Wyoming .....	3	9,106	95,905
Other assets .....	—	—	1,028,946
Total United States .....	220	\$1,096,465	\$12,003,045
<b>International:</b>			
Australia .....	11	\$ 61,239	\$ 854,582
Colombia .....	4	13,659	143,127
Germany .....	82	33,049	664,900 (F)
Italy .....	8	—	86,245 (F)
Portugal .....	2	3,232	50,072
Spain .....	9	7,274	222,316 (E)(F)
Switzerland .....	17	1,752	748,947 (F)
United Kingdom .....	87	317,013	4,083,244
Finland .....	4	9,168	219,309
Other assets .....	—	—	582,213
Total International .....	224	\$ 446,386	\$ 7,654,955
<b>Total</b> .....	<b>444</b>	<b>\$1,542,851</b>	<b>\$19,658,000</b>

- (A) Represents total assets at December 31, 2022.
- (B) Includes one development project still under construction at December 31, 2022.
- (C) Includes one facility that was vacant at December 31, 2022.
- (D) Includes two development projects still under construction and four facilities that were vacant at December 31, 2022. Our investment in facilities that were vacant at December 31, 2022 is less than 0.3% of total assets.
- (E) Includes three development projects still under construction at December 31, 2022.
- (F) For Germany, the U.S., Switzerland, Spain, and Italy, we own properties through five real estate joint venture arrangements. The table below shows revenues earned from our joint venture arrangements:

	<b>Total Properties</b>	<b>Total 2022 Revenues</b>
	<b>(Dollars in thousands)</b>	
Germany .....	71	\$ 60,637
U.S. .... (1)	8	55,443
Switzerland .....	17	44,345
Spain .....	2	6,806
Italy .....	8	7,709
<b>Total</b> .....	<u>106</u>	<u>\$174,940</u>

- (1) On March 14, 2022, we completed a transaction with MAM to form a joint venture (the “Macquarie Transaction”) in which we contributed eight Massachusetts-based general acute care hospitals that are leased to Steward for cash consideration and a 50% interest in the partnership. See Note 3 to Item 8 of this Annual Report on Form 10-K for more information regarding this transaction.

A breakout of our facilities at December 31, 2022 based on property type is as follows:

	<b>Number of Properties</b>	<b>Total Square Footage</b>	<b>Total Licensed Beds(A)</b>
General acute care hospitals .....	202	37,578,686	23,059
Behavioral health facilities .....	67	3,205,254	4,496
IRFs .....	112	12,692,798	16,244
LTACHs .....	20	1,174,007	939
FSERs .....	43	407,936	—
	<u>444</u>	<u>55,058,681</u>	<u>44,738</u>

- (A) Excludes our seven facilities that are under development.

The following table shows lease and loan expirations, assuming that none of the tenants/borrowers exercise any of their renewal options (dollars in thousands):

Total Lease and Loan Portfolio(1)	Total Leases/ Loans(2)	Annualized Base Rent/ Interest(3)	% of Total Annualized Base Rent/ Interest	Total Square Footage	Total Licensed Beds
2023 .....	4	\$ 14,903	1.2%	912,652	703
2024 .....	1	2,731	0.2%	115,039	170
2025 .....	7	18,785	1.5%	1,371,928	792
2026 .....	4	2,333	0.2%	332,221	238
2027 .....	1	3,346	0.3%	102,948	13
2028 .....	4	5,832	0.5%	142,328	74
2029 .....	6	15,788	1.2%	689,378	405
2030 .....	11	6,053	0.5%	220,258	59
2031 .....	4	4,236	0.3%	172,655	89
2032 .....	41	64,384	5.1%	1,291,879	803
Thereafter .....	346	1,117,664	89.0%	47,798,993	40,684
Total .....	<u>429</u>	<u>\$1,256,055</u>	<u>100.0%</u>	<u>53,150,279</u>	<u>44,030</u>

- (1) Schedule includes leases and mortgage loans.
- (2) Reflects all properties, including properties owned through our real estate joint ventures, except vacant properties, seven facilities that are under development, and three properties leased to Prospect that we have agreed to sell as further described in Note 8 of Item 8 of this Annual Report on Form 10-K.
- (3) The December 2022 base rent and mortgage loan interest are annualized. This does not include tenant recoveries, additional rents, and other lease/loan-related adjustments to revenue (i.e., straight-line rents and deferred revenues).

### ITEM 3. Legal Proceedings

From time to time, we are a party to various legal proceedings, claims, or regulatory inquiries and investigations arising out of, or incident to, our ordinary course of business. While we are unable to predict with certainty the outcome of any particular matter, management does not expect, when such matters are resolved, that our resulting exposure to loss contingencies, if any, will have a material adverse effect on our consolidated financial position.

### ITEM 4. Mine Safety Disclosures

None.

## PART II

### ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

(a) Our common stock is traded on the New York Stock Exchange under the symbol "MPW." The following table sets forth the high and low sales prices for the common stock for the periods indicated, as reported by the New York Stock Exchange Composite Tape, and the dividends per share declared by us with respect to each such period.

	<u>High</u>	<u>Low</u>	<u>Dividends</u>
<b>Year Ended December 31, 2022</b>			
First Quarter . . . . .	\$ 24.13	\$ 19.51	\$ 0.29
Second Quarter . . . . .	21.55	14.10	0.29
Third Quarter . . . . .	17.36	11.35	0.29
Fourth Quarter . . . . .	13.33	9.90	0.29
<b>Year Ended December 31, 2021</b>			
First Quarter . . . . .	\$ 22.75	\$ 19.91	\$ 0.28
Second Quarter . . . . .	22.82	19.80	0.28
Third Quarter . . . . .	21.99	19.39	0.28
Fourth Quarter . . . . .	23.74	19.45	0.28

On February 17, 2023, the closing price for our common stock, as reported on the New York Stock Exchange, was \$12.96 per share. As of February 17, 2023, there were 44 holders of record of our common stock. This figure does not reflect the beneficial ownership of shares held in nominee name.

(b) Not applicable.

(c) Stock repurchases:


The table below summarizes repurchases of our common stock made during the quarter ended December 31, 2022:

<u>Period</u>	<u>Total number of shares purchased(1) (in thousands)</u>	<u>Average price per share</u>	<u>Total number of shares purchased as part of publicly announced programs(2) (in thousands)</u>	<u>Approximate dollar value of shares that may yet be purchased under the plans or programs (in thousands)</u>
October 1-October 31, 2022 . . . . .	1,116	\$10.88	1,075	
November 1-November 30, 2022 . . . . .	220	11.13	220	
December 1-December 31, 2022 . . . . .	349	10.89	349	
Total . . . . .	<u>1,685</u>	<u>\$10.92</u>	<u>1,644</u>	<u>\$482,085</u>

- (1) The number of shares purchased consists of shares of common stock purchased as part of a publicly announced program to purchase common stock of the Company as well as shares of common stock tendered by employees to satisfy the employees' tax withholding obligations arising as a result of vesting of restricted stock awards under the 2019 Equity Incentive Plan (the "Equity Incentive Plan"), which shares were purchased based on their fair market value on the vesting date.
- (2) On October 9, 2022, the board of directors of the Company authorized a stock repurchase program (the "Stock Repurchase Program") for up to \$500 million of common stock, par value \$0.001 per share. The

repurchase authorization expires October 10, 2023, does not obligate us to acquire any common stock, and is subject to market conditions and our ongoing determination of the best use of available cash.

The following graph provides comparison of cumulative total stockholder return for the period from December 31, 2017 through December 31, 2022, among us, the S&P 500 Index, MSCI U.S. REIT Index, and Dow Jones U.S. Real Estate Health Care Index. The stock performance graph assumes an investment of \$100 in us and the three indices, and the reinvestment of dividends. The historical information below is not indicative of future performance.



Index	Period Ending					
	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022
Medical Properties Trust, Inc. ....	100.00	125.03	173.20	188.88	215.82	110.06
S&P 500 Index .....	100.00	95.62	125.72	148.85	191.58	156.88
MSCI U.S. REIT Index .....	100.00	95.43	120.09	110.99	158.79	119.87
Dow Jones U.S. Real Estate Health Care Index .....	100.00	107.51	130.61	117.81	136.94	107.01

*The graph and accompanying text shall not be deemed incorporated by reference by any general statement incorporating by reference this Annual Report on Form 10-K into any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended.*

**ITEM 6. Reserved.**



## **ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*Unless otherwise indicated, references to "our," "we," and "us" in this management's discussion and analysis of financial condition and results of operations refer to Medical Properties Trust, Inc. and its consolidated subsidiaries, including MPT Operating Partnership, L.P.*

### **Overview**

We are a self-advised healthcare REIT that was incorporated in Maryland on August 27, 2003, primarily for the purpose of investing in and owning healthcare facilities to be leased to healthcare operators under long-term net leases. We may also make mortgage loans to healthcare operators that are collateralized by the underlying real estate. We conduct our business operations in one segment. We currently have healthcare investments in the U.S., Europe, Australia, and South America. Our existing tenants are, and our prospective tenants will generally be, healthcare operating companies and other healthcare providers that use substantial real estate assets in their operations. We offer financing to these operators through 100% lease and mortgage financing and generally seek lease and loan terms on a long-term basis (typically at least 15 years) with a series of shorter renewal terms, generally in five year increments, at the option of our tenants and borrowers. We also have included and intend to include in our lease and loan agreements annual contractual minimum rate increases. Our existing portfolio's minimum escalators are typically at least 2.0%. In addition, most of our leases and loans include rate increases based on the general rate of inflation (based on CPI or similar indices) if greater than the minimum contractual increases. Beyond rent or mortgage interest, our leases and loans typically require our tenants to pay all operating costs and expenses associated with the facility. Finally, from time-to-time, we may make noncontrolling investments in our tenants, typically in conjunction with larger real estate transactions with the tenant, that give us a right to share in such tenant's profits and losses and provide for certain minority rights and protections.

We may make other loans to certain of our operators through our TRSs, which the operators use for working capital. Although it represents only 1% of our total assets at December 31, 2022, we consider our lending business an important element of our overall business strategy for two primary reasons: (1) it provides opportunities to make income-earning investments that yield attractive risk-adjusted returns in an industry in which our management has expertise, and (2) by making debt capital available to certain qualified operators, we believe we create a competitive advantage for our company over other buyers of, and financing sources for, healthcare facilities.

At December 31, 2022, our portfolio (including real estate assets in joint ventures) consisted of 444 properties leased or loaned to 55 operators, of which seven were under development and five were in the form of mortgage loans.

The information set forth in this Item 7 is intended to provide readers with an understanding of our financial condition, changes in financial condition, and results of operations. This section generally discusses the results of our operations for the year ended December 31, 2022 compared to the year ended December 31, 2021. For a discussion of the year ended December 31, 2021 compared to the year ended December 31, 2020, please refer to Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022.

### **Selected Financial Data**

The following sets forth selected consolidated financial and operating data. You should read the following selected financial data in conjunction with the consolidated financial statements and notes thereto of each of Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. and their respective subsidiaries included in Item 8 to this Annual Report on Form 10-K.

	For the Years Ended December 31,	
	2022	2021
	(In thousands except per share data)	
<b>OPERATING DATA</b>		
Total revenues	\$1,542,851	\$1,544,669
Expenses:		
Interest	359,036	367,393
Real estate depreciation and amortization	332,977	321,249
Property-related	45,697	39,098
General and administrative	160,494	145,638
Total expenses	898,204	873,378
Other income (expense):		
Gain on sale of real estate	536,755	52,471
Real estate and other impairment charges, net	(268,375)	(39,411)
Earnings from equity interests	40,800	28,488
Debt refinancing and unutilized financing costs	(9,452)	(27,650)
Other (including fair value adjustments on securities)	15,344	45,699
Income tax (expense)	(55,900)	(73,948)
Net income	903,819	656,940
Net income attributable to non-controlling interests	(1,222)	(919)
Net income attributable to MPT common stockholders	\$ 902,597	\$ 656,021
Net income attributable to MPT common stockholders per diluted share	\$ 1.50	\$ 1.11
Weighted-average shares outstanding — diluted	598,837	590,139
<b>OTHER DATA</b>		
Dividends declared per common share	\$ 1.16	\$ 1.12
FFO(1)	\$ 934,312	\$ 975,988
Normalized FFO(1)	\$1,087,603	\$1,035,920
Normalized FFO per share(1)	\$ 1.82	\$ 1.75
Cash paid for acquisitions and other related investments	\$1,332,962	\$4,246,829

	December 31,	
	2022	2021
	(In thousands)	
<b>BALANCE SHEET DATA</b>		
Real estate assets — at cost . . . . .	\$15,917,839	\$17,425,765
Real estate accumulated depreciation/amortization . . . . .	(1,193,312)	(993,100)
Cash and cash equivalents . . . . .	235,668	459,227
Investments in unconsolidated real estate joint ventures . . . .	1,497,903	1,152,927
Investments in unconsolidated operating entities . . . . .	1,444,872	1,289,434
Other loans . . . . .	227,839	67,317
Other . . . . .	1,527,191	1,118,231
Total assets . . . . .	<u>\$19,658,000</u>	<u>\$20,519,801</u>
Debt, net . . . . .	\$10,268,412	\$11,282,770
Other liabilities . . . . .	795,181	791,360
Total Medical Properties Trust, Inc. stockholders' equity . . .	8,592,838	8,440,188
Non-controlling interests . . . . .	1,569	5,483
Total equity . . . . .	<u>8,594,407</u>	<u>8,445,671</u>
Total liabilities and equity . . . . .	<u>\$19,658,000</u>	<u>\$20,519,801</u>

- (1) See section titled “Non-GAAP Financial Measures” for an explanation of why these non-GAAP financial measures are useful along with a reconciliation to our GAAP earnings.

### **2022 Highlights**

In 2022, the value of our well-underwritten hospital investments was confirmed through strategic property sales that generated gains over \$535 million and cash proceeds of approximately \$2.2 billion. These sales were highlighted by the previously described partnership with MAM in which we sold the real estate of eight Massachusetts-based general acute care hospitals with a fair value of approximately \$1.7 billion, using proceeds to pay off an interim credit facility. Despite the economic uncertainty, high interest rates, and inflationary pressures that were prevalent throughout most of 2022, we invested approximately \$1 billion in hospital real estate, including expanding our footprint in Europe with our investment in four facilities in Finland. We also increased our availability and extended and improved pricing on our revolving credit and term loan facility in 2022. In addition, we initiated a stock repurchase program, through which we repurchased 1.6 million shares of common stock for \$17.9 million through December 31, 2022. Lastly, we increased our dividend to \$0.29 per share per quarter in 2022, which is the 8<sup>th</sup> consecutive year for such an increase.

A summary of additional 2022 activity is as follows:

- Acquired an additional six behavioral health facilities in the UK for approximately £233 million that are leased to Priory;
- Funded £96.5 million towards a £100 million participation in a syndicated term loan originated on behalf of Priory;
- Completed the Bakersfield development for \$47 million and commenced development of five additional facilities, including three in Spain;
- Re-tenanted our Watsonville facility, after the previous tenant filed for bankruptcy, and recovered \$32 million on a working capital loan that was previously reserved;
- Acquired six general acute care facilities, three located throughout Spain, two in the U.S., and one in Colombia, for approximately \$135 million that are leased to three different operators;

- Selected as one of Modern Healthcare’s Best Places to Work in healthcare in 2022, for the second consecutive year;
- Achieved internal growth by approximately \$30 million from increases in CPI above the contractual minimum escalations in our leases and loans; and
- Recorded a \$283 million impairment charge related to our tenant, Prospect, including \$171 million impairment on the Pennsylvania real estate and a \$112 million reserve on non-cash rent. We expect to record rent on our Prospect leases on a cash only basis for the foreseeable future.

Subsequent to December 31, 2022, the following activity took place:

- Announced the agreement to lease five facilities in Utah to Catholic Health Initiatives Colorado, a wholly-owned subsidiary of CommonSpirit Health, that are currently leased to Steward, subject to receipt of certain regulatory approvals and other customary closing conditions and
- Received approximately \$205 million from Lifepoint to pay off an outstanding loan, plus accrued interest, as part of their acquisition of a majority ownership interest in Springstone. We had funded this loan in October 2021 as part of our non-controlling investment in Springstone’s operations that was needed for us to complete the larger acquisition of Springstone’s 18 behavioral health hospitals. We will continue leasing these 18 facilities to Lifepoint.

### **2021 Highlights**

During 2021, our business and that of our tenants continued to be impacted by the COVID-19 pandemic. Like most of the world, our employees worked remotely through much of the year. While our offices re-opened in October 2021, we had less than 100% of our employees in the office due to spikes in COVID-19 and related variants throughout the fourth quarter. Despite the continued effects of the pandemic, MPT had a record year. In 2021, we invested approximately \$3.9 billion in hospital real estate, and our revenues surpassed \$1.5 billion for the first time in our history. Additionally, we maintained a strong liquidity position throughout the year and kept our leverage substantially in line with 2020 by raising more than \$1.0 billion in proceeds through sales of our common stock and receiving approximately \$0.5 billion from payoffs on our loan portfolio and proceeds from strategic divestitures. In addition, we lowered our weighted-average interest rate during 2021 by extending and improving pricing on our revolving credit and term loan facilities, completing an £850 million senior unsecured notes offering at a weighted-average rate of 2.9%, and completing a €500 million 0.993% senior unsecured notes offering, of which all of the proceeds were used to redeem our outstanding €500 million senior unsecured notes that had a higher interest rate of 4.000%. Finally, we increased our dividend to \$0.28 per share per quarter in 2021.

The COVID-19 pandemic had a severe impact on the world from a business and personal health perspective. However, as we have noted before, we believe this pandemic further validated our business model, which focuses on hospitals as the centerpiece of healthcare delivery across the world. In addition, the pandemic proved the ability of our employees and our hospital operators to overcome significant challenges for the good of our stakeholders and mankind.

A summary of additional 2021 activity is as follows:

- Increased the number of our properties to 438, added eight new operators, and significantly expanded our footprint in the behavioral health space by the following:
  - Acquired 35 behavioral health facilities operated by Priory for an aggregate purchase price of approximately £800 million;
  - Invested in 18 inpatient behavioral health facilities throughout the U.S., leased to Springstone and an interest in the operations of Springstone for approximately \$950 million;

- Acquired five general acute care facilities in South Florida for approximately \$900 million that are leased to Steward; and
- Acquired four acute care facilities and two on-campus medical office buildings in California for \$215 million, leased to Pipeline.
- Grew net income and Normalized FFO (both on a per diluted share basis) by 37% and 11%, respectively; and
- Selected as one of Modern Healthcare’s Best Places to Work in healthcare in 2021.

## Critical Accounting Estimates

In order to prepare financial statements in conformity with generally accepted accounting principles (“GAAP”) in the U.S., we must make estimates about certain types of transactions and account balances. We believe that our estimates of the amount and timing of credit losses, fair value adjustments (either as part of a purchase price allocation, recurring accounting for those investments that we have selected under the fair value option method, or impairment analyses), and periodic depreciation of our real estate assets, along with our assessment as to whether investments we make in certain businesses/entities should be consolidated with our results, have significant effects on our financial statements. Each of these items involves estimates that require us to make subjective judgments. We rely on our experience, collect historical and current market data, and develop relevant assumptions to arrive at what we believe to be reasonable estimates. Under different conditions or assumptions, materially different amounts could be reported related to the critical accounting policies described below. In addition, application of these critical accounting policies involves the exercise of judgment on the use of assumptions as to future uncertainties (such as uncertainties caused by the COVID-19 pandemic) and, as a result, actual results could materially differ from these estimates. See Note 2 to Item 8 of this Annual Report on Form 10-K for more information regarding our accounting policies and recent accounting developments. Our accounting estimates include the following:

### *Credit Losses:*

Losses from Rent Receivables: For all leases, we continuously monitor the performance of our existing tenants including, but not limited to: admission levels and surgery/procedure volumes by type; current operating margins; ratio of our tenant’s operating margins both to facility rent and to facility rent plus other fixed costs; trends in revenue, cash collections, patient mix; and the effect of evolving healthcare regulations, adverse economic and political conditions, such as rising inflation and interest rates, and other events ongoing on a tenant’s profitability and liquidity.

Losses from Operating Lease Receivables: We utilize the information above along with the tenant’s payment and default history in evaluating (on a property-by-property basis) whether or not a provision for losses on outstanding billed rent and/or straight-line rent receivables is needed. A provision for losses on rent receivables (including straight-line rent receivables) is ultimately recorded when it becomes probable that the receivable will not be collected in full. The provision is an amount which reduces the receivable to its estimated net realizable value based on a determination of the eventual amounts to be collected either from the debtor or from existing collateral, if any.

Losses on Financing Lease Receivables: We apply a forward-looking “expected credit loss” model to all of our financing receivables, including financing leases and loans. To do this, we have grouped our financial instruments into two primary pools of similar credit risk: secured and unsecured. The secured instruments include our investments in financing receivables as all are secured by the underlying real estate, among other collateral. Within the two primary pools, we further grouped our instruments into sub-pools based on several tenant/borrower characteristics, including years of experience in the healthcare industry and in a particular market or region and overall capitalization. We then determined a credit loss percentage per pool based on our history over a period of time that closely matches the remaining terms of the financial

instruments being analyzed and adjusted as needed for current trends or unusual circumstances. We have applied these credit loss percentages to the book value of the related instruments to establish a credit loss reserve on our financing lease receivables and such credit loss reserve (including the underlying assumptions) is reviewed and adjusted quarterly. If a financing receivable is underperforming and is deemed uncollectible based on the lessee's overall financial condition, we will adjust the credit loss reserve based on the fair value of the underlying collateral.

We exclude interest receivables from the credit loss reserve model. Instead, such receivables are impaired and an allowance recorded when it is deemed probable that we will be unable to collect all amounts due. Like operating lease receivables, the need for an allowance is based upon our assessment of the lessee's overall financial condition, economic resources and payment record, the prospects for support from any financially responsible guarantors, and, if appropriate, the realizable value of any collateral. Financing leases are placed on non-accrual status when we determine that the collectability of contractual amounts is not reasonably assured. If on non-accrual status, we generally account for the financing lease on a cash basis, in which income is recognized only upon receipt of cash.

Loans: Loans consist of mortgage loans, working capital loans, and other loans. Mortgage loans are collateralized by interests in real property. Working capital and other loans are generally collateralized by interests in receivables and corporate and individual guarantees. We record loans at cost. Like our financing lease receivables, we establish credit loss reserves on all outstanding loans based on historical credit losses of similar instruments. Such credit loss reserves, including the underlying assumptions, are reviewed and adjusted quarterly. If a loan's performance worsens and foreclosure is deemed probable for our collateral-based loans (after considering the borrower's overall financial condition as described above for leases), we will adjust the allowance for expected credit losses based on the current fair value of such collateral at the time the loan is deemed uncollectible. If the loan is not collateralized, the loan will be reserved for/written-off once it is determined that such loan is no longer collectible. Interest receivables on loans are excluded from the forward-looking credit loss reserve model; however, we assess their collectability similar to how we assess collectability for interest receivables on financing leases described above.

*Investments in Real Estate:* We maintain our investments in real estate at cost, and we capitalize improvements and replacements when they extend the useful life or improve the efficiency of the asset. While our tenants are generally responsible for all operating costs at a facility, in the event we incur costs of repairs and maintenance, we expense those costs as incurred. We compute depreciation using the straight-line method over the weighted-average useful life of approximately 39.0 years for buildings and improvements.

When circumstances indicate a possible impairment of the value of our real estate investments, we review the recoverability of the facility's carrying value. The review of the recoverability is generally based on our estimate of the future undiscounted cash flows from the facility's use and eventual disposition. Our forecast of these cash flows considers factors such as expected future operating income, market and other applicable trends, and residual value, as well as the effects of leasing demand, competition, and other factors. If impairment exists due to the inability to recover the carrying value of a facility on an undiscounted basis, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair value of the facility. In making estimates of fair value for purposes of impairment assessments, we will look to a number of sources including independent appraisals, available broker data, or our internal data from recent transactions involving similar properties in similar markets. Given the highly specialized aspects of our properties, no assurance can be given that future impairment charges will not be taken.

*Acquired Real Estate Purchase Price Allocation:* For properties acquired for operating leasing purposes, we currently account for such acquisitions based on asset acquisition accounting rules. Under this accounting method, we allocate the purchase price of acquired properties to net tangible and identified intangible assets acquired based on their relative fair values. In making estimates of fair value for purposes of allocating purchase prices of acquired real estate, we may utilize a number of sources, including available real estate broker data,

independent appraisals that may be obtained in connection with the acquisition or financing of the respective property, internal data from previous acquisitions or developments, and other market data, including market comparables for significant assumptions such as market rental, capitalization, and discount rates. We also consider information obtained about each property as a result of our pre-acquisition due diligence, marketing, and leasing activities in estimating the fair value of the tangible and intangible assets acquired.

We record above-market and below-market in-place lease values, if any, for the facilities we own which are based on the present value of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) management's estimate of fair market lease rates for the corresponding in-place leases, measured over a period equal to the remaining non-cancelable term of the lease. We amortize any resulting capitalized above-market lease values as a reduction of rental income over the lease term. We amortize any resulting capitalized below-market lease values as an increase to rental income over the lease term. Because our strategy to a large degree involves the origination and acquisition of long-term lease arrangements at market rates with independent parties, we do not expect the above-market or below-market in-place lease values to be significant for many of our transactions.

We measure the aggregate value of other lease intangible assets to be acquired based on the difference between (i) the property valued with new or in-place leases adjusted to market rental rates and (ii) the property valued as if vacant when acquired. Management's estimates of value are made using methods similar to those used by independent appraisers (*e.g.*, discounted cash flow analysis). Factors considered by management in our analysis include an estimate of carrying costs during hypothetical expected lease-up periods, considering current market conditions, and costs to execute similar leases. We also consider information obtained about each targeted facility as a result of our pre-acquisition due diligence, marketing, and leasing activities in estimating the fair value of the intangible assets acquired. In estimating carrying costs, management includes real estate taxes, insurance, and other operating expenses, and estimates of lost rentals at market rates during the expected lease-up periods, which we expect to be about six months (based on experience) but can be longer depending on specific local market conditions. Management also estimates costs to execute similar leases including leasing commissions, legal costs, and other related expenses to the extent that such costs are not already incurred in connection with a new lease origination.

Other intangible assets acquired may include customer relationship intangible values, which are based on management's evaluation of the specific characteristics of each prospective tenant's lease and our overall relationship with that tenant. Characteristics to be considered by management in allocating these values include the nature and extent of our existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant's credit quality, and expectations of lease renewals, including those existing under the terms of the lease agreement, among other factors. At December 31, 2022, we have not assigned any value to customer relationship intangibles.

We amortize the value of lease intangibles to expense over the term of the respective leases, which have a weighted-average useful life of 26.8 years at December 31, 2022. If a lease is terminated early, the unamortized portion of the lease intangible is charged to expense.

*Fair Value Option Election:* We elected to account for certain investments using the fair value option method, which means we mark these investments to fair market value on a recurring basis. At December 31, 2022, the amount of investments recorded using the fair value option were approximately \$575 million made up of loans and equity investments. Our loans are recorded at fair value based on Level 2 inputs by discounting the estimated cash flows using the market rates which similar loans would be made to borrowers with similar credit ratings and the same remaining maturities.

For our equity investments in Springstone and the international joint venture, fair value is determined based on Level 3 inputs, by using a discounted cash flow model, which required significant estimates of our investee such as projected revenue and expenses and appropriate consideration of the underlying risk profile of the

forecasted assumptions associated with the investee. We classified these equity investments as Level 3, as we used certain unobservable inputs to the valuation methodology that were significant to the fair value measurement, and the valuation required management judgment due to the absence of quoted market prices. For the cash flow model, our observable inputs included use of a capitalization rate, discount rate (which was based on a weighted average cost of capital), and market interest rates, and our unobservable input included an adjustment for a marketability discount (“DLOM”) on our Springstone equity investment of 40%. In regards to the underlying projection of revenues and expenses used in the discounted cash flow model, such projections were provided by the investees. However, we modified such projections (including underlying assumptions used) as needed based on our review and analysis of their historical results, meetings with key members of management, and our understanding of trends and developments within the healthcare industry. In arriving at the DLOM, we started with a DLOM range based on the results of studies supporting valuation discounts for other transactions or structures without a public market. To select the appropriate DLOM within the range, we then considered many qualitative factors including the percent of control, the nature of the underlying investee’s business along with our rights as an investor pursuant to the operating agreement, the size of investment, expected holding period, number of shareholders, access to the capital marketplace, etc. See Note 10 to Item 8 of this Annual Report on Form 10-K for additional details.

*Principles of Consolidation:* Property holding entities and other subsidiaries of which we own 100% of the equity or have a controlling financial interest evidenced by ownership of a majority voting interest are consolidated. All inter-company balances and transactions are eliminated. For entities in which we own less than 100% of the equity interest, we consolidate the property if we have the direct or indirect ability to control the entity’s activities based upon the terms of the respective entity’s ownership agreements. For these entities, we record a non-controlling interest representing equity held by non-controlling interests.

We continually evaluate all of our transactions and investments to determine if they represent variable interests in a variable interest entity. If we determine that we have a variable interest in a variable interest entity, we then evaluate if we are the primary beneficiary of the variable interest entity. The evaluation is a qualitative assessment as to whether we have the ability to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance. We consolidate each variable interest entity in which we, by virtue of or transactions with our investments in the entity, are considered to be the primary beneficiary. At December 31, 2022 and 2021, we determined that we were not the primary beneficiary of any variable interest entity in which we hold a variable interest because we do not control the activities (such as the day-to-day operations) that most significantly impact the economic performance of these entities.

## **Liquidity and Capital Resources**

Our typical sources of cash include our monthly rent and interest receipts, distributions from our real estate joint venture agreements, borrowings under our revolving credit facility, public issuances of debt and equity securities, and proceeds from bank debt, asset dispositions (either one-off or group asset sales through joint venture transactions), and principal payments on loans. Our primary uses of cash include dividend distributions, debt service (including principal and interest), new investments (including acquisitions, developments, or capital improvement projects), loan advances, property expenses, and general and administrative expenses.

Absent our requirements to make distributions to maintain our REIT qualification (as described earlier and further described in Note 5 within Item 8 of this Annual Report on Form 10-K) and our current contractual commitments discussed later in this section, we do not have any material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.



See below for highlights of our sources and uses of cash for the past two years:

#### *2022 Cash Flow Activity*

We generated cash of \$740 million from operating activities during 2022, primarily consisting of rent and interest from mortgage and other loans. We used these operating cash flows to fund our dividends of \$699 million.

In regards to investing and financing activities in 2022, we did the following:

- a) Invested approximately \$1.3 billion in hospital real estate, representing 16 facilities across five countries;
- b) Funded \$524.2 million of development, capital addition, and other projects;
- c) Completed the Macquarie Transaction in which we contributed eight Massachusetts-based general acute care hospitals to form a partnership, resulting in a gain on real estate of approximately \$600 million and proceeds of approximately \$1.3 billion, which were partially used to pay off our \$1 billion interim credit facility;
- d) Exercised the \$500 million accordion feature to our revolving credit facility and extended the term on both the revolver and term loan portions of our Credit Facility;
- e) Authorized a stock repurchase program for up to \$500 million of common stock, of which we repurchased 1.6 million shares of common stock for approximately \$17.9 million through December 31, 2022; and
- f) Separate from the Macquarie Transaction, we sold 15 facilities and five ancillary properties generating net proceeds of approximately \$522 million.

Subsequent to December 31, 2022, we received approximately \$205 million from Lifepoint to pay off an outstanding loan, plus accrued interest, as part of their acquisition of a majority ownership interest in Springstone. See Note 13 to Item 8 of this Annual Report on Form 10-K for further details on this transaction.

#### *2021 Cash Flow Activity*

We generated cash of \$812 million from operating activities during 2021, primarily consisting of rent and interest from mortgage and other loans. We used these operating cash flows to fund our dividends of \$643 million and certain investing activities.

In regards to investing and financing activities in 2021, we did the following:

- a) Invested approximately \$4.0 billion in hospital real estate, representing over 65 facilities across five countries, headlined by the £800 million Priory acquisition of 35 properties in January 2021;
- b) Funded \$415.9 million of development, capital addition, and other projects;
- c) Issued 16.3 million shares of common stock under our at-the-market equity offering program, resulting in net proceeds of approximately \$340 million;
- d) Completed an underwritten public offering of 36.8 million shares, resulting in net proceeds of \$711 million;
- e) Amended and extended our unsecured revolving and term loan facility;
- f) Entered into a \$900 million interim credit facility on January 15, 2021, of which we borrowed £500 million. This facility was paid off and terminated on March 26, 2021, after the completion of an £850 million unsecured notes offering on March 24, 2021 that was issued in two tranches;

- g) Received \$11 million from Steward as a return of capital distribution;
- h) Entered into a \$1 billion interim credit facility in July 2021 (“July 2021 Interim Credit Facility”) to fund new investments;
- i) Completed a €500 million, 0.993% senior unsecured notes offering on October 6, 2021, using proceeds to pay off €500 million of senior unsecured notes with an interest rate of 4.000% on October 22, 2021;
- j) Received approximately \$0.5 billion in loan principal repayments; and
- k) Sold 16 facilities and an ancillary property generating net proceeds of \$246 million.

#### *Debt Restrictions and REIT Requirements*

Our debt facilities impose certain restrictions on us, including, but not limited to, restrictions on our ability to: incur debt; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem, or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate or other assets; and change our business. In addition, the credit agreement governing our Credit Facility limits the amount of dividends we can pay to 95% of NAFFO, as defined in the agreements, on a rolling four quarter basis. The indentures governing our senior unsecured notes also limit the amount of dividends we can pay based on the sum of 95% of funds from operations, proceeds of equity issuances, and certain other net cash proceeds. Finally, our senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness.

In addition to these restrictions, the Credit Facility contains customary financial and operating covenants, including covenants relating to our total leverage ratio, fixed charge coverage ratio, secured leverage ratio, unsecured leverage ratio, consolidated adjusted net worth, and unsecured interest coverage ratio. This facility also contains customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations, and failure to comply with our covenants. If an event of default occurs and is continuing under the facility, the entire outstanding balance may become immediately due and payable. At December 31, 2022, we were in compliance with all such financial and operating covenants.

In order for us to continue to qualify as a REIT we are required to distribute annual dividends equal to a minimum of 90% of our REIT taxable income, computed without regard to the dividends paid deduction and our net capital gains. See section titled “Distribution Policy” within this Item 7 of this Annual Report on Form 10-K for further information on our dividend policy along with the historical dividends paid on a per share basis.

#### *Short-term Liquidity Requirements:*

As of February 17, 2023, our liquidity approximates \$1.2 billion. We believe this liquidity, along with our current monthly cash receipts from rent and loan interest and regular distributions from our joint venture arrangements, is sufficient to fund our operations, dividends in order to comply with REIT requirements, our current firm commitments (capital expenditures and expected funding requirements on development projects) and debt service obligations for the next twelve months (including contractual interest payments and our December 2023 debt maturity of approximately \$450 million). If the sale of three Prospect facilities (as more fully described in Note 8 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K) are consummated in 2023, we would have additional liquidity.

#### *Long-term Liquidity Requirements:*

As of February 17, 2023, our liquidity approximates \$1.2 billion. We believe that this liquidity, along with monthly cash receipts from rent and loan interest (of which 99% of such leases and mortgage loans include escalation provisions that compound annually) and regular distributions from our joint venture arrangements, is sufficient to fund our operations, interest obligations, debt principal payments coming due in 2023, our current firm commitments, and dividends in order to comply with REIT requirements.

However, in order to make additional investments, to fund other debt maturities coming due in 2024 and beyond (as outlined below in our commitment schedule), or to strategically refinance any existing debt in order to reduce interest rates, or to further improve our leverage ratios, we may need to access one or a combination of the following sources of capital:

- strategic property sales or joint ventures (including sale of three Prospect facilities as described in Note 8 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K);
- sale of equity securities;
- new bank term loans;
- new USD, EUR, or GBP denominated debt securities, including senior unsecured notes; and/or
- new secured loans on real estate.

However, there is no assurance that conditions will be favorable for such possible transactions or that our plans will be successful.

### Contractual Commitments

The following table summarizes known material contractual commitments including debt service commitments (principal and interest payments) as of February 17, 2023 (amounts in thousands):

	2023	2024	2025	2026	2027	Thereafter	Total
Senior unsecured notes(1) . . .	\$ 722,215	\$ 262,395	\$ 797,145	\$1,881,214	\$1,598,008	\$3,655,335	\$ 8,916,312
Revolving credit facility(2) . .	45,187	51,806	51,806	964,676	—	—	1,113,475
Term loan . . . . .	10,414	12,023	11,990	11,990	205,946	—	252,363
Australian term loan facility(1) . . . . .	17,563	833,458	—	—	—	—	851,021
British pound sterling term loans(1) . . . . .	20,015	148,918	843,265	—	—	—	1,012,198
Operating lease commitments(1)(3) . . . . .	8,058	9,074	8,400	7,933	7,888	239,375	280,728
Purchase obligations(1)(4) . . .	358,439	169,760	106,710	59,980	41,274	44,193	780,356
Totals . . . . .	<u>\$1,181,891</u>	<u>\$1,487,434</u>	<u>\$1,819,316</u>	<u>\$2,925,793</u>	<u>\$1,853,116</u>	<u>\$3,938,903</u>	<u>\$13,206,453</u>

(1) We used the exchange rates at February 17, 2023 in preparing this table.

(2) As of February 17, 2023, we have a \$1.8 billion revolving credit facility. This table assumes the balance outstanding under the revolver (which was \$939 million as of February 17, 2023) and interest rate in effect at February 17, 2023 remain in effect through maturity.

(3) Much of our contractual obligations to make operating lease payments are related to ground leases for which we are reimbursed by our tenants along with corporate office and equipment leases.

(4) Includes approximately \$239.2 million of future expenditures related to development projects and \$436.6 million of future expenditures on committed capital improvement projects.

### Results of Operations

Our operating results may vary significantly from year-to-year due to a variety of reasons including acquisitions made during the year, incremental revenues and expenses from acquisitions made in the prior year, revenues and expenses from completed development properties, property disposals, annual escalation provisions, foreign currency exchange rate changes, new or amended debt agreements, issuances of shares through an equity offering, impact from accounting changes, etc. Thus, our operating results for the current year are not necessarily indicative of the results that may be expected in future years.

### ***Year Ended December 31, 2022 Compared to the Year Ended December 31, 2021***

Net income for the year ended December 31, 2022, was \$902.6 million (\$1.50 per diluted share) compared to net income of \$656.0 million (\$1.11 per diluted share) for the year ended December 31, 2021. This 38% increase in net income is primarily due to \$0.5 billion of gains on sales of real estate in 2022 (including the Macquarie Transaction as described in Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K), incremental revenue from new investments and annual escalations, and lower tax expense due to the unfavorable adjustment in 2021 to recognize an increase in the United Kingdom corporate income tax rate, partially offset by \$283 million of impairment charges related to our tenant, Prospect (see Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K for further details), \$41.9 million of straight-line rent write-offs related to our sale of non-Macquarie Transaction disposals, and higher depreciation expense and general and administrative costs. Normalized FFO, after adjusting for certain items (as more fully described in the section titled “Non-GAAP Financial Measures” in this Item 7 of this Annual Report on Form 10-K), was \$1.1 billion for 2022, or \$1.82 per diluted share, as compared to \$1.0 billion, or \$1.75 per diluted share, for 2021. This 5% increase in Normalized FFO is primarily due to incremental revenue from new investments made in 2021 and 2022 and annual escalations.

A comparison of revenues for the years ended December 31, 2022 and 2021 is as follows (dollar amounts in thousands):

	<u>2022</u>		<u>2021</u>		<u>Change</u>
Rent billed . . . . .	\$ 968,874	62.8%	\$ 931,942	60.4%	\$ 36,932
Straight-line rent . . . . .	204,159	13.2%	241,433	15.6%	(37,274)
Income from financing leases . . . . .	203,580	13.2%	202,599	13.1%	981
Interest and other income . . . . .	166,238	10.8%	168,695	10.9%	(2,457)
Total revenues . . . . .	<u>\$1,542,851</u>	<u>100.0%</u>	<u>\$1,544,669</u>	<u>100.0%</u>	<u>\$ (1,818)</u>

Our total revenues for 2022 are down \$1.8 million or 0.1% over the prior year. This change is made up of the following:

- Operating lease revenue (includes rent billed and straight-line rent) — was basically flat year over year. However, from a detailed perspective, 2022 saw a decrease in approximately \$165.8 million from disposals in 2021 and 2022 (including a \$96.9 million decrease from the properties disposed of in the Macquarie Transaction as described in Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K, along with lower revenues due to Prime Healthcare Services, Inc.’s (“Prime”) repurchase transaction in the 2022 third quarter and \$41.9 million of straight-line rent and other write-offs associated with non-Macquarie Transaction disposals in 2022) and \$36.2 million from unfavorable foreign currency fluctuations. This decrease was partially offset by \$172.5 million of incremental revenue from acquisitions made in late 2021 (including approximately \$55.8 million from Springstone) and 2022 (primarily our Finland acquisition in the 2022 first quarter). In addition, rent revenues are up approximately \$23 million year-over-year from increases in CPI above the contractual minimum escalations in our leases, \$1.5 million from capital additions in 2022, and \$4.8 million from the commencement of rent on a development property in the first quarter of 2022.
- Income from financing leases — up \$1.0 million as 2022 annual rent escalations exceeded lease contractual minimums due to the increase in CPI by approximately \$5.3 million, partially offset by \$4.3 million of lower revenues from the disposal of two financing leases related to the Prime repurchase transaction in the 2022 third quarter.
- Interest and other income — down \$2.5 million from the prior year due to the following:
  - Interest from loans — down \$10.8 million over the prior year due to \$41.5 million from loan payoffs, including \$37.4 million of less interest revenue earned on the Priory loans from the conversion of the £800 million mortgage loan to fee simple assets in the second quarter of 2021

and the repayment of the £250 million acquisition loan in the 2021 fourth quarter as described in Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K, along with approximately \$7.7 million of unfavorable foreign currency fluctuations. This decrease is partially offset by \$37.2 million of incremental revenue earned on new investments, including Springstone in the 2021 fourth quarter and the Priory syndicated loan in the 2022 first quarter and higher income from annual escalations due to increases in CPI of approximately \$1.2 million.

- Other income — up \$8.3 million from the prior year as we received more direct reimbursements from our tenants for ground lease, property taxes, and insurance.

Interest expense for 2022 and 2021 totaled \$359.0 million and \$367.4 million, respectively. This decrease is related to lowering our outstanding debt using proceeds from the Macquarie Transaction and other property sales, the reduction of the interest rate on our €500 million senior unsecured notes tranche in October 2021 from 4.000% to 0.993%, and foreign currency fluctuations. Overall, our weighted-average interest rate was 3.3%, same as 2021.

Real estate depreciation and amortization during 2022 increased to \$333.0 million from \$321.2 million in 2021 due to new investments made in 2021 and 2022, partially offset by foreign currency fluctuations and property sales in 2022.

Property-related expenses for 2022 increased to \$45.7 million, compared to \$39.1 million in 2021. Of the property expenses in 2022 and 2021, approximately \$36 million and \$28 million, respectively, represents costs that were reimbursed by our tenants and included in the “Interest and other income” line on our consolidated statements of net income. Excluding the reimbursable amounts, property expenses are \$1.4 million less in 2022 compared to 2021 due to the re-leasing and sales of vacant properties in 2022.

As a percentage of revenue and after adjusting for non-cash rent write-offs noted above, general and administrative expenses represented 10.1% for 2022, slightly higher than 9.4% in the prior year. On a dollar basis, general and administrative expenses totaled \$160.5 million for 2022, which is a \$14.9 million increase from 2021. This increase reflects continued ESG efforts in additional charitable giving, further board diversification, and additional benefits to our employees, along with higher professional expenses. Compensation expense was slightly lower overall compared to 2021, as the cost of additional non-executive headcount and benefits were more than offset by a reduction in stock and cash bonus compensation expense.

During the year ended December 31, 2022, we realized \$536.8 million from the sales of real estate, including the completion of the Macquarie Transaction in which we sold the real estate of eight Massachusetts-based general acute care hospitals, resulting in a gain on real estate of approximately \$600 million, partially offset by approximately \$125 million of write-offs of non-cash straight-line rent receivables. We also disposed of 11 facilities previously leased to Prime, resulting in a gain on real estate of approximately \$67 million. In addition, we disposed of four other properties and five ancillary properties, resulting in a net gain of \$33 million. In comparison, we sold 16 properties and one ancillary property in 2021 for a net gain of \$52.5 million.

In December 2022, we recorded a \$283 million impairment charge related to our tenant, Prospect — see Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K for further details. As part of this charge, we reduced the carrying value of the Pennsylvania real estate by \$171 million and reserved all non-cash rent, representing \$112 million. We expect to record rent on our Prospect leases on a cash only basis for the foreseeable future.

In 2021, we recorded an approximate \$40 million impairment charge related to loans made to the previous operator for services to continue at our Watsonville Community Hospital — see Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K for further details. In 2022 and after finding a replacement operator through a bankruptcy process with the former operator, we were repaid a significant amount of this loan, resulting in a net credit loss recovery of approximately \$15 million.

Earnings from equity interests was \$40.8 million for 2022, up \$12.3 million from 2021. This increase is primarily due to \$13.0 million of income generated on our Massachusetts-based partnership with MAM entered into during March 2022 (part of the Macquarie Transaction) and approximately \$4 million of dividend income we received in 2022 from our Switzerland investments (see Note 3 to the consolidated financial statements in Item 8 to this Annual Report on Form 10-K for more detail), partially offset by the loss of equity interest income from the remaining 50% interest of the IMED Hospitales joint venture that we acquired during December 2021 and the impact from foreign currency fluctuations.

Debt refinancing and unutilized financing costs were \$9.5 million in 2022 due to the termination of our \$1 billion interim credit facility in March 2022 and the amendment of our Credit Facility in the second quarter of 2022 (see Note 4 to Item 8 of this Annual Report on Form 10-K for further details). In 2021, these costs were \$27.7 million as a result of the early termination of our \$900 million interim credit facility and 4.000% Senior Unsecured Notes due 2022 in the fourth quarter of 2021.

Other income for 2022 was \$15.3 million compared to \$45.7 million in 2021. Other income in 2022 includes unrealized gains on our investments in marketable securities plus dividend income on such investments in 2022. In regards to 2021, in addition to unrealized gains from our investment in marketable securities, we realized approximately \$40 million in net pre-tax gains on the sale of investments in operators (two of which were in Europe).

Income tax expense includes U.S. federal and state income taxes on our TRS entities, as well as non-U.S. income based or withholding taxes on certain investments located in jurisdictions outside the U.S. The \$55.9 million income tax expense for 2022 is primarily based on the income generated by our investments in the United Kingdom, Colombia, and Australia along with an additional \$5 million U.S. tax expense related to our Watsonville loan recovery in 2022. In comparison, we incurred a \$73.9 million income tax expense in 2021 from income generated by our investments in the United Kingdom, Colombia, and Australia, including an adjustment to our net deferred tax liabilities of approximately \$43 million to reflect an increase in the United Kingdom corporate tax rate from 19% to 25%, partially offset by an approximate \$10 million U.S. tax benefit from the Watsonville loan impairment in 2021. For more detailed information, see Note 5 to Item 8 of this Annual Report on Form 10-K.

We utilize the asset and liability method of accounting for income taxes. Deferred tax assets are recorded to the extent we believe these assets will more likely than not be realized. In making such determination, all available positive and negative evidence is considered, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Based upon our review of all positive and negative evidence, including our three-year cumulative pre-tax book loss position in certain entities, we concluded that a valuation allowance of approximately \$71 million should be reflected against certain of our international and domestic net deferred tax assets at December 31, 2022. In the future, if we determine that it is more likely than not that we will realize our net deferred tax assets, we will reverse the applicable portion of the valuation allowance, recognize an income tax benefit in the period in which such determination is made, and incur higher income taxes in future periods as income is earned. For more detailed information, see Note 5 to Item 8 of this Annual Report on Form 10-K.

## **Non-GAAP Financial Measures**

We consider non-GAAP financial measures to be useful supplemental measures of our operating performance. A non-GAAP financial measure is a measure of financial performance, financial position, or cash flows that excludes or includes amounts that are not so excluded from or included in the most directly comparable measure calculated and presented in accordance with GAAP. Described below are the non-GAAP financial measures used by management to evaluate our operating performance and that we consider most useful to investors, together with reconciliations of these measures to the most directly comparable GAAP measures.

### ***Funds From Operations and Normalized Funds From Operations***

Investors and analysts following the real estate industry utilize funds from operations (“FFO”) as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or Nareit, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization and after adjustments for unconsolidated partnerships and joint ventures.

In addition to presenting FFO in accordance with the Nareit definition, we disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts.

We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs (if any not paid by our tenants) to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity.

The following table presents a reconciliation of net income attributable to MPT common stockholders to FFO and Normalized FFO for the years ended December 31, 2022 and 2021 (amounts in thousands except per share data):

	<b>For the Years Ended December 31,</b>	
	<b>2022</b>	<b>2021</b>
<b>FFO Information</b>		
Net income attributable to MPT common stockholders . . . . .	\$ 902,597	\$ 656,021
Participating securities' share in earnings . . . . .	(1,602)	(2,161)
Net income, less participating securities' share in earnings . . . . .	\$ 900,995	\$ 653,860
Depreciation and amortization . . . . .	399,622	374,599
Gain on sale of real estate . . . . .	(536,887)	(52,471)
Real estate impairment charges . . . . .	170,582	—
Funds from operations . . . . .	\$ 934,312	\$ 975,988
Write-off of unbilled rent and other . . . . .	37,682	7,213
Gain on sale of equity investments . . . . .	—	(40,945)
Other impairment charges, net . . . . .	97,793	39,411
Non-cash fair value adjustments . . . . .	(2,333)	(8,193)
Tax rate changes and other . . . . .	10,697	34,796
Debt refinancing and unutilized financing costs . . . . .	9,452	27,650
Normalized funds from operations . . . . .	<u>\$1,087,603</u>	<u>\$1,035,920</u>
<b>Per diluted share data</b>		
Net income, less participating securities' share in earnings . . . .	\$ 1.50	\$ 1.11
Depreciation and amortization . . . . .	0.67	0.63
Gain on sale of real estate . . . . .	(0.90)	(0.09)
Real estate impairment charges . . . . .	0.29	—
Funds from operations . . . . .	\$ 1.56	\$ 1.65
Write-off of unbilled rent and other . . . . .	0.07	0.01
Gain on sale of equity investments . . . . .	—	(0.07)
Other impairment charges, net . . . . .	0.16	0.07
Non-cash fair value adjustments . . . . .	—	(0.01)
Tax rate changes and other . . . . .	0.02	0.06
Debt refinancing and unutilized financing costs . . . . .	0.01	0.04
Normalized funds from operations . . . . .	<u>\$ 1.82</u>	<u>\$ 1.75</u>



### ***Total Adjusted Gross Assets***

Total adjusted gross assets is total assets before accumulated depreciation/amortization (adjusted for our investments in unconsolidated real estate joint ventures), assumes material transaction commitments are completed, and assumes cash on hand at period-end and cash generated from or to be generated from transaction commitments or financing activities subsequent to period-end are either used in these transactions or used to reduce debt. We believe total adjusted gross assets is useful to investors as it provides a more current view of our portfolio and allows for a better understanding of our concentration levels as our commitments close. The following table presents a reconciliation of total assets to total adjusted gross assets (in thousands):

	As of December 31, 2022	As of December 31, 2021
Total assets .....	\$19,658,000	\$20,519,801
Add: Accumulated depreciation and amortization .....	1,193,312	993,100
Add: Incremental gross assets of our Investments in Unconsolidated Real Estate Joint Ventures(1) .....	1,698,917	1,713,603
Net: Reclassification between operators(2) .....	—	—
Less: Gross book value of the transactions, net(3) .....	(1,074,024)	(437,940)
Decrease in cash from the transactions(4) .....	(235,668)	(459,227)
Total adjusted gross assets .....	<u>\$21,240,537</u>	<u>\$22,329,337</u>

- (1) Reflects an addition to total assets to present our total share of each joint venture's gross assets. See below for details of the calculation. While we do not control any of our unconsolidated real estate joint venture arrangements and do not have direct legal claim to the underlying assets of the unconsolidated real estate joint ventures, we believe this adjustment allows investors to view certain concentration information on a basis comparable to the remainder of our real estate portfolio. This presentation is also consistent with how our management team reviews our portfolio (dollar amounts in thousands):

	As of December 31, 2022	As of December 31, 2021
Real estate joint venture total gross real estate and other assets .....	\$ 5,921,188	\$ 5,898,342
Weighted-average equity ownership percentage .....	55%	55%
	3,261,727	3,242,505
Investments in Unconsolidated Real Estate Joint Ventures(A) .....	(1,562,810)	(1,528,902)
Incremental gross assets of our Investments in Unconsolidated Real Estate Joint Ventures .....	<u>\$ 1,698,917</u>	<u>\$ 1,713,603</u>

- (A) Includes amount shown on the "Investments in unconsolidated real estate joint ventures" line on our consolidated balance sheets, along with a CHF 60 million mortgage loan included in the "Mortgage loans" line on our consolidated balance sheet for 2022 and \$0.4 billion for the Macquarie Transaction for 2021.
- (2) The 2022 column reflects a reclass of \$0.8 billion of gross assets between Springstone and Lifepoint along with a \$0.9 billion reclass of gross assets between Steward and CommonSpirit Health as part of the transactions described in Note 13 to Item 8 of this Annual Report on Form 10-K.

- (3) Represents the gross book value of assets sold or written off due to the committed transactions, partially offset by the addition of new gross assets from the committed transactions. See detail below (in thousands):

	As of December 31, 2022	As of December 31, 2021
Gross book value of assets in transactions as described in Notes 8 and 13 .....	\$ (655,354)	\$ —
Book value of Massachusetts assets held-for-sale .....	—	(1,096,505)
Expected book value of our 50% interest in the Massachusetts joint venture .....	—	375,975
Unfunded amounts on development deals and commenced capital improvement projects .....	—	480,132
Non-cash write-offs related to transactions .....	(418,670)	(197,542)
Gross book value of the transactions, net .....	<u><u>\$ (1,074,024)</u></u>	<u><u>\$ (437,940)</u></u>

- (4) Represents cash expected from the proceeds generated by the transactions along with cash on hand to fund the transactions or reduce debt as detailed below (in thousands):

	As of December 31, 2022	As of December 31, 2021
Expected cash proceeds generated by the transactions as described in Notes 3, 8 and 13 .....	\$ 659,000	\$1,280,000
Paydown of July 2021 Interim Credit Facility .....	—	(869,606)
Reduction of revolver balance .....	(894,668)	(389,489)
Unfunded amounts on development deals and commenced capital improvement projects .....	—	(480,132)
Net decrease in cash from the transactions .....	<u><u>\$(235,668)</u></u>	<u><u>\$(459,227)</u></u>

### ***Total Adjusted Revenues***

Total adjusted revenues are total revenues adjusted for our pro rata portion of similar revenues in our unconsolidated real estate joint venture arrangements. We believe total adjusted revenues are useful to investors as it provides a more complete view of revenues across all of our investments and allows for better understanding of our revenue concentration. The following table presents a reconciliation of total revenues to total adjusted revenues (in thousands):

	For the Years Ended December 31,	
	2022	2021
Total revenues .....	\$1,542,851	\$1,544,669
Revenues from investments in unconsolidated real estate joint ventures .....	174,940	131,013
Total adjusted revenues .....	<u><u>\$1,717,791</u></u>	<u><u>\$1,675,682</u></u>

### **Distribution Policy**

We have elected to be taxed as a REIT commencing with our taxable year that began on April 6, 2004 and ended on December 31, 2004. To qualify as a REIT, we must meet a number of organizational and operational requirements, including a requirement that we distribute at least 90% of our REIT taxable income, excluding net capital gain, to our stockholders. It is our current intention to comply with these requirements and maintain such status going forward.

The table below is a summary of our distributions declared for the three year period ended December 31, 2022:

Declaration Date	Record Date	Date of Distribution	Distribution per Share
November 10, 2022	December 8, 2022	January 12, 2023	\$0.29
August 18, 2022	September 15, 2022	October 13, 2022	\$0.29
May 26, 2022	June 16, 2022	July 14, 2022	\$0.29
February 17, 2022	March 17, 2022	April 14, 2022	\$0.29
November 11, 2021	December 9, 2021	January 13, 2022	\$0.28
August 19, 2021	September 16, 2021	October 14, 2021	\$0.28
May 26, 2021	June 17, 2021	July 8, 2021	\$0.28
February 18, 2021	March 18, 2021	April 8, 2021	\$0.28
November 12, 2020	December 10, 2020	January 7, 2021	\$0.27
August 13, 2020	September 10, 2020	October 8, 2020	\$0.27
May 21, 2020	June 18, 2020	July 16, 2020	\$0.27
February 14, 2020	March 12, 2020	April 9, 2020	\$0.27

On February 16, 2023, we announced that our Board of Directors declared a regular quarterly cash dividend of \$0.29 per share of common stock to be paid on April 13, 2023, to stockholders of record on March 16, 2023.

We intend to pay to our stockholders, within the time periods prescribed by the Code, all or substantially all of our annual taxable income, including taxable gains from the sale of real estate and recognized gains on the sale of securities. It is our policy to make sufficient cash distributions to stockholders in order for us to maintain our status as a REIT under the Code and to avoid corporate income and excise taxes on undistributed income, although there is no assurance as to further dividends because they depend on future earnings, capital requirements, and our financial condition. In addition, our Credit Facility limits the amount of dividends we can pay — see Note 4 to our consolidated financial statements in Item 8 to this Annual Report on Form 10-K for further information.

#### **ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk**

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices, and other market changes that affect market sensitive instruments. We seek to mitigate the effects of fluctuations in interest rates by matching the terms of new investments with new long-term fixed rate borrowings to the extent possible. We may or may not elect to use financial derivative instruments to hedge interest rate or foreign currency exposure. For interest rate hedging, these decisions are principally based on our policy to match investments with comparable borrowings, but are also based on the general trend in interest rates at the applicable dates and our perception of the future volatility of interest rates. For foreign currency hedging, these decisions are principally based on how our investments are financed, the long-term nature of our investments, the need to repatriate earnings back to the U.S., and the general trend in foreign currency exchange rates.

In addition, the value of our facilities will be subject to fluctuations based on changes in local and regional economic conditions and changes in the ability of our tenants to generate profits.

Our primary exposure to market risks relates to fluctuations in interest rates and foreign currency. The following analyses present the sensitivity of the market value, earnings, and cash flows of our significant financial instruments to hypothetical changes in interest rates and exchange rates as if these changes had occurred. The hypothetical changes chosen for these analyses reflect our view of changes that are reasonably possible over a one-year period. These forward looking disclosures are selective in nature and only address the potential impact from these hypothetical changes. They do not include other potential effects which could impact our business as a result of changes in market conditions. In addition, they do not include measures we may take

to minimize our exposure such as entering into future interest rate swaps to hedge against interest rate increases on our variable rate debt.

### Interest Rate Sensitivity

For fixed rate debt, interest rate changes affect the fair market value but do not impact net income to common stockholders or cash flows. Conversely, for floating rate debt, interest rate changes generally do not affect the fair market value but do impact net income to common stockholders and cash flows, assuming other factors are held constant. At December 31, 2022, our outstanding debt totaled \$10.3 billion, which consisted of fixed-rate debt of approximately \$9.2 billion (after considering interest rate swaps in-place) and variable rate debt of \$1.1 billion. If market interest rates increase by 10%, the fair value of our debt at December 31, 2022 would decrease by approximately \$228.4 million. Changes in the fair value of our fixed rate debt will not have any impact on us unless we decided to repurchase the debt in the open market.

If market rates of interest on our variable rate debt increase by 10%, the increase in annual interest expense on our variable rate debt would decrease future earnings and cash flows by \$5.4 million per year. If market rates of interest on our variable rate debt decrease by 10%, the decrease in interest expense on our variable rate debt would increase future earnings and cash flows by \$5.4 million per year. This assumes that the average amount outstanding under our variable rate debt for a year is \$1.1 billion, the balance of such variable rate debt at December 31, 2022.

### Foreign Currency Sensitivity

With our investments in the United Kingdom, Germany, Spain, Italy, Portugal, Switzerland, Finland, Australia, and Colombia, we are subject to fluctuations in the British pound, euro, Swiss franc, Australian dollar, and Colombian peso to U.S. dollar currency exchange rates. Although we generally deem investments in these countries to be of a long-term nature, are typically able to match any non-U.S. dollar borrowings with investments in such currencies, and historically have not needed to repatriate a material amount of earnings back to the U.S., increases or decreases in the value of the respective non-U.S. dollar currencies to U.S. dollar exchange rates may impact our financial condition and/or our results of operations. Based solely on our 2022 operating results, a 10% change to the following exchange rates would have impacted our net income, FFO, and Normalized FFO by the amounts below (in thousands):

	<b>Net Income Impact</b>	<b>FFO Impact</b>	<b>NFFO Impact</b>
British pound (£) .....	\$ 9,242	\$ 17,949	\$ 18,021
Euro (€) .....	1,937	6,055	6,444
Swiss franc (CHF) .....	2,920	5,137	3,648
Australian dollar (A\$) .....	1,125	3,151	3,151
Colombian peso (COP) .....	1,137	1,167	1,167

## **ITEM 8. Financial Statements and Supplementary Data**

### **Report of Independent Registered Public Accounting Firm**

To the Board of Directors and Stockholders of Medical Properties Trust, Inc.

#### ***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of Medical Properties Trust, Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of net income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes and financial statement schedules listed in the index appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in *Internal Control — Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in *Internal Control — Integrated Framework* (2013) issued by the COSO.

#### ***Basis for Opinions***

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

#### ***Definition and Limitations of Internal Control over Financial Reporting***

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable

assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### ***Critical Audit Matters***

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

#### ***Acquired Real Estate Purchase Price Allocations***

As described in Notes 2 and 3 to the consolidated financial statements, management allocates the purchase price of acquired properties to tangible and identified lease intangible assets based on their fair values. In 2022, the Company acquired a total of \$668 million of land, building and intangible lease assets. In making estimates of fair values for purposes of allocating purchase prices of acquired real estate to tangible and identified lease intangible assets, management utilizes information from a number of sources including available real estate broker data, independent appraisals that may be obtained in connection with the acquisition of the respective property, internal data from previous acquisitions or developments, other market data, and significant assumptions such as capitalization rates and market rental rates.

The principal considerations for our determination that performing procedures relating to the acquired real estate purchase price allocations is a critical audit matter are (i) the significant judgments by management when developing the fair value measurements and allocating the purchase price of the acquired properties to the tangible and lease intangible assets acquired, which in turn led to a high degree of auditor judgment and subjectivity in performing procedures and evaluating audit evidence, (ii) significant audit effort was required in assessing the reasonableness of significant assumptions such as capitalization rates and market rental rates used by management to estimate the fair value of each tangible and lease intangible asset component, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included testing the effectiveness of controls relating to management's acquired real estate purchase price allocations, including controls over the fair value of each tangible and identified lease intangible asset acquired. These procedures also included, among others, testing management's process by evaluating the significant assumptions related to capitalization rates and market rental rates, and the methodology used by management in developing the estimated fair values and allocations of the purchase price to the tangible and identified lease intangible assets acquired. Testing management's process included using professionals with specialized skill and knowledge to assist in evaluating the valuation methodologies and significant assumptions used by management, such as capitalization rates and market rental rates, for certain acquisitions. Evaluating the reasonableness of assumptions involved considering internal data from previous acquisitions, where relevant.

/s/ PricewaterhouseCoopers LLP  
Birmingham, Alabama  
March 1, 2023

We have served as the Company's auditor since 2008.

## **Report of Independent Registered Public Accounting Firm**

To the Partners of MPT Operating Partnership, L.P.:

### ***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of MPT Operating Partnership, L.P. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of net income, of comprehensive income, of capital and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes and financial statement schedules listed in the index appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in *Internal Control — Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in *Internal Control — Integrated Framework* (2013) issued by the COSO.

### ***Basis for Opinions***

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

### ***Definition and Limitations of Internal Control over Financial Reporting***

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance

with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### ***Critical Audit Matters***

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

#### ***Acquired Real Estate Purchase Price Allocations***

As described in Notes 2 and 3 to the consolidated financial statements, management allocates the purchase price of acquired properties to tangible and identified lease intangible assets based on their fair values. In 2022, the Company acquired a total of \$668 million of land, building and intangible lease assets. In making estimates of fair values for purposes of allocating purchase prices of acquired real estate to tangible and identified lease intangible assets, management utilizes information from a number of sources including available real estate broker data, independent appraisals that may be obtained in connection with the acquisition of the respective property, internal data from previous acquisitions or developments, other market data, and significant assumptions such as capitalization rates and market rental rates.

The principal considerations for our determination that performing procedures relating to the acquired real estate purchase price allocations is a critical audit matter are (i) the significant judgments by management when developing the fair value measurements and allocating the purchase price of the acquired properties to the tangible and lease intangible assets acquired, which in turn led to a high degree of auditor judgment and subjectivity in performing procedures and evaluating audit evidence, (ii) significant audit effort was required in assessing the reasonableness of significant assumptions such as capitalization rates and market rental rates used by management to estimate the fair value of each tangible and lease intangible asset component, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included testing the effectiveness of controls relating to management's acquired real estate purchase price allocations, including controls over the fair value of each tangible and identified lease intangible asset acquired. These procedures also included, among others, testing management's process by evaluating the significant assumptions related to capitalization rates and market rental rates, and the methodology used by management in developing the estimated fair values and allocations of the purchase price to the tangible and identified lease intangible assets acquired. Testing management's process included using professionals with specialized skill and knowledge to assist in evaluating the valuation methodologies and significant assumptions used by management, such as capitalization rates and market rental rates, for certain acquisitions. Evaluating the reasonableness of assumptions involved considering internal data from previous acquisitions, where relevant.

/s/ PricewaterhouseCoopers LLP  
Birmingham, Alabama  
March 1, 2023

We have served as the Company's auditor since 2008.



**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES**  
**Consolidated Balance Sheets**

	December 31,	
	2022	2021
	(Amounts in thousands, except for per share data)	
ASSETS		
Real estate assets		
Land . . . . .	\$ 1,948,216	\$ 1,961,478
Buildings and improvements . . . . .	10,352,308	10,581,992
Construction in progress . . . . .	167,420	101,439
Intangible lease assets . . . . .	1,394,471	1,417,813
Investment in financing leases . . . . .	1,691,323	2,053,327
Real estate held for sale . . . . .	—	1,096,505
Mortgage loans . . . . .	364,101	213,211
Gross investment in real estate assets . . . . .	15,917,839	17,425,765
Accumulated depreciation . . . . .	(1,008,340)	(853,879)
Accumulated amortization . . . . .	(184,972)	(139,221)
Net investment in real estate assets . . . . .	14,724,527	16,432,665
Cash and cash equivalents . . . . .	235,668	459,227
Interest and rent receivables . . . . .	167,035	56,229
Straight-line rent receivables . . . . .	787,166	728,522
Investments in unconsolidated real estate joint ventures . . . . .	1,497,903	1,152,927
Investments in unconsolidated operating entities . . . . .	1,444,872	1,289,434
Other loans . . . . .	227,839	67,317
Other assets . . . . .	572,990	333,480
Total Assets . . . . .	\$19,658,000	\$20,519,801
LIABILITIES AND EQUITY		
Liabilities		
Debt, net . . . . .	\$10,268,412	\$11,282,770
Accounts payable and accrued expenses . . . . .	621,324	607,792
Deferred revenue . . . . .	27,727	25,563
Obligations to tenants and other lease liabilities . . . . .	146,130	158,005
Total Liabilities . . . . .	11,063,593	12,074,130
Commitments and Contingencies		
Equity		
Preferred stock, \$0.001 par value. Authorized 10,000 shares; no shares outstanding . . . . .	—	—
Common stock, \$0.001 par value. Authorized 750,000 shares; issued and outstanding — 597,476 shares at December 31, 2022 and 596,748 shares at December 31, 2021 . . . . .	597	597
Additional paid-in capital . . . . .	8,535,140	8,564,009
Retained earnings (deficit) . . . . .	116,285	(87,691)
Accumulated other comprehensive loss . . . . .	(59,184)	(36,727)
Total Medical Properties Trust, Inc. stockholders' equity . . . . .	8,592,838	8,440,188
Non-controlling interests . . . . .	1,569	5,483
Total Equity . . . . .	8,594,407	8,445,671
Total Liabilities and Equity . . . . .	\$19,658,000	\$20,519,801

See accompanying notes to consolidated financial statements.

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES**  
**Consolidated Statements of Net Income**

	For the Years Ended December 31,		
	2022	2021	2020
	(Amounts in thousands, except for per share data)		
<b>Revenues</b>			
Rent billed . . . . .	\$ 968,874	\$ 931,942	\$ 741,311
Straight-line rent . . . . .	204,159	241,433	158,881
Income from financing leases . . . . .	203,580	202,599	206,550
Interest and other income . . . . .	166,238	168,695	142,496
Total revenues . . . . .	1,542,851	1,544,669	1,249,238
<b>Expenses</b>			
Interest . . . . .	359,036	367,393	328,728
Real estate depreciation and amortization . . . . .	332,977	321,249	264,245
Property-related . . . . .	45,697	39,098	24,890
General and administrative . . . . .	160,494	145,638	131,663
Total expenses . . . . .	898,204	873,378	749,526
<b>Other income (expense)</b>			
Gain (loss) on sale of real estate . . . . .	536,755	52,471	(2,833)
Real estate and other impairment charges, net . . . . .	(268,375)	(39,411)	(19,006)
Earnings from equity interests . . . . .	40,800	28,488	20,417
Debt refinancing and unutilized financing costs . . . . .	(9,452)	(27,650)	(28,180)
Other (including fair value adjustments on securities) . . . . .	15,344	45,699	(6,782)
Total other income (expense) . . . . .	315,072	59,597	(36,384)
<b>Income before income tax</b> . . . . .	959,719	730,888	463,328
Income tax expense . . . . .	(55,900)	(73,948)	(31,056)
<b>Net income</b> . . . . .	903,819	656,940	432,272
Net income attributable to non-controlling interests . . . . .	(1,222)	(919)	(822)
<b>Net income attributable to MPT common stockholders</b> . . . . .	<u>\$ 902,597</u>	<u>\$ 656,021</u>	<u>\$ 431,450</u>
<b>Earnings per common share — basic and diluted</b>			
Net income attributable to MPT common stockholders . . . . .	<u>\$ 1.50</u>	<u>\$ 1.11</u>	<u>\$ 0.81</u>
Weighted average shares outstanding — basic . . . . .	<u>598,634</u>	<u>588,817</u>	<u>529,239</u>
Weighted average shares outstanding — diluted . . . . .	<u>598,837</u>	<u>590,139</u>	<u>530,461</u>

See accompanying notes to consolidated financial statements.

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES**  
**Consolidated Statements of Comprehensive Income**

(In thousands)	For the Years Ended December 31,		
	2022	2021	2020
Net income .....	\$ 903,819	\$656,940	\$432,272
Other comprehensive income:			
Unrealized gain (loss) on interest rate swaps, net of tax .....	100,550	52,288	(33,091)
Foreign currency translation (loss) gain .....	(123,007)	(37,691)	44,672
Total comprehensive income .....	881,362	671,537	443,853
Comprehensive income attributable to non-controlling interests .....	(1,222)	(919)	(822)
Comprehensive income attributable to MPT common stockholders .....	<u>\$ 880,140</u>	<u>\$670,618</u>	<u>\$443,031</u>

See accompanying notes to consolidated financial statements.

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES**  
**Consolidated Statements of Equity**  
**For the Years Ended December 31, 2022, 2021 and 2020**

(In thousands, except per share amounts)	Preferred		Common		Additional Paid-in Capital	Retained Earnings (Deficit)	Accumulated Other Comprehensive Loss	Non- Controlling Interests	Total Equity
	Shares	Par Value	Shares	Par Value					
<b>Balance at December 31, 2019</b> . . . .	—	\$—	517,456	\$518	\$7,007,422	\$ 83,012	\$ (62,905)	\$ 107	\$7,028,154
Net income . . . . .	—	—	—	—	—	431,450	—	822	432,272
Cumulative effect of change in accounting principles . . . . .	—	—	—	—	—	(8,399)	—	—	(8,399)
Unrealized loss on interest rate swaps, net of tax . . . . .	—	—	—	—	—	—	(33,091)	—	(33,091)
Foreign currency translation gain . . .	—	—	—	—	—	—	44,672	—	44,672
Stock vesting and amortization of stock-based compensation . . . . .	—	—	2,893	2	47,152	—	—	—	47,154
Sale of non-controlling interests . . . .	—	—	—	—	—	—	—	5,097	5,097
Redemption of MOP units . . . . .	—	—	—	—	(4,928)	—	—	—	(4,928)
Distributions to non-controlling interests . . . . .	—	—	—	—	—	—	—	(701)	(701)
Proceeds from offering (net of offering costs) . . . . .	—	—	21,004	21	411,080	—	—	—	411,101
Dividends declared (\$1.08 per common share) . . . . .	—	—	—	—	—	(577,474)	—	—	(577,474)
<b>Balance at December 31, 2020</b> . . . .	—	\$—	541,353	\$541	\$7,460,726	\$ (71,411)	\$ (51,324)	\$ 5,325	\$7,343,857
Net income . . . . .	—	—	—	—	—	656,021	—	919	656,940
Unrealized gain on interest rate swaps, net of tax . . . . .	—	—	—	—	—	—	52,288	—	52,288
Foreign currency translation loss . . .	—	—	—	—	—	—	(37,691)	—	(37,691)
Stock vesting and amortization of stock-based compensation . . . . .	—	—	2,332	3	52,107	—	—	—	52,110
Distributions to non-controlling interests . . . . .	—	—	—	—	—	—	—	(761)	(761)
Proceeds from offering (net of offering costs) . . . . .	—	—	53,063	53	1,051,176	—	—	—	1,051,229
Dividends declared (\$1.12 per common share) . . . . .	—	—	—	—	—	(672,301)	—	—	(672,301)
<b>Balance at December 31, 2021</b> . . . .	—	\$—	596,748	\$597	\$8,564,009	\$ (87,691)	\$ (36,727)	\$ 5,483	\$8,445,671
Net income . . . . .	—	—	—	—	—	902,597	—	1,222	903,819
Unrealized gain on interest rate swaps, net of tax . . . . .	—	—	—	—	—	—	100,550	—	100,550
Foreign currency translation loss . . .	—	—	—	—	—	—	(123,007)	—	(123,007)
Stock vesting and amortization of stock-based compensation . . . . .	—	—	3,675	3	49,418	—	—	—	49,421
Stock vesting — satisfaction of tax withholdings . . . . .	—	—	(1,302)	(1)	(29,921)	—	—	—	(29,922)
Repurchase of common stock . . . . .	—	—	(1,645)	(2)	(17,938)	—	—	—	(17,940)
Acquisition of non-controlling interest . . . . .	—	—	—	—	(30,428)	—	—	(4,594)	(35,022)
Issuance of non-controlling interests . . . . .	—	—	—	—	—	—	—	1,054	1,054
Distributions to non-controlling interests . . . . .	—	—	—	—	—	—	—	(1,596)	(1,596)
Dividends declared (\$1.16 per common share) . . . . .	—	—	—	—	—	(698,621)	—	—	(698,621)
<b>Balance at December 31, 2022</b> . . . .	—	\$—	597,476	\$597	\$8,535,140	\$ 116,285	\$ (59,184)	\$ 1,569	\$8,594,407

See accompanying notes to consolidated financial statements.

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES**  
**Consolidated Statements of Cash Flows**

	For the Years Ended December 31,		
	2022	2021	2020
	(Amounts in thousands)		
<b>Operating activities</b>			
Net income	\$ 903,819	\$ 656,940	\$ 432,272
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	345,577	333,781	275,953
Amortization of deferred financing costs and debt discount	17,045	16,856	13,099
Straight-line rent revenue and other	(282,504)	(288,717)	(226,906)
Stock-based compensation	49,421	52,110	47,154
(Gain) loss from sale of real estate	(536,755)	(52,471)	2,833
Real estate and other impairment charges	268,375	39,411	19,006
Write-off of unbilled rent and other	34,605	7,213	26,415
Debt refinancing and unutilized financing costs	9,452	27,650	28,180
Gain on sale of equity investments	—	(40,945)	—
Tax rate and other changes	10,697	34,796	9,295
Pre-acquisition rent collected — Circle Transaction	—	—	(35,020)
Other adjustments	6,108	11,913	8,134
Changes in:			
Interest and rent receivables	(116,420)	(23,867)	(2,438)
Other assets	(4,029)	(4,375)	18,264
Accounts payable and accrued expenses	33,576	54,058	(18,424)
Deferred revenue	43	(12,697)	19,819
Net cash provided by operating activities	739,010	811,656	617,636
<b>Investing activities</b>			
Cash paid for acquisitions and other related investments	(1,332,962)	(5,350,239)	(4,249,180)
Net proceeds from sale of real estate	2,185,574	246,468	94,177
Principal received on loans receivable	53,322	1,595,708	1,306,187
Investment in loans receivable	(207,542)	(58,932)	(62,651)
Construction in progress and other	(109,237)	(67,725)	(68,350)
Proceeds from sale and return of equity investment	14,295	65,546	69,224
Capital additions and other investments, net	(207,394)	(289,239)	(36,180)
Net cash provided by (used for) investing activities	396,056	(3,858,413)	(2,946,773)
<b>Financing activities</b>			
Proceeds from term debt, net of discount	128,536	3,407,535	2,215,950
Payments of term debt	(869,606)	(1,390,994)	(800,000)
Revolving credit facilities, net	203,576	559,985	162,633
Dividends paid	(698,535)	(643,473)	(567,969)
Lease deposits and other obligations to tenants	(5,020)	17,815	21,706
Proceeds from sale of common shares, net of offering costs	—	1,051,229	411,101
Repurchase of common stock	(17,940)	—	—
Stock vesting — satisfaction of tax withholdings	(29,922)	—	—
Payment of debt refinancing, deferred financing costs, and other financing activities	(53,612)	(54,489)	(42,347)
Net cash (used for) provided by financing activities	(1,342,523)	2,947,608	1,401,074
Decrease in cash, cash equivalents, and restricted cash for the year	(207,457)	(99,149)	(928,063)
Effect of exchange rate changes	(12,887)	4,662	16,441
Cash, cash equivalents, and restricted cash at beginning of year	461,882	556,369	1,467,991
<b>Cash, cash equivalents, and restricted cash at end of year</b>	<b>\$ 241,538</b>	<b>\$ 461,882</b>	<b>\$ 556,369</b>
Interest paid, including capitalized interest of \$6,454 in 2022, \$3,289 in 2021, and \$3,030 in 2020	\$ 353,838	\$ 326,406	\$ 309,920
Supplemental schedule of non-cash financing activities:			
Dividends declared, unpaid	\$ 176,580	\$ 176,494	\$ 147,666
Cash, cash equivalents, and restricted cash are comprised of the following:			
Beginning of period:			
Cash and cash equivalents	\$ 459,227	\$ 549,884	\$ 1,462,286
Restricted cash, included in Other assets	2,655	6,485	5,705
	<u>\$ 461,882</u>	<u>\$ 556,369</u>	<u>\$ 1,467,991</u>
End of period:			
Cash and cash equivalents	\$ 235,668	\$ 459,227	\$ 549,884
Restricted cash, included in Other assets	5,870	2,655	6,485
	<u>\$ 241,538</u>	<u>\$ 461,882</u>	<u>\$ 556,369</u>

See accompanying notes to consolidated financial statements.

**MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES**  
**Consolidated Balance Sheets**

	December 31,	
	2022	2021
	(Amounts in thousands, except for per unit data)	
ASSETS		
Real estate assets		
Land . . . . .	\$ 1,948,216	\$ 1,961,478
Buildings and improvements . . . . .	10,352,308	10,581,992
Construction in progress . . . . .	167,420	101,439
Intangible lease assets . . . . .	1,394,471	1,417,813
Investment in financing leases . . . . .	1,691,323	2,053,327
Real estate held for sale . . . . .	—	1,096,505
Mortgage loans . . . . .	364,101	213,211
Gross investment in real estate assets . . . . .	15,917,839	17,425,765
Accumulated depreciation . . . . .	(1,008,340)	(853,879)
Accumulated amortization . . . . .	(184,972)	(139,221)
Net investment in real estate assets . . . . .	14,724,527	16,432,665
Cash and cash equivalents . . . . .	235,668	459,227
Interest and rent receivables . . . . .	167,035	56,229
Straight-line rent receivables . . . . .	787,166	728,522
Investments in unconsolidated real estate joint ventures . . . . .	1,497,903	1,152,927
Investments in unconsolidated operating entities . . . . .	1,444,872	1,289,434
Other loans . . . . .	227,839	67,317
Other assets . . . . .	572,990	333,480
Total Assets . . . . .	\$19,658,000	\$20,519,801
LIABILITIES AND CAPITAL		
Liabilities		
Debt, net . . . . .	\$10,268,412	\$11,282,770
Accounts payable and accrued expenses . . . . .	444,354	430,908
Deferred revenue . . . . .	27,727	25,563
Obligations to tenants and other lease liabilities . . . . .	146,130	158,005
Payable due to Medical Properties Trust, Inc. . . . .	176,580	176,494
Total Liabilities . . . . .	11,063,203	12,073,740
Commitments and Contingencies		
Capital		
General partner — issued and outstanding — 5,976 units at December 31, 2022 and 5,968 units at December 31, 2021 . . . . .	86,599	84,847
Limited Partners — issued and outstanding — 591,500 units at December 31, 2022 and 590,780 units at December 31, 2021 . . . . .	8,565,813	8,392,458
Accumulated other comprehensive loss . . . . .	(59,184)	(36,727)
Total MPT Operating Partnership, L.P. capital . . . . .	8,593,228	8,440,578
Non-controlling interests . . . . .	1,569	5,483
Total Capital . . . . .	8,594,797	8,446,061
Total Liabilities and Capital . . . . .	\$19,658,000	\$20,519,801

See accompanying notes to consolidated financial statements.

**MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES**  
**Consolidated Statements of Net Income**

	For the Years Ended December 31,		
	2022	2021	2020
	(Amounts in thousands, except for per unit data)		
<b>Revenues</b>			
Rent billed . . . . .	\$ 968,874	\$ 931,942	\$ 741,311
Straight-line rent . . . . .	204,159	241,433	158,881
Income from financing leases . . . . .	203,580	202,599	206,550
Interest and other income . . . . .	166,238	168,695	142,496
Total revenues . . . . .	1,542,851	1,544,669	1,249,238
<b>Expenses</b>			
Interest . . . . .	359,036	367,393	328,728
Real estate depreciation and amortization . . . . .	332,977	321,249	264,245
Property-related . . . . .	45,697	39,098	24,890
General and administrative . . . . .	160,494	145,638	131,663
Total expenses . . . . .	898,204	873,378	749,526
<b>Other income (expense)</b>			
Gain (loss) on sale of real estate . . . . .	536,755	52,471	(2,833)
Real estate and other impairment charges, net . . . . .	(268,375)	(39,411)	(19,006)
Earnings from equity interests . . . . .	40,800	28,488	20,417
Debt refinancing and unutilized financing costs . . . . .	(9,452)	(27,650)	(28,180)
Other (including fair value adjustments on securities) . . . . .	15,344	45,699	(6,782)
Total other income (expense) . . . . .	315,072	59,597	(36,384)
<b>Income before income tax</b> . . . . .	959,719	730,888	463,328
Income tax expense . . . . .	(55,900)	(73,948)	(31,056)
<b>Net income</b> . . . . .	903,819	656,940	432,272
Net income attributable to non-controlling interests . . . . .	(1,222)	(919)	(822)
<b>Net income attributable to MPT Operating Partnership partners</b> . .	<u><u>\$ 902,597</u></u>	<u><u>\$ 656,021</u></u>	<u><u>\$ 431,450</u></u>
<b>Earnings per unit — basic and diluted</b>			
Net income attributable to MPT Operating Partnership partners . . . . .	<u><u>\$ 1.50</u></u>	<u><u>\$ 1.11</u></u>	<u><u>\$ 0.81</u></u>
Weighted average units outstanding — basic . . . . .	<u><u>598,634</u></u>	<u><u>588,817</u></u>	<u><u>529,239</u></u>
Weighted average units outstanding — diluted . . . . .	<u><u>598,837</u></u>	<u><u>590,139</u></u>	<u><u>530,461</u></u>

See accompanying notes to consolidated financial statements.

**MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES**  
**Consolidated Statements of Comprehensive Income**

(In thousands)	For the Years Ended December 31,		
	2022	2021	2020
Net income .....	\$ 903,819	\$656,940	\$432,272
Other comprehensive income:			
Unrealized gain (loss) on interest rate swaps, net of tax .....	100,550	52,288	(33,091)
Foreign currency translation (loss) gain .....	(123,007)	(37,691)	44,672
Total comprehensive income .....	881,362	671,537	443,853
Comprehensive income attributable to non-controlling interests .....	(1,222)	(919)	(822)
Comprehensive income attributable to MPT Operating Partnership partners .....	<u>\$ 880,140</u>	<u>\$670,618</u>	<u>\$443,031</u>

See accompanying notes to consolidated financial statements.



**MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES**  
**Consolidated Statements of Capital**  
**For the Years Ended December 31, 2022, 2021 and 2020**

	General Partner		Limited Partners				Accumulated Other Comprehensive Loss	Non-Controlling Interests	Total Capital
	Units	Unit Value	Units	Unit Value	Units	Unit Value			
(In thousands, except per unit amounts)									
<b>Balance at December 31, 2019</b>	5,176	\$70,939	512,280	\$7,020,403	232	\$—	\$ (62,905)	\$ 107	\$7,028,544
Net income	—	4,315	—	427,135	—	—	—	822	432,272
Cumulative effect of change in accounting principles	—	(84)	—	(8,315)	—	—	—	—	(8,399)
Unrealized loss on interest rate swaps, net of tax	—	—	—	—	—	—	(33,091)	—	(33,091)
Foreign currency translation gain	—	—	—	—	—	—	44,672	—	44,672
Unit vesting and amortization of unit-based compensation	29	472	2,864	46,682	—	—	—	—	47,154
Sale of non-controlling interests	—	—	—	—	—	—	—	5,097	5,097
Conversion of LTIP units to common units	—	—	232	—	(232)	—	—	—	—
Redemption of common units	—	—	(232)	(4,928)	—	—	—	—	(4,928)
Distributions to non-controlling interests	—	—	—	—	—	—	—	(701)	(701)
Proceeds from offering (net of offering costs)	209	4,111	20,795	406,990	—	—	—	—	411,101
Distributions declared (\$1.08 per unit)	—	(5,776)	—	(571,698)	—	—	—	—	(577,474)
<b>Balance at December 31, 2020</b>	5,414	\$73,977	535,939	\$7,316,269	—	\$—	\$ (51,324)	\$ 5,325	\$7,344,247
Net income	—	6,560	—	649,461	—	—	—	919	656,940
Unrealized gain on interest rate swaps, net of tax	—	—	—	—	—	—	52,288	—	52,288
Foreign currency translation loss	—	—	—	—	—	—	(37,691)	—	(37,691)
Unit vesting and amortization of unit-based compensation	23	521	2,309	51,589	—	—	—	—	52,110
Distributions to non-controlling interests	—	—	—	—	—	—	—	(761)	(761)
Proceeds from offering (net of offering costs)	531	10,512	52,532	1,040,717	—	—	—	—	1,051,229
Distributions declared (\$1.12 per unit)	—	(6,723)	—	(665,578)	—	—	—	—	(672,301)
<b>Balance at December 31, 2021</b>	5,968	\$84,847	590,780	\$8,392,458	—	\$—	\$ (36,727)	\$ 5,483	\$8,446,061
Net income	—	9,026	—	893,571	—	—	—	1,222	903,819
Unrealized gain on interest rate swaps, net of tax	—	—	—	—	—	—	100,550	—	100,550
Foreign currency translation loss	—	—	—	—	—	—	(123,007)	—	(123,007)
Unit vesting and amortization of unit-based compensation	37	494	3,638	48,927	—	—	—	—	49,421
Unit vesting—satisfaction of tax withholdings	(13)	(299)	(1,289)	(29,623)	—	—	—	—	(29,922)
Repurchase of units	(16)	(179)	(1,629)	(17,761)	—	—	—	—	(17,940)
Acquisition of non-controlling interest	—	(304)	—	(30,124)	—	—	—	(4,594)	(35,022)
Issuance of non-controlling interests	—	—	—	—	—	—	—	1,054	1,054
Distributions to non-controlling interests	—	—	—	—	—	—	—	(1,596)	(1,596)
Distributions declared (\$1.16 per unit)	—	(6,986)	—	(691,635)	—	—	—	—	(698,621)
<b>Balance at December 31, 2022</b>	5,976	\$86,599	591,500	\$8,565,813	—	\$—	\$ (59,184)	\$ 1,569	\$8,594,797

See accompanying notes to consolidated financial statements.

**MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES**  
**Consolidated Statements of Cash Flows**

	For the Years Ended December 31,		
	2022	2021	2020
	(Amounts in thousands)		
<b>Operating activities</b>			
Net income	\$ 903,819	\$ 656,940	\$ 432,272
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	345,577	333,781	275,953
Amortization of deferred financing costs and debt discount	17,045	16,856	13,099
Straight-line rent revenue and other	(282,504)	(288,717)	(226,906)
Unit-based compensation	49,421	52,110	47,154
(Gain) loss from sale of real estate	(536,755)	(52,471)	2,833
Real estate and other impairment charges	268,375	39,411	19,006
Write-off of unbilled rent and other	34,605	7,213	26,415
Debt refinancing and unutilized financing costs	9,452	27,650	28,180
Gain on sale of equity investments	—	(40,945)	—
Tax rate and other changes	10,697	34,796	9,295
Pre-acquisition rent collected — Circle Transaction	—	—	(35,020)
Other adjustments	6,108	11,913	8,134
Changes in:			
Interest and rent receivables	(116,420)	(23,867)	(2,438)
Other assets	(4,029)	(4,375)	18,264
Accounts payable and accrued expenses	33,576	54,058	(18,424)
Deferred revenue	43	(12,697)	19,819
Net cash provided by operating activities	739,010	811,656	617,636
<b>Investing activities</b>			
Cash paid for acquisitions and other related investments	(1,332,962)	(5,350,239)	(4,249,180)
Net proceeds from sale of real estate	2,185,574	246,468	94,177
Principal received on loans receivable	53,322	1,595,708	1,306,187
Investment in loans receivable	(207,542)	(58,932)	(62,651)
Construction in progress and other	(109,237)	(67,725)	(68,350)
Proceeds from sale and return of equity investment	14,295	65,546	69,224
Capital additions and other investments, net	(207,394)	(289,239)	(36,180)
Net cash provided by (used for) investing activities	396,056	(3,858,413)	(2,946,773)
<b>Financing activities</b>			
Proceeds from term debt, net of discount	128,536	3,407,535	2,215,950
Payments of term debt	(869,606)	(1,390,994)	(800,000)
Revolving credit facilities, net	203,576	559,985	162,633
Distributions paid	(698,535)	(643,473)	(567,969)
Lease deposits and other obligations to tenants	(5,020)	17,815	21,706
Proceeds from sale of units, net of offering costs	—	1,051,229	411,101
Repurchase of units	(17,940)	—	—
Unit vesting — satisfaction of tax withholdings	(29,922)	—	—
Payment of debt refinancing, deferred financing costs, and other financing activities	(53,612)	(54,489)	(42,347)
Net cash (used for) provided by financing activities	(1,342,523)	2,947,608	1,401,074
Decrease in cash, cash equivalents, and restricted cash for the year	(207,457)	(99,149)	(928,063)
Effect of exchange rate changes	(12,887)	4,662	16,441
Cash, cash equivalents, and restricted cash at beginning of year	461,882	556,369	1,467,991
<b>Cash, cash equivalents and restricted cash at end of year</b>	<b>\$ 241,538</b>	<b>\$ 461,882</b>	<b>\$ 556,369</b>
Interest paid, including capitalized interest of \$6,454 in 2022, \$3,289 in 2021, and \$3,030 in 2020	\$ 353,838	\$ 326,406	\$ 309,920
Supplemental schedule of non-cash financing activities:			
Dividends declared, unpaid	\$ 176,580	\$ 176,494	\$ 147,666
Cash, cash equivalents, and restricted cash are comprised of the following:			
Beginning of period:			
Cash and cash equivalents	\$ 459,227	\$ 549,884	\$ 1,462,286
Restricted cash, included in Other assets	2,655	6,485	5,705
	<u>\$ 461,882</u>	<u>\$ 556,369</u>	<u>\$ 1,467,991</u>
End of period:			
Cash and cash equivalents	\$ 235,668	\$ 459,227	\$ 549,884
Restricted cash, included in Other assets	5,870	2,655	6,485
	<u>\$ 241,538</u>	<u>\$ 461,882</u>	<u>\$ 556,369</u>

See accompanying notes to consolidated financial statements.

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES**  
**MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES**  
**Notes To Consolidated Financial Statements**

**1. Organization**

Medical Properties Trust, Inc., a Maryland corporation, was formed on August 27, 2003, under the Maryland General Corporation Law for the purpose of engaging in the business of investing in, owning, and leasing healthcare real estate. Our operating partnership subsidiary, MPT Operating Partnership, L.P. (the “Operating Partnership”), through which we conduct substantially all of our operations, was formed in September 2003. At present, we own all of the partnership interests in the Operating Partnership and have elected to report our required disclosures and that of the Operating Partnership on a combined basis, except where material differences exist.

We operate as a real estate investment trust (“REIT”). Accordingly, we are generally not subject to United States (“U.S.”) federal income tax on our REIT taxable income, provided that we continue to qualify as a REIT and our distributions to our stockholders equal or exceed such taxable income. Certain non-real estate activities we undertake are conducted by entities which we elected to be treated as taxable REIT subsidiaries (“TRS”). Our TRS entities are subject to both U.S. federal and state income taxes. For our properties located outside the U.S., we are subject to the local taxes of the jurisdictions where our properties reside and/or legal entities are domiciled; however, we do not expect to incur additional taxes, of a significant nature, in the U.S. from foreign-based income as the majority of such income flows through our REIT.

Our primary business strategy is to acquire and develop real estate and improvements, primarily for long-term lease to providers of healthcare services, such as operators of general acute care hospitals, behavioral health facilities, inpatient physical rehabilitation facilities, long-term acute care hospitals, and freestanding ER/urgent care facilities. We also make mortgage loans to healthcare operators collateralized by their real estate. In addition, we may make noncontrolling investments in our tenants, from time-to-time, typically in conjunction with larger real estate transactions with the tenant, which may enhance our overall return and provide for certain minority rights and protections.

Our business model facilitates acquisitions and recapitalizations, and allows operators of healthcare facilities to unlock the value of their real estate to fund facility improvements, technology upgrades, and other investments in operations. At December 31, 2022, we have investments in 444 facilities in 31 states in the U.S., in seven countries in Europe, one country in South America, and across Australia. We manage our business as a single business segment.

**2. Summary of Significant Accounting Policies**

*Use of Estimates:* The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We believe the estimates and assumptions underlying our consolidated financial statements at December 31, 2022 are reasonable and supportable based on the information available (particularly as it relates to our assessments of the recoverability of our real estate and the adequacy of our credit loss reserves on loans and financing receivables). Actual results could differ from those estimates.

*Principles of Consolidation:* Property holding entities and other subsidiaries of which we own 100% of the equity or have a controlling financial interest evidenced by ownership of a majority voting interest are consolidated. All inter-company balances and transactions are eliminated. For entities in which we own less than 100% of the equity interest, we consolidate the property if we have the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. For these entities, we record a non-controlling interest representing equity held by non-controlling interests.

We continually evaluate all of our transactions and investments to determine if they represent variable interests in a variable interest entity. If we determine that we have a variable interest in a variable interest entity, we then evaluate if we are the primary beneficiary of the variable interest entity. The evaluation is a qualitative assessment as to whether we have the ability to direct the activities of a variable interest entity that most significantly impact the entity's economic performance. We consolidate each variable interest entity in which we, by virtue of or transactions with our investments in the entity, are considered to be the primary beneficiary.

At December 31, 2022, we had loans and/or equity investments in certain variable interest entities approximating \$633 million, which represents our maximum exposure to loss as a result of our involvement in such entities. We have determined that we were not the primary beneficiary of any variable interest entity in which we hold a variable interest because we do not control the activities (such as the day-to-day operations) that most significantly impact the economic performance of these entities.

*Investments in Unconsolidated Entities:* Investments in entities in which we have the ability to significantly influence (but not control) are accounted for by the equity method. This includes the five investments in unconsolidated real estate joint ventures at December 31, 2022. Under the equity method of accounting, our share of the investee's earnings or losses are included in the "Earnings from equity interests" line of our consolidated statements of net income. Except for our joint ventures with Primotop Holdings S.à.r.l. ("Primotop") and Macquarie Asset Management ("MAM") (for which we handle the accounting of), we have elected to record our share of such investee's earnings or losses on a lag basis (not to exceed three months). The initial carrying value of investments in unconsolidated entities is based on the amount paid to purchase the interest in the investee entity. Subsequently, our investments are increased/decreased by our share in the investees' earnings/losses and decreased by cash distributions from our investees. To the extent that our cost basis is different from the basis reflected at the investee entity level, the basis difference is generally amortized over the lives of the related assets and liabilities, and such amortization is included in our share of equity in earnings of the investee.

We evaluate our equity method investments for impairment based upon a comparison of the fair value of the equity method investment to its carrying value, when impairment indicators exist. If we determine a decline in the fair value of an investment in an unconsolidated investee entity below its carrying value is other-than-temporary, an impairment is recorded.

Investments in entities in which we do not control nor do we have the ability to significantly influence and for which there is no readily determinable fair value (such as our investment in Steward Health Care System LLC ("Steward")) are accounted for at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions involving the investee. Cash distributions on these types of investments are recorded to either income upon receipt (if a return on investment) or as a reduction of our investment (if the distributions received are in excess of our share of the investee's earnings). For similar investments but for which there are readily determinable fair values, such investments are measured at fair value, with unrealized gains and losses recorded in income.

*Cash and Cash Equivalents:* Certificates of deposit, short-term investments with original maturities of three months or less, and money-market mutual funds are considered cash equivalents. The majority of our cash and cash equivalents are held at major commercial banks, which at times may exceed the Federal Deposit Insurance Corporation limit. We have not experienced any losses to-date on our invested cash. Cash and cash equivalents which have been restricted as to its use are recorded in other assets.

*Revenue Recognition:* Our revenues are primarily from leases and loans. For leases, we follow Accounting Standards Update ("ASU") 2016-02, "Leases", ("ASU 2016-02"). ASU 2016-02 sets out the principles for the recognition, measurement, presentation, and disclosure of leases for both parties to a contract (i.e. lessees and lessors). For lessors, we apply this standard as follows:

### Operating Lease Revenue

We receive income from operating leases based on the fixed required rents (base rents) per the lease agreements. Rent revenue from base rents is recorded on the straight-line method, when collectability of the lease payments is deemed probable, over the terms of the related lease agreements for new leases and the remaining terms of existing leases for those acquired as part of a property acquisition. The straight-line method records the periodic average amount of base rents earned over the term of a lease, taking into account contractual rent increases over the lease term. The straight-line method typically has the effect of recording more rent revenue from a lease than a tenant is required to pay early in the term of the lease. During the later parts of a lease term, this effect reverses with less rent revenue recorded than a tenant is required to pay. Rent revenue, as recorded on the straight-line method, in our consolidated statements of net income is presented as two amounts: rent billed and straight-line rent. Rent billed revenue is the amount of base rent actually billed to our tenants each period as required by the lease. Straight-line rent revenue is the difference between rent revenue earned based on the straight-line method and the amount recorded as rent billed revenue. We record the difference between rent revenues earned and amounts due per the respective lease agreements, as applicable, as an increase or decrease to straight-line rent receivables.

Rental payments received prior to their recognition as income are classified as deferred revenue.

### Financing Lease Revenue

Under ASU 2016-02, if an acquisition and subsequent lease of a property back to the seller does not meet the definition of a sale, we must account for the transaction as a financing lease with income recognized using the imputed interest method.

Another type of financing lease is a direct financing lease (“DFL”). For leases accounted for as DFLs, the future minimum lease payments are recorded as a receivable at lease inception, while, the difference between the future minimum lease payments and the estimated residual values less the cost of the properties is recorded as unearned income. Unearned income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Investments in DFLs are presented net of unearned income.

### Other Leasing Revenue

We begin recording base rent income from our development projects when the lessee takes physical possession of the facility, which may be different from the stated start date of the lease. Also, during construction of our development projects, we may be entitled to accrue rent based on the cost paid during the construction period (construction period rent). We accrue construction period rent as a receivable with a corresponding offset to deferred revenue during the construction period. When the lessee takes physical possession of the facility, we begin recognizing the deferred construction period revenue on the straight-line method over the term of the lease.

We also receive additional rent (contingent rent) under some leases based on increases in the consumer price index (“CPI”) (or similar index outside the U.S.) or when CPI exceeds the annual minimum percentage increase as stipulated in the lease. Contingent rents are recorded as rent billed revenue in the period earned.

Tenant payments for ground leases along with other operating expenses, such as property taxes and insurance, that are paid directly by us and reimbursed by our tenants are presented on a gross basis with the related revenues recorded in “Interest and other income” and the related expenses in “Property-related” in our consolidated statements of net income. All payments of other operating expenses made directly by the tenant to the applicable government or appropriate third-party vendor are recorded on a net basis.

### Interest Revenue

We receive interest income from our tenants/borrowers on mortgage loans, working capital loans, and other long-term loans. Interest income from these loans is recognized as earned based upon the principal outstanding and terms of the loans.

### Other Revenue

Commitment fees received from lessees for development and leasing services are initially recorded as deferred revenue and recognized as income over the initial term of a lease to produce a constant effective yield on the lease (interest method). Commitment and origination fees from lending services are also recorded as deferred revenue initially and recognized as income over the life of the loan using the interest method.

*Acquired Real Estate Purchase Price Allocation:* We account for acquisitions of real estate under asset acquisition accounting rules. Under this accounting standard, we allocate the purchase price (including any third-party transaction costs directly related to the acquisition) of acquired properties to tangible and identified intangible assets acquired and liabilities assumed (if any) based on their relative fair values. In making estimates of fair values for purposes of allocating purchase prices of acquired real estate, we may utilize a number of sources, from time-to-time, including available real estate broker data, independent appraisals that may be obtained in connection with the acquisition, internal data from previous acquisitions or developments, and other market data, including market comparables for significant assumptions such as market rental, capitalization, and discount rates. We also consider information obtained about each property as a result of our pre-acquisition due diligence, marketing, and leasing activities in estimating the fair value of the tangible and intangible assets acquired.

We measure the aggregate value of lease intangible assets acquired based on the difference between (i) the property valued with new or in-place leases adjusted to market rental rates and (ii) the property valued as if vacant. Management's estimates of value are made using methods similar to those used by independent appraisers (e.g., discounted cash flow analysis). Factors considered by management in our analysis include an estimate of carrying costs during hypothetical expected lease-up periods, considering current market conditions, and costs to execute similar leases. We also consider information obtained about each targeted facility as a result of our pre-acquisition due diligence, marketing, and leasing activities in estimating the fair value of the intangible assets acquired. In estimating carrying costs, management includes real estate taxes, insurance, and other operating expenses and estimates of lost rentals at market rates during the expected lease-up periods, which we expect to be about six months, but can be longer depending on specific local market conditions. Management also estimates costs to execute similar leases including leasing commissions, legal costs, and other related expenses to the extent that such costs are not already incurred in connection with a new lease origination as part of the transaction.

Other intangible assets acquired may include customer relationship intangible values which are based on management's evaluation of the specific characteristics of each prospective tenant's lease and our overall relationship with that tenant. Characteristics to be considered by management in allocating these values include the nature and extent of our existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant's credit quality, and expectations of lease renewals, including those existing under the terms of the lease agreement, among other factors.

We amortize the value of our lease intangible assets to expense over the term of the respective leases. If a lease is terminated early, the unamortized portion of the lease intangibles are charged to expense.

We record above-market and below-market in-place lease values, if any, for our facilities, which are based on the present value of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) management's estimate of fair market lease rates for the corresponding in-place leases, measured over a period equal to the remaining non-cancelable term of the lease. We amortize any resulting capitalized above-market lease values as a reduction of rental income over the lease term. We amortize any resulting

capitalized below-market lease values as an increase to rental income over the lease term. If a lease is terminated early, the unamortized portion of the capitalized above/below market lease value is recognized in rental income at that time.

*Real Estate and Depreciation:* Real estate, consisting of land, buildings and improvements, is maintained at cost. Although typically paid by our tenants, any expenditure for ordinary maintenance and repairs that we pay are expensed to operations as incurred. Significant renovations and improvements, which improve and/or extend the useful life of the asset, are capitalized and depreciated over their estimated useful lives. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets, including an estimated liquidation amount, during the expected holding periods are less than the carrying amounts of those assets. Impairment losses are measured as the difference between carrying value and fair value of the assets. For assets held for sale, we cease recording depreciation expense and adjust the assets' value to the lower of its carrying value or fair value, less cost of disposal. Fair value is based on estimated cash flows discounted at a risk-adjusted rate of interest. We classify real estate assets as held for sale when we have commenced an active program to sell the assets, and in the opinion of management, it is probable the asset will be sold within the next 12 months.

Construction in progress includes the cost of land, the cost of construction of buildings, improvements, and fixed equipment, and costs for design and engineering. Other costs, such as interest, legal, property taxes, and corporate project supervision, which can be directly associated with the project during construction, are also included in construction in progress. We commence capitalization of costs associated with a development project when the development of the future asset is probable and activities necessary to get the underlying property ready for its intended use have been initiated. We stop the capitalization of costs when the property is substantially complete and ready for its intended use.

Depreciation is calculated on the straight-line method over the estimated useful lives of the related real estate and other assets. Our weighted-average useful lives at December 31, 2022 are as follows:

Buildings and improvements .....	39.0 years
Lease intangibles .....	26.8 years
Leasehold improvements .....	14.4 years
Furniture, equipment, and other .....	9.8 years

#### *Credit Losses:*

Losses from Rent Receivables: For all leases, we continuously monitor the performance of our existing tenants including, but not limited to: admission levels and surgery/procedure volumes by type; current operating margins; ratio of our tenant's operating margins both to facility rent and to facility rent plus other fixed costs; trends in revenue, cash collections, patient mix; and the effect of evolving healthcare regulations, adverse economic and political conditions, such as rising inflation and interest rates, and other events ongoing on a tenant's profitability and liquidity.

Losses from Operating Lease Receivables: We utilize the information above along with the tenant's payment and default history in evaluating (on a property-by-property basis) whether or not a provision for losses on outstanding billed rent and/or straight-line rent receivables is needed. A provision for losses on rent receivables (including straight-line rent receivables) is ultimately recorded when it becomes probable that the receivable will not be collected in full. The provision is an amount which reduces the receivable to its estimated net realizable value based on a determination of the eventual amounts to be collected either from the debtor or from existing collateral, if any.

Losses on Financing Lease Receivables: We apply a forward-looking "expected credit loss" model to all of our financing receivables, including financing leases and loans. To do this, we have grouped our financial instruments into two primary pools of similar credit risk: secured and unsecured. The secured

instruments include our investments in financing receivables as all are secured by the underlying real estate, among other collateral. Within the two primary pools, we further grouped our instruments into sub-pools based on several tenant/borrower characteristics, including years of experience in the healthcare industry and in a particular market or region and overall capitalization. We then determined a credit loss percentage per pool based on our history over a period of time that closely matches the remaining terms of the financial instruments being analyzed and adjusted as needed for current trends or unusual circumstances. We have applied these credit loss percentages to the book value of the related instruments to establish a credit loss reserve on our financing lease receivables and such credit loss reserve (including the underlying assumptions) is reviewed and adjusted quarterly. If a financing receivable is under performing and is deemed uncollectible based on the lessee's overall financial condition, we will adjust the credit loss reserve based on the fair value of the underlying collateral.

We made the accounting policy election to exclude interest receivables from the credit loss reserve model. Instead, such receivables are impaired and an allowance recorded when it is deemed probable that we will be unable to collect all amounts due. Like operating lease receivables, the need for an allowance is based upon our assessment of the lessee's overall financial condition, economic resources and payment record, the prospects for support from any financially responsible guarantors, and, if appropriate, the realizable value of any collateral. Financing leases are placed on non-accrual status when we determine that the collectability of contractual amounts is not reasonably assured. If on non-accrual status, we generally account for the financing lease on a cash basis, in which income is recognized only upon receipt of cash.

**Loans:** Loans consist of mortgage loans, working capital loans, and other loans. Mortgage loans are collateralized by interests in real property. Working capital and other loans are typically collateralized by interests in receivables and corporate and individual guarantees. We record loans at cost. Like our financing lease receivables, we establish credit loss reserves on all outstanding loans based on historical credit losses of similar instruments. Such credit loss reserves, including the underlying assumptions, are reviewed and adjusted quarterly. If a loan's performance worsens and foreclosure is deemed probable for our collateral-based loans (after considering the borrower's overall financial condition as described above for leases), we will adjust the allowance for expected credit losses based on the current fair value of such collateral at the time the loan is deemed uncollectible. If the loan is not collateralized, the loan will be reserved for/written-off once it is determined that such loan is no longer collectible. Interest receivables on loans are excluded from the forward looking credit loss reserve model; however, we assess their collectability similar to how we assess collectability for interest receivables on financing leases described above.

The following table summarizes our credit loss reserves (in thousands):

	<u>December 31, 2022</u>	<u>December 31, 2021</u>
Balance at beginning of the year . . . . .	\$ 48,527	\$ 8,726
Provision (recovery) for credit loss, net . . . . .	99,009	41,710
Expected credit loss reserve related to financial instruments sold, repaid, or satisfied . .	(26,390)	(1,909)
Balance at end of year . . . . .	<u>\$121,146</u>	<u>\$48,527</u>

**Earnings Per Share/Units:** Basic earnings per common share/unit is computed by dividing net income by the weighted-average number of shares/units outstanding during the period. Diluted earnings per common share/unit is calculated by including the effect of dilutive securities.

Our unvested restricted stock awards contain non-forfeitable rights to dividends, and accordingly, these awards are deemed to be participating securities. These participating securities are included in the earnings allocation in computing both basic and diluted earnings per common share/unit.



*Income Taxes:* We conduct our business as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (“the Code”). To qualify as a REIT, we must meet certain organizational and operational requirements, including a requirement to distribute to stockholders at least 90% of our REIT’s ordinary taxable income. As a REIT, we generally pay little U.S. federal and state income tax because of the dividends paid deduction that we are allowed to take. If we fail to qualify as a REIT in any taxable year, we will then be subject to U.S. federal income taxes on our taxable income at regular corporate rates and will not be permitted to qualify for treatment as a REIT for federal income tax purposes for four years following the year during which qualification is lost, unless the Internal Revenue Service grants us relief under certain statutory provisions. Such an event could materially adversely affect our net income and net cash available for distribution to stockholders. However, we intend to operate in such a manner so that we will remain qualified as a REIT for U.S. federal income tax purposes.

Our financial statements include the operations of TRS entities. None of our TRS entities are entitled to a dividends paid deduction and are subject to U.S. federal, state, and local income taxes. Our TRS entities are authorized to provide property development, leasing, and management services for third-party owned properties, and we will make non-mortgage loans to and/or investments in our lessees through these entities.

With the property acquisitions and investments in Europe, Australia, and South America, we are subject to income taxes internationally. However, we do not expect to incur any additional income taxes, of a significant nature, in the U.S. as the majority such income from our international properties flows through our REIT income tax returns. For our TRS entities and international subsidiaries, we determine deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in our deferred tax assets/liabilities that results from a change in circumstances and that causes us to change our judgment about expected future tax consequences of events, is reflected in our tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss carryforwards. A valuation allowance is provided if we believe it is more likely than not that all or some portion of our deferred tax assets will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes us to change our judgment about our ability to realize the related deferred tax asset, is reflected in our tax provision when such changes occur.

The calculation of our income taxes involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. An income tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of technical merits. However, if a more likely than not position cannot be reached, we record a liability as an offset to the tax benefit and adjust the liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the uncertain tax position liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.

*Stock-Based Compensation:* We adopted the 2019 Equity Incentive Plan (the “Equity Incentive Plan”) during the second quarter of 2019, which was amended during the second quarter of 2022. Awards of restricted stock and other equity-based awards with service conditions are valued at the average stock price per share on the date of grant and are amortized to compensation expense over the service periods (typically three years), using the straight-line method. Awards that contain market conditions are valued on the grant date using a Monte Carlo valuation model and are amortized to compensation expense over the derived service periods, which correspond to the periods over which we estimate the awards will be earned, which generally range from three to five years, using the straight-line method. Awards with performance conditions are valued at the average stock price per share on the date of grant and are amortized using the straight-line method over the service period, adjusted for the probability of achieving the performance conditions. Forfeitures of stock-based awards are recognized as they occur.

*Deferred Costs:* Costs incurred that directly relate to the offerings of stock are deferred and netted against proceeds received from the offering. Leasing commissions and other third-party leasing costs that would not have been incurred if the lease was not obtained are capitalized as deferred leasing costs and amortized on the straight-line method over the terms of the related lease agreements. Costs identifiable with loans made to borrowers are capitalized and recognized as a reduction in interest income over the life of the loan.

*Deferred Financing Costs:* We generally capitalize financing costs incurred in connection with new financings and refinancings of debt. These costs are amortized over the lives of the related debt as an addition to interest expense. For debt with defined principal re-payment terms, the deferred costs are amortized to produce a constant effective yield on the debt (interest method) and are included within “Debt, net” on our consolidated balance sheets. For debt without defined principal repayment terms, such as our revolving credit facility, the deferred costs are amortized on the straight-line method over the term of the debt and are included as a component of “Other assets” on our consolidated balance sheets.

*Foreign Currency Translation and Transactions:* Certain of our international subsidiaries’ functional currencies are the local currencies of their respective countries. We translate the results of operations of our foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period, and we translate balance sheet accounts using exchange rates in effect at the end of the period. We record resulting currency translation adjustments in accumulated other comprehensive income (loss), a component of stockholders’ equity/partnership capital on our consolidated balance sheets.

Certain of our U.S. subsidiaries will enter into short-term and long-term transactions denominated in a foreign currency from time-to-time. Gains or losses resulting from these foreign currency transactions are revalued into U.S. dollars at the rates of exchange prevailing at the dates of the transactions. The effects of revaluation gains or losses on our short-term transactions are included in other income (expense) in the consolidated statements of income, while the revaluation effects on our long-term investments are recorded in accumulated other comprehensive income (loss) on our consolidated balance sheets.

*Derivative Financial Investments and Hedging Activities:* During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and/or foreign currency risk. We record our derivative and hedging instruments at fair value on the balance sheet. Changes in the estimated fair value of derivative instruments that are not designated as hedges or that do not meet the criteria for hedge accounting are recognized in earnings. For derivatives designated as cash flow hedges, the change in the estimated fair value of the effective portion of the derivative is recognized in accumulated other comprehensive income (loss) on our consolidated balance sheets, whereas the change in the estimated fair value of the ineffective portion is recognized in earnings. For derivatives designated as fair value hedges, the change in the estimated fair value of the effective portion of the derivatives offsets the change in the estimated fair value of the hedged item, whereas the change in the estimated fair value of the ineffective portion is recognized in earnings.

To qualify for hedge accounting, we formally document all relationships between hedging instruments and hedged items, as well as our risk management objective and strategy for undertaking the hedge prior to entering into a derivative transaction. This process includes specific identification of the hedging instrument and the hedge transaction, the nature of the risk being hedged and how the hedging instrument’s effectiveness in hedging the exposure to the hedged transaction’s variability in cash flows attributable to the hedged risk will be assessed. Both at the inception of the hedge and on an ongoing basis, we assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in cash flows or fair values of hedged items. In addition, for cash flow hedges, we assess whether the underlying forecasted transaction will occur. We discontinue hedge accounting if a derivative is not determined to be highly effective as a hedge or that it is probable that the underlying forecasted transaction will not occur.

*Fair Value Measurement:* We measure and disclose the estimated fair value of financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are

considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:

- *Level 1* — quoted prices for *identical* instruments in active markets;
- *Level 2* — quoted prices for *similar* instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
- *Level 3* — fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are *unobservable*.

We measure fair value using a set of standardized procedures that are outlined herein for all assets and liabilities which are required to be measured at their estimated fair value on either a recurring or non-recurring basis. When available, we utilize quoted market prices from an independent third party source to determine fair value and classify such items in Level 1. In some instances where a market price is available, but the instrument is in an inactive or over-the-counter market, we apply the dealer (market maker) pricing estimate and classify the asset or liability in Level 2.

If quoted market prices or inputs are not available, fair value measurements are based upon valuation models that utilize current market or independently sourced market inputs, such as interest rates, option volatilities, credit spreads, market capitalization rates, etc. Items valued using such internally-generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a result, the asset or liability could be classified in either Level 2 or 3 even though there may be some significant inputs that are readily observable. Internal fair value models and techniques that have been used by us include discounted cash flow and Monte Carlo valuation models. We also consider counterparty's and our own credit risk on derivatives and other liabilities measured at their estimated fair value.

*Fair Value Option Election:* For our equity investment in the international joint venture and equity interest in Springstone Health Opco, LLC ("Springstone"), along with any related investments such as loans (see Note 3 for more details), we have elected to account for these investments at fair value due to the size of the investments and because we believe this method is more reflective of current values. We have not made a similar election for other investments that exist at December 31, 2022.

#### *Leases (Lessee)*

Pursuant to ASU 2016-02, we are required to apply a dual approach, classifying leases (in which we are the lessee) as either financing or operating leases based on the principle of whether or not the lease is effectively a financed purchase. This classification determines whether lease expense is recognized based on an effective interest method (for finance leases) or on a straight-line basis (for operating leases) over the term of the lease. We record a right-of-use asset and a lease liability for all material leases with a term greater than 12 months regardless of their classification. Leases with a term of 12 months or less are off balance sheet with lease expense recognized on a straight-line basis over the lease term.

*Reclassifications:* Certain amounts in the consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. For the year ended December 31, 2021, \$39.4 million has been reclassified from "Other (including fair value adjustments on securities)" to "Real estate and other impairment charges, net" in our consolidated statements of Net Income. There is no impact to net income.

### 3. Real Estate and Other Activities

#### *New Investments*

For the years ended December 31, 2022, 2021, and 2020, we acquired or invested in the following net assets (in thousands):

	2022	2021	2020
Land and land improvements	\$ 135,301	\$ 642,312	\$ 365,281
Buildings	487,698	2,381,654	2,547,313
Intangible lease assets — subject to amortization (weighted-average useful life of 21.3 years in 2022, 34.5 years in 2021, and 27.5 years in 2020)	45,394	262,385	642,699
Investment in financing leases	—	—	114,797
Mortgage loans(1)(2)	159,735	1,113,300	176,840
Investments in unconsolidated real estate joint ventures	399,456	—	233,593
Investments in unconsolidated operating entities	131,105	1,033,096	205,000
Other loans	—	—	103,195
Other assets	—	—	1,328
Liabilities assumed	(25,727)	(82,508)	(140,866)
	\$1,332,962	\$ 5,350,239	\$4,249,180
Loans repaid(1)	—	(1,103,410)	(834,743)
Total net assets acquired	\$1,332,962	\$ 4,246,829	\$3,414,437

- (1) The 2021 column includes an £800 million mortgage loan advanced to the Priory Group (“Priory”) in the first quarter of 2021 and converted to fee simple ownership of 35 properties in the second quarter of 2021 as described below. The 2020 column includes approximately \$740 million of loans advanced to Steward in 2017 and exchanged for the fee simple real estate of two hospitals as described below, as well as approximately \$100 million of loans advanced to Ernest Health, Inc. (“Ernest”) in 2012 and exchanged for the fee simple real estate of four hospitals as described below.
- (2) In the 2022 second quarter, we increased our mortgage loan to Prospect Medical Holdings, Inc. (“Prospect”) that was originated in 2019 and that is secured by a first lien on a California hospital. The loan bears interest at a current market rate plus a component of additional interest upon repayment.

#### 2022 Activity

##### Macquarie Transaction

On March 14, 2022, we completed a transaction with Macquarie Asset Management (“MAM”), an unrelated party, to form a partnership (the “Macquarie Transaction”), pursuant to which we contributed eight Massachusetts-based general acute care hospitals that are leased to Steward, and a fund managed by MAM acquired, for cash consideration, a 50% interest in the partnership. The transaction valued the portfolio at approximately \$1.7 billion, and we recognized a gain on sale of real estate of approximately \$600 million from this transaction, partially offset by the write-off of unbilled straight-line rent receivables. The partnership raised nonrecourse secured debt of 55% of asset value, and we received proceeds, including from the secured debt, of approximately \$1.3 billion. We obtained a 50% interest in the real estate partnership valued at approximately \$400 million (included in the “Investments in unconsolidated real estate joint ventures” line of our consolidated balance sheets), which is being accounted for under the equity method of accounting.

In connection with this transaction, we separated the eight Massachusetts-based facilities into a separate master lease with terms generally identical to the other master lease, and the initial fixed lease term of both master leases were extended to 2041.

### Other Transactions

On December 9, 2022, we acquired six behavioral health facilities in the United Kingdom for £233 million (\$286 million), plus customary tax and other transaction costs. These hospitals are leased to Priory pursuant to separate long-term leases with inflation-based escalators. As part of this transaction, the third-party seller of the real estate provided £105 million of seller financing — see Note 4 for further details on this debt.

On March 11, 2022, we acquired four general acute care hospitals in Finland for €178 million (\$194 million). These hospitals are leased to Pihlajalinna pursuant to a long-term lease with annual inflation-based escalators. We acquired these facilities by the share purchase of real estate holding entities that included deferred income tax and other liabilities of approximately \$26 million.

On February 16, 2022, we agreed to participate in an existing syndicated term loan with a term of six years originated on behalf of Priory. We funded £96.5 million towards a £100 million participation level, reflecting a 3.5% discount. The loan carries a variable rate that was 8.3% at December 31, 2022.

Other investments in 2022 included the acquisition of six general acute care facilities and the origination of a CHF 60 million mortgage loan to Infracore SA (“Infracore”). Of the assets acquired, three were general acute care facilities located throughout Spain, acquired on April 29, 2022 for €27 million, and leased to GenesisCare pursuant to a long-term lease with annual inflation-based escalators. In addition, two general acute care facilities, one in Arizona and the other in Florida, were acquired on April 18 and 25, 2022, respectively, for approximately \$80 million and leased to Steward pursuant to an already existing master lease agreement with annual inflation-based escalators. The other general acute care facility, located in Colombia, was acquired on July 29, 2022 for \$26 million and leased to Fundación Cardiovascular de Colombia pursuant to a long-term lease with inflation-based escalators.

### 2021 Activity

#### Priory Group Transaction

On January 19, 2021, we completed the first of two phases in the Priory transaction in which we funded an £800 million interim mortgage loan on an identified portfolio of Priory real estate assets in the United Kingdom. On June 25, 2021, we completed the second phase of the transaction in which we converted this mortgage loan to fee simple ownership in a portfolio of 35 select real estate assets from Priory (which is currently owned by Waterland Private Equity Fund VII C.V. (“Waterland VII”)) in individual sale-and-leaseback transactions. Therefore, the net aggregate purchase price for the real estate assets we acquired from Priory was approximately £800 million, plus customary stamp duty, tax, and other transaction costs. As part of the real estate acquisition (for which some of the assets were acquired by the share purchase of real estate holding entities), we incurred deferred income tax liabilities and other liabilities of approximately £47.1 million.

In addition to the real estate investment, on January 19, 2021, we made a £250 million acquisition loan to Waterland VII, in connection with the closing of Waterland VII’s acquisition of Priory, which was repaid in full plus interest on October 22, 2021.

Finally, we acquired a 9.9% passive equity interest in the Waterland VII affiliate that indirectly owns Priory.

### Other Transactions

On December 2, 2021, we acquired the remaining 50% interest in a general acute hospital operated by IMED Hospitales (“IMED”) in Valencia, Spain, which was formerly owned by our joint venture partner. We followed the asset acquisition cost accumulation model to account for this acquisition and included the carrying amount of our previously held equity interest, along with the approximately €46 million consideration paid and direct transaction costs incurred, in determining the total cost allocated to the net assets acquired.

On October 21, 2021, we acquired an acute care facility in Portugal for €17.8 million. This facility is leased to Atrys Health pursuant to a long-term master lease with annual escalations.

On October 19, 2021, we invested in 18 inpatient behavioral health facilities throughout the U.S. and an interest in the operations of Springstone for total consideration of \$950 million (including an acquisition loan of approximately \$185 million), plus closing and other transaction costs. We also incurred deferred income tax liabilities of approximately \$8.0 million. These facilities are leased to Springstone pursuant to a long-term master lease with annual escalations and multiple extension options.

On August 1, 2021, we completed the acquisition of five general acute care hospitals located in South Florida for approximately \$900 million, plus closing and other transaction costs. These hospitals are leased to Steward pursuant to a master lease, with annual inflation-based escalators.

On July 6, 2021, we acquired four acute care hospitals and two on-campus medical office buildings in Los Angeles, California for \$215 million. These hospitals are leased to Pipeline Health System, LLC (“Pipeline”) pursuant to a long-term lease with annual inflation-based escalators.

On July 6, 2021, we also acquired an acute care hospital in Stirling, Scotland for £15.6 million. This hospital is leased to Circle Health Ltd. (“Circle”) pursuant to a long-term lease with annual inflation-based escalators.

On April 16, 2021, we made a CHF 145 million investment in Swiss Medical Network, our tenant via our Infracore equity investment.

On January 8, 2021, we made a \$335 million loan to affiliates of Steward, all of the proceeds of which were used to redeem a similarly sized convertible loan held by Steward’s former private equity sponsor.

## 2020 Activity

### Circle Transaction

On January 8, 2020, we acquired a portfolio of 30 acute care hospitals located throughout the United Kingdom for approximately £1.5 billion from affiliates of BMI Healthcare, Inc. (“BMI”), as part of a share purchase in which we also inherited certain net deferred income tax and other liabilities and £27.6 million of unearned rent revenue. In a related transaction, affiliates of Circle acquired BMI and assumed its operations in the United Kingdom. As part of our acquisition, we inherited 30 existing leases with the operator that had initial fixed terms ending in 2050, with no renewal options but with annual inflation-based escalators. Effective June 16, 2020, these 30 leases were amended to include two five-year renewal options and improve the annual inflation-based escalators. These 30 leases are cross-defaulted and guaranteed by Circle.

### Other Transactions

On December 31, 2020, we acquired an inpatient rehabilitation hospital in South Carolina for approximately \$17 million. As part of the transaction, we acquired the fee simple real estate of three inpatient rehabilitation hospitals and one long-term acute care hospital in exchange for the reduction of the mortgage loans made to Ernest for such properties in 2012. These five facilities, with an approximate \$115 million total investment, are leased to Ernest pursuant to an existing long-term master lease with multiple extension options and annual escalation provisions.

On December 29, 2020, we increased our equity ownership and related investment in Infracore by investing an additional CHF 206.5 million. We are accounting for our total investment in this joint venture (this investment along with our initial investment in 2019 as noted below) under the equity method.

On August 13, 2020, we acquired a general acute care hospital in Lynwood, California for a total investment of approximately \$300 million. This property is leased to Prime Healthcare Services, Inc. (“Prime”) pursuant to a long-term master lease with annual escalations and multiple extension options.

On July 8, 2020, we acquired the fee simple real estate of two general acute care hospitals located in the Salt Lake City, Utah area, Davis Hospital & Medical Center and Jordan Valley Medical Center, in exchange for the reduction of the mortgage loans made to Steward for such properties and additional cash consideration of \$200 million based on their relative fair value. The approximate \$950 million investment in these two facilities is subject to a Steward master lease.

On June 24, 2020, we originated a CHF 45 million secured loan to Infracore, which was paid in full on December 2, 2020.

On May 13, 2020, we formed a joint venture for the purpose of investing in the operations of international hospitals. As part of the formation, we originated a \$205 million acquisition loan. We have a 49% interest in this joint venture and are accounting for our investment using the fair value option election. The joint venture simultaneously purchased from Steward the rights and existing assets related to all present and future international opportunities previously owned by Steward for strategic, regulatory, and risk management purposes. Through this joint venture, we invested, on November 17, 2020, in the real estate of three general acute care hospitals in Colombia for approximately \$135 million. These properties are operated by the international joint venture.

Other acquisitions in 2020 included three inpatient rehabilitation hospitals, two general acute care hospitals, and one private acute care hospital totaling approximately \$300 million. One inpatient rehabilitation facility, located in Dahlen, Germany, was acquired on August 5, 2020 for €12.5 million and is leased to MEDIAN Kliniken S.á.r.l. (“MEDIAN”) pursuant to the existing master lease. One of the general acute care facilities, located in Darlington, United Kingdom, was acquired on August 7, 2020 for £29.4 million and is leased to Circle pursuant to a long-term lease. The other general acute care hospital, located in London, United Kingdom, was acquired on November 25, 2020 for £50 million via the purchase of a 999-year ground lease and is leased to The Royal Marsden NHS Foundation Trust pursuant to a long-term lease. The inpatient rehabilitation hospitals, one in Texas and one in Indiana, were acquired on December 17, 2020 for approximately \$58 million and are leased to Post Acute Medical, LLC pursuant to a long-term lease. The private acute care hospital, located in Reading, United Kingdom, was acquired on December 18, 2020 for £85.0 million and is leased to Circle pursuant to the existing long-term Circle master lease.

## ***Development Activities***

### ***2022 Activity***

During 2022, we agreed to finance the development of five new projects. One of these development projects is a behavioral health facility in McKinney, Texas with a total budget of approximately \$35 million. This facility will be leased to Springstone pursuant to the existing long-term master lease. The second development project is an inpatient rehabilitation facility in Cayce, South Carolina with a total budget of approximately \$22 million. This facility will be leased to Ernest pursuant to an existing long-term master lease. In addition, we agreed to finance the development of and lease three general acute care facilities located throughout Spain for a total commitment of approximately €120 million. These facilities will be leased to our existing tenant, IMED, under a long-term master lease agreement.

During the 2022 first quarter, we completed construction and began recording rental income on an inpatient rehabilitation facility located in Bakersfield, California. This facility commenced rent on March 1, 2022 and is being leased to Ernest pursuant to an existing long-term master lease.

### 2021 Activity

In the fourth quarter of 2021, we agreed to finance the development of and lease an acute care facility in Texarkana, Texas for \$169.4 million. After initial delays with a change in the general contractor, physical construction has begun with an updated expected completion date of the first quarter of 2026. This facility will be leased to Steward pursuant to an existing long-term master lease.

### 2020 Activity

On November 23, 2020, we agreed to finance the development of and lease an inpatient rehabilitation facility in Stockton, California for \$47.7 million. This facility will be leased to Ernest pursuant to an existing long-term master lease.

During 2020, we completed construction on two general acute care facilities and one inpatient rehabilitation facility and began recognizing revenue on these properties immediately thereafter.

See table below for a status summary of our current development projects (in thousands):

<u>Property</u>	<u>Commitment</u>	<u>Costs Incurred as of December 31, 2022</u>	<u>Estimated Rent Commencement Date</u>
Ernest (Stockton, California) . . . . .	\$ 47,700	\$ 45,739	1Q 2023
IMED (Spain) . . . . .	50,411	13,037	2Q 2023
Ernest (South Carolina) . . . . .	22,400	7,541	2Q 2023
IMED (Spain) . . . . .	45,408	33,801	3Q 2023
Springstone (Texas) . . . . .	34,600	1,962	1Q 2024
IMED (Spain) . . . . .	36,734	8,320	3Q 2024
Steward (Texas) . . . . .	169,408	57,020	1Q 2026
	<u>\$406,661</u>	<u>\$167,420</u>	

### *Disposals*

#### 2022 Activity

On March 14, 2022, we completed the previously described partnership with MAM, in which we sold the real estate of eight Massachusetts-based general acute care hospitals, with a fair value of approximately \$1.7 billion. See “New Investments” in this Note 3 for further details on this transaction.

During 2022, we also completed the sale of 15 other facilities (including 11 properties sold on September 1, 2022 related to the Prime repurchase option for proceeds of \$366 million) and five ancillary properties for total proceeds of approximately \$522 million and recognized a gain on real estate of approximately \$100 million, along with a \$42 million write-off of straight-line rent receivables due to the early termination of certain properties’ expected lease terms.



## Summary of Operations for Disposed Assets in 2022

The properties sold during 2022 do not meet the definition of discontinued operations. However, the following represents the operating results from these properties for the periods presented (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2022</b>	<b>2021</b>	<b>2020</b>
Revenues(1) .....	\$ 17,831	\$180,549	\$174,362
Real estate depreciation and amortization(2) .....	(4,683)	(28,579)	(38,059)
Property-related expenses .....	(1,588)	(5,065)	(12,509)
Other income(3) .....	536,813	181	1,228
Income from real estate dispositions, net .....	<u>\$548,373</u>	<u>\$147,086</u>	<u>\$125,022</u>

- (1) Includes approximately \$42 million of straight-line rent and other write-offs associated with the non-Macquarie disposal transactions for the year ended December 31, 2022.
- (2) Lower in 2022 as we stopped depreciating the properties making up the Macquarie Transaction once deemed held for sale in September 2021.
- (3) Includes \$536.8 million of gains (net of \$125 million write-off of straight-line rent receivables related to the Macquarie Transaction) for the year ended December 31, 2022.

## 2021 Activity

During the 2021 fourth quarter, we sold our interest in the operations of three operators (two of which were in Germany) for proceeds of approximately \$54.5 million, resulting in a net gain of approximately \$40 million.

During 2021, we also completed the sale of 16 facilities and an ancillary property for approximately \$246 million, resulting in a net gain on real estate of approximately \$52.5 million.

## 2020 Activity

During 2020, we completed the sale of nine facilities and six ancillary properties for approximately \$94 million, resulting in a net loss of \$2.8 million.

## ***Intangible Assets***

At December 31, 2022 and 2021, our intangible lease assets were \$1.4 billion (\$1.2 billion, net of accumulated amortization) and \$1.4 billion (\$1.3 billion, net of accumulated amortization), respectively.

We recorded amortization expense related to intangible lease assets of \$55.9 million, \$56.0 million, and \$42.4 million in 2022, 2021, and 2020, respectively, and expect to recognize amortization expense from existing lease intangible assets as follows (amounts in thousands):

<b>For the Year Ended December 31:</b>	
2023 .....	\$ 56,740
2024 .....	56,683
2025 .....	56,535
2026 .....	56,266
2027 .....	55,932

As of December 31, 2022, capitalized lease intangibles have a weighted-average remaining life of 23.7 years.

### ***Leasing Operations (Lessor)***

We acquire and develop healthcare facilities and lease the facilities to healthcare operating companies. The initial fixed lease terms of these infrastructure-type assets are typically at least 15 years, and most include renewal options at the election of our tenants, generally in five year increments. Over 99% of our leases provide annual rent escalations based on increases in the CPI (or similar indices outside the U.S.) and/or fixed minimum annual rent escalations. Many of our domestic leases contain purchase options with pricing set at various terms but in no case less than our total initial investment. For three properties with a carrying value of approximately \$110 million at December 31, 2022, our leases require a residual value guarantee from the tenant. Our leases typically require the tenant to handle and bear most of the costs associated with our properties including repair/maintenance, property taxes, and insurance. We routinely inspect our properties to ensure our assets are being maintained properly and in compliance with the terms of our leases.

The following table summarizes total future minimum lease payments to be received, excluding operating expense reimbursements, from tenants under noncancelable leases as of December 31, 2022 (amounts in thousands):

	<b>Total Under Operating Leases</b>	<b>Total Under Financing Leases</b>	<b>Total</b>
2023 .....	\$ 984,353	\$ 161,079	\$ 1,145,432
2024 .....	1,001,456	164,357	1,165,813
2025 .....	1,016,367	167,701	1,184,068
2026 .....	1,031,717	171,112	1,202,829
2027 .....	1,048,409	174,591	1,223,000
Thereafter .....	25,851,987	4,376,304	30,228,291
	<u>\$30,934,289</u>	<u>\$5,215,144</u>	<u>\$36,149,433</u>

For all of our properties subject to lease, we are the legal owner of the property and the tenant's right to use and possess such property is guided by the terms of a lease. At December 31, 2022, we account for all of these leases as operating leases, except where GAAP requires alternative classification, including leases on 13 Ernest facilities and three Prime facilities that are accounted for as DFLs and leases on 13 of our Prospect facilities and five of our Ernest facilities that are accounted for as a financing. The components of our total investment in financing leases consisted of the following (in thousands):

	<b>As of December 31, 2022</b>	<b>As of December 31, 2021</b>
Minimum lease payments receivable .....	\$ 880,253	\$1,183,855
Estimated unguaranteed residual values .....	203,818	203,818
Less: Unearned income and allowance for credit loss .....	(731,915)	(918,584)
Net investment in direct financing leases .....	352,156	469,089
Other financing leases (net of allowance for credit loss) .....	1,339,167	1,584,238
Total investment in financing leases .....	<u>\$1,691,323</u>	<u>\$2,053,327</u>

The decrease in total investment in financing leases during 2022 is primarily related to financing leases associated with two properties sold on September 1, 2022 associated with the Prime repurchase transaction, along with the impairment associated with our Prospect properties, as discussed further below.

### COVID-19 Rent Deferrals

Due to the COVID-19 pandemic and its impact on our tenants' business, we agreed to defer collection of a certain amount of rent for a few tenants. Pursuant to our agreements with these tenants, we expect repayments of previously deferred rent to continue, with the remaining outstanding deferred rent balance of approximately \$14.6 million as of December 31, 2022, to be paid over specified periods in the future with interest.

### Prospect Medical Holdings

In August 2019, we invested in a portfolio of 14 acute care hospitals in three states (California, Pennsylvania, and Connecticut) operated by Prospect for a combined purchase price of approximately \$1.5 billion. In addition, we originated a \$112.9 million term loan secured by a parent guaranty. In the 2022 second quarter, we funded an additional \$100 million towards the existing mortgage loan that is secured by a first lien on a California hospital.

Prospect (like other healthcare systems around the world) struggled through the COVID-19 pandemic, starting in early 2020 and continuing through much of the 2022 first quarter with the impact from the Omicron variant. Although admissions, surgeries, and ER visits are back above pre-COVID levels at their California and Connecticut properties, Prospect's four Pennsylvania facilities are still trailing. Now with the impact of higher labor and other costs due to inflation, Prospect has experienced a decline in cash flows during 2022. Prospect has been working through various restructuring plans to manage their cash flow. Some of these plans have made it to the binding commitment stage, including the expected sale of their Connecticut properties to Yale New Haven Health ("Yale") announced in October 2022, while others have not.

Until the 2022 fourth quarter, Prospect was current on its rent and interest obligations under the various agreements. However, with rent and interest now past due and certain of Prospect's restructuring plans yet to be finalized, we recorded an approximate \$280 million impairment charge in the 2022 fourth quarter, as shown in "Real estate and other impairment charges, net" on the consolidated statements of net income. As part of this charge, we reduced the carrying value of the underperforming Pennsylvania properties by approximately \$170 million (to approximately \$250 million) and reserved all non-cash rent for a total of \$112 million. We expect to record rent on our Prospect leases on a cash basis for the foreseeable future. At December 31, 2022, we believe our remaining investment in the Prospect real estate and other assets are fully recoverable, but no assurances can be given that we will not have any further impairments in future periods.

### Pipeline Health System

On October 2, 2022, Pipeline filed for reorganization relief under Chapter 11 protection of the United States Bankruptcy Code in the Southern District of Texas, while keeping its hospitals open to continue providing care to the communities served. On February 6, 2023, Pipeline emerged from bankruptcy. Per the bankruptcy settlement, Pipeline's current lease of our California assets remains in place, and we were repaid on February 7, 2023 for all rent that was outstanding at December 31, 2022, along with what was due for January and February 2023. We have agreed to defer \$5.6 million, or approximately 30%, of rent in 2023 to be paid in 2024 with interest. We also agreed to provide approximately \$11 million in capital funding for Pipeline to complete their behavioral facility addition to the Coast Plaza Hospital, which will result in increased rent to us upon completion. As of December 31, 2022, assets leased to Pipeline represent 1% of our total assets, which we believe are fully recoverable at this time. However, no assurances can be given that we will not have any write-offs or impairments in future periods.

### Watsonville Community Hospital

On September 30, 2019, we acquired the real estate of Watsonville Community Hospital in Watsonville, California for \$40 million, which was then leased to Halsen Healthcare. In addition, we made a working capital

loan to Halsen Healthcare. The hospital operator faced significant financial challenges over a two-year period that were worsened by the COVID-19 pandemic. During this time, we increased the loan in an effort to support the operator of this facility, allowing it to continue to serve the community's needs. On December 5, 2021, Halsen Healthcare filed Chapter 11 bankruptcy in order to reorganize, while keeping the hospital open. As such, we recorded a credit loss reserve of approximately \$40 million against the estimated uncollectible portion of the loan and wrote off approximately \$2.5 million of billed and straight-line rent receivables.

On February 23, 2022, the bankruptcy court approved the bid by Pajaro Valley Healthcare District Corporation ("Pajaro") to purchase the operations of the Watsonville Community Hospital and lease the real estate from us. On August 31, 2022, Pajaro completed this purchase of the operations of the Watsonville Community Hospital. As a result of this transaction, we were repaid approximately \$32 million of the loans previously provided to the hospital. This loan repayment resulted in a net credit loss recovery of approximately \$15 million in 2022 and reflected in the "Real estate and other impairment charges, net" line of the consolidated statements of net income. To date, Pajaro has been current on its monthly rental payments to us.

### Other Leasing Activities

#### 2022 Activity

At September 30, 2022, 99% of our properties are occupied by tenants, leaving five properties as vacant, representing less than 0.3% of total assets. We are in various stages of either releasing or selling these vacant properties, for one of which we received and recorded a significant termination fee in 2019.

#### 2021 Activity

On December 23, 2021, Lifepoint Health, Inc. ("Lifepoint") announced the completion of the transaction with Kindred Healthcare ("Kindred"), in which Lifepoint acquired Kindred, and announced the related launch of ScionHealth, a new healthcare company made up of a combination of former Kindred and Lifepoint hospitals. With this transaction, we have eight properties leased to ScionHealth and nine properties leased to Lifepoint.

#### 2020 Activity

On July 24, 2020, we re-leased our five San Antonio, Texas free standing emergency facilities (with a total investment of approximately \$30 million) to Methodist Healthcare System of San Antonio, a joint venture between HCA and Methodist Healthcare Ministries of South Texas, pursuant to a long-term master lease. As a result, we recorded an approximate \$1.5 million write-off of straight-line rent in the 2020 third quarter.

### ***Investments in Unconsolidated Entities***

#### Investments in Unconsolidated Real Estate Joint Ventures

Our primary business strategy is to acquire real estate and lease to providers of healthcare services. Typically, we directly own 100% of such investment. However, from time-to-time, we will co-invest with other investors that share a similar view that hospital real estate is a necessary infrastructure-type asset in communities. In these types of investments, we will own undivided interests of less than 100% of the real estate and share control over the assets through unconsolidated real estate joint ventures. The underlying real estate and leases in these unconsolidated real estate joint ventures are structured similarly and carry a similar risk profile to the rest of our real estate portfolio.

The following is a summary of our investments in unconsolidated real estate joint ventures by operator (amounts in thousands):

<u>Operator</u>	<u>Ownership Percentage</u>	<u>As of December 31, 2022</u>	<u>As of December 31, 2021</u>
MEDIAN .....	50%	\$ 482,735	\$ 517,648
Swiss Medical Network .....	70%	454,083	476,193
Steward (Macquarie Transaction) .....	50%	417,701	—
Policlinico di Monza .....	50%	86,245	95,468
HM Hospitales .....	45%	57,139	63,618
Total .....		<u>\$1,497,903</u>	<u>\$1,152,927</u>

For the increase in our investments in unconsolidated real estate joint ventures since December 31, 2021, see “New Investments” section in this same Note 3 for a discussion of the Macquarie Transaction.

#### Investments in Unconsolidated Operating Entities

Our investments in unconsolidated operating entities are noncontrolling investments that are typically made in conjunction with larger real estate transactions in which the operators are vetted as part of our overall underwriting process. In many cases, we would not be able to acquire the larger real estate portfolio without such investments in operators. These investments also offer the opportunity to enhance our overall return and provide for certain minority rights and protections.

The following is a summary of our investments in unconsolidated operating entities (amounts in thousands):

<u>Operator</u>	<u>As of December 31, 2022</u>	<u>As of December 31, 2021</u>
Steward (loan investment) .....	\$ 362,831	\$ 360,164
International joint venture .....	231,402	219,387
Springstone .....	200,827	187,450
Priory .....	156,575	42,315
Swiss Medical Network .....	157,145	159,208
Steward (equity investment) .....	125,862	139,000
Prospect .....	112,777	112,283
Aevis Victoria SA (“Aevis”) .....	72,904	61,271
Aspris Children’s Services (“Aspris”) .....	16,023	8,356
Caremax .....	8,526	—
Total .....	<u>\$1,444,872</u>	<u>\$1,289,434</u>

The increase during 2022 is primarily due to our investment in the Priory syndicated term loan as described under “New Investments” in this Note 3. In the 2022 fourth quarter, Steward sold its managed care business to Caremax and received shares of Caremax plus cash, along with the potential for additional stock contingent on performance. As part of this transaction, we received a dividend of Caremax shares that are marked to fair value each period.

Pursuant to our approximate 5% stake in Aevis and other investments marked to fair value, we recorded a \$2.3 million favorable non-cash fair value adjustment during 2022 as shown in the “Other (including fair value adjustments on securities)” line of the consolidated statements of net income; whereas, this was an \$8.2 million favorable non-cash fair value adjustment in 2021. We also earned approximately \$4 million of dividend income from our Switzerland investments during 2022.

Pursuant to our existing 9.9% equity interest in Steward, we received an \$11 million cash distribution during 2021, which was accounted for as a return of capital.

#### *Other Investment Activities*

In the 2022 second quarter, we loaned \$150 million to Steward pursuant to a five-year secured loan. The loan bears interest at a current market rate (comparable to recent lease rates) plus a component of additional interest upon repayment. The loan is prepayable without penalty and is mandatorily prepayable upon certain sales of Steward assets and operations.

#### ***Concentration of Credit Risks***

We monitor concentration risk in several ways due to the nature of our real estate assets that are vital to the communities in which they are located and given our history of being able to replace inefficient operators of our facilities, if needed, with more effective operators:

- 1) Facility concentration — At December 31, 2022 and December 31, 2021, our largest single property represented approximately 2.7% of our total assets.
- 2) Operator concentration — For the years ended December 31, 2022 and December 31, 2021, revenue from each of Steward, Circle, and Prospect individually represented more than 10% of our total revenues.
- 3) Geographic concentration — At December 31, 2022, investments in the U.S, Europe, Australia, and South America represented approximately 61%, 33%, 5%, and 1%, respectively, of our total assets compared to 64%, 30%, 5%, and 1%, respectively, of our total assets at December 31, 2021.
- 4) Facility type concentration — For the year ended December 31, 2022, approximately 76% of our revenues were generated from our general acute care facilities, while revenues from our behavioral and rehabilitation facilities made up 13% and 7%, respectively. Freestanding ER/urgent care facilities and long-term acute care facilities combined to make up the remaining 4%. In comparison, general acute care, behavioral, and rehabilitation facilities made up 81%, 8%, and 7%, respectively, of our total revenues for the year ended December 31, 2021. Revenues from our freestanding ER/urgent care, and long-term acute care facilities combined to make up approximately 4% for the year ended December 31, 2021.

(For geographic and facility type concentration metrics above, we allocate our investments in operating entities pro rata based on the gross book value of the real estate. Such pro rata allocations are subject to change from period to period.)

#### ***Related Party Transactions***

Lease and interest revenue earned from tenants and real estate joint ventures in which we had an equity interest (accounted for under either the equity or fair value option methods) during the year were \$135.5 million, \$63.9 million, and \$29.8 million for 2022, 2021, and 2020, respectively.

See subsections “New Investments” and “Disposals” in this Note 3 as it relates to our investments in Springstone and the international and Infracore ventures for other related party transactions during 2022, 2021, and 2020.

#### 4. Debt

The following is a summary of debt (dollar amounts in thousands):

	As of December 31, 2022	As of December 31, 2021
Revolving credit facility(A) .....	\$ 929,584	\$ 730,000
Interim credit facility .....	—	869,606
Term loan .....	200,000	200,000
British pound sterling term loan due 2024(B) .....	126,690	—
British pound sterling term loan due 2025(B) .....	845,810	947,240
Australian term loan facility(B) .....	817,560	871,560
2.550% Senior Unsecured Notes due 2023(B) .....	483,320	541,280
3.325% Senior Unsecured Notes due 2025(B) .....	535,250	568,500
0.993% Senior Unsecured Notes due 2026(B) .....	535,250	568,500
2.500% Senior Unsecured Notes due 2026(B) .....	604,150	676,600
5.250% Senior Unsecured Notes due 2026 .....	500,000	500,000
5.000% Senior Unsecured Notes due 2027 .....	1,400,000	1,400,000
3.692% Senior Unsecured Notes due 2028(B) .....	724,980	811,920
4.625% Senior Unsecured Notes due 2029 .....	900,000	900,000
3.375% Senior Unsecured Notes due 2030(B) .....	422,905	473,620
3.500% Senior Unsecured Notes due 2031 .....	1,300,000	1,300,000
	<u>\$10,325,499</u>	<u>\$11,358,826</u>
Debt issue costs and discount, net .....	(57,087)	(76,056)
	<u>\$10,268,412</u>	<u>\$11,282,770</u>

(A) Includes £90 million of GBP-denominated borrowings and €253 million of Euro-denominated borrowings that reflect the exchange rate at December 31, 2022.

(B) Non-U.S. dollar denominated debt that reflects the exchange rate at period-end.

As of December 31, 2022, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (amounts in thousands):

2023 .....	\$ 483,320
2024 .....	944,250
2025 .....	1,381,060
2026 .....	2,568,984
2027 .....	1,600,000
Thereafter .....	3,347,885
Total .....	<u>\$10,325,499</u>

#### **Credit Facility**

On May 6, 2022, we increased the amount of our unsecured credit facility (“Credit Facility”) by \$500 million by exercising the accordion feature. In addition, our revolver and U.S. dollar term loan were modified with Secured Overnight Financing Rate as a replacement reference rate to U.S. dollar LIBOR. Currently, our Credit Facility includes a \$1.8 billion unsecured revolving loan facility and a \$200 million unsecured term loan facility.

On June 29, 2022, we amended our Credit Facility. The amendment extended the maturity date of our revolving facility to June 30, 2026 with our option to extend for an additional 12 months. The maturity date of

our \$200 million unsecured term loan facility was extended to June 30, 2027. Additionally, we may request incremental term loan and/or revolving loan commitments in an aggregate amount not to exceed \$1 billion.

In addition, the amendment improved interest rate spreads for both facilities. Under the amended Credit Facility and at our election, loans may be made as either ABR Loans or Term Benchmark Loans. The applicable margin for term loans that are ABR Loans is adjustable on a sliding scale from 0.00% to 0.70% based on current credit rating. The applicable margin for term loans that are Term Benchmark Loans is adjustable on a sliding scale from 0.875% to 1.70% based on current credit rating. The applicable margin for revolving loans that are ABR Loans is adjustable on a sliding scale from 0.00% to 0.50% based on current credit rating. The applicable margin for revolving loans that are Term Benchmark Loans or RFR Loans, as defined in the Credit Facility agreement, is adjustable on a sliding scale from 0.80% to 1.50% based on current credit rating. The facility fee is adjustable on a sliding scale from 0.125% to 0.30% (currently 0.25%) based on current credit rating and is payable on the revolving loan facility.

At December 31, 2022, we had \$929.6 million outstanding on the revolving credit facility, whereas, we had \$730.0 million outstanding on our revolving credit facility at December 31, 2021. At December 31, 2022 and 2021, our availability under our revolving credit facility was \$0.9 billion and \$0.6 billion, respectively. The weighted-average interest rate on the revolving facility was 3.8% and 1.3% during 2022 and 2021, respectively.

At December 31, 2022 and 2021, the interest rate in effect on our term loan was 5.70% and 1.56%, respectively.

### ***Interim Credit Facilities***

#### **January 2021 Interim Credit Facility**

On January 15, 2021, we entered into a \$900 million interim credit facility (“January 2021 Interim Credit Facility”), of which we borrowed £500 million to partially fund the Priory Group Transaction. We paid off and terminated this facility on March 26, 2021 with proceeds from the issuance of the 2.500% Senior Unsecured Notes due 2026 and the 3.375% Senior Unsecured Notes due 2030.

#### **July 2021 Interim Credit Facility**

On July 27, 2021, we entered into a \$1 billion interim credit facility with Barclays Bank PLC as administrative agent (“July 2021 Interim Credit Facility”), and several lenders from time-to-time are parties thereto. We used this facility to partially fund the acquisition of five South Florida facilities in August 2021 and the Springstone investments in October 2021. At December 31, 2021, the outstanding balance under this facility was \$869.6 million.

On March 15, 2022, we paid off and terminated the July 2021 Interim Credit Facility with proceeds from the Macquarie Transaction as more fully described in Note 3 to the consolidated financial statements.

### ***Non-U.S. Term Loans***

#### **British Pound Sterling Term Loan due 2024**

On December 9, 2022, we entered into a £105 million unsecured sterling-denominated term loan, of which we used to partially fund the Priory acquisition on the same date. This term loan matures on December 9, 2024, and has a fixed interest rate of 5.250%.

#### **British Pound Sterling Term Loan due 2025**

On January 6, 2020, we entered into a £700 million unsecured sterling-denominated term loan with Bank of America, N.A., as administrative agent, and several lenders from time-to-time are parties thereto. The term loan



matures on January 15, 2025. The applicable margin under the term loan is adjustable based on a pricing grid from 0.85% to 1.65% dependent on our current credit rating. On March 4, 2020, we entered into an interest rate swap transaction (effective March 6, 2020) to fix the interest rate to approximately 0.70% for the duration of the loan. The current applicable margin for the pricing grid (which can vary based on our credit rating) is 1.25% for an all-in fixed rate of 1.95%.

### **Australian Term Loan**

On May 23, 2019, we entered into an A\$1.2 billion term loan with Bank of America, N.A., as administrative agent, and several lenders from time-to-time are parties thereto. The term loan matures on May 23, 2024. The interest rate under the term loan is adjustable based on a pricing grid from 0.85% to 1.65%, dependent on our current senior unsecured credit rating. On June 27, 2019, we entered into an interest rate swap transaction (effective July 3, 2019) to fix the interest rate to approximately 1.20% for the duration of the loan as long as the reference rate stays above 0.00%. The current applicable margin for the pricing grid (which can vary based on our credit rating) is 1.25% for an all-in fixed rate of 2.45%.

### **Interest Rate Swaps**

At December 31, 2022, we had a derivative asset of approximately \$93.2 million related to the combination of the sterling-denominated term loan interest rate swap and the Australian dollar term loan interest rate swap. At December 31, 2021, we had a derivative asset of approximately \$12.4 million related to the sterling-denominated term loan interest rate swap and a derivative liability of approximately \$4.2 million related to the Australian dollar term loan interest rate swap. Derivative assets are included in “Other assets” while, the derivative liabilities are included in “Accounts payable and accrued expenses” on our consolidated balance sheets.

### **Senior Unsecured Notes**

The following are the basic terms of our senior unsecured notes at December 31, 2022 (par value amounts in thousands):

	<b>Offering Completion Date</b>	<b>Maturity Date</b>	<b>Par Value</b>	<b>% of Par Value</b>	<b>Interest Payment Frequency</b>
2.550% Senior Unsecured Notes due 2023	December 5, 2019	December 5, 2023	£ 400,000	100.000%	Annually
3.325% Senior Unsecured Notes due 2025	March 24, 2017	March 24, 2025	€ 500,000	100.000%	Annually
0.993% Senior Unsecured Notes due 2026	October 6, 2021	October 15, 2026	€ 500,000	100.000%	Annually
2.500% Senior Unsecured Notes due 2026	March 24, 2021	March 24, 2026	£ 500,000	99.937%	Annually
5.250% Senior Unsecured Notes due 2026	July 22, 2016	August 1, 2026	\$ 500,000	100.000%	Semi-annually
5.000% Senior Unsecured Notes due 2027	September 7, 2017	October 15, 2027	\$1,400,000	100.000%	Semi-annually
3.692% Senior Unsecured Notes due 2028	December 5, 2019	June 5, 2028	£ 600,000	99.998%	Annually
4.625% Senior Unsecured Notes due 2029	July 26, 2019	August 1, 2029	\$ 900,000	99.500%	Semi-annually
3.375% Senior Unsecured Notes due 2030	March 24, 2021	April 24, 2030	£ 350,000	99.448%	Annually
3.500% Senior Unsecured Notes due 2031	December 4, 2020	March 15, 2031	\$1,300,000	100.000%	Semi-annually

We may repurchase, redeem, or refinance senior unsecured notes from time-to-time. We may purchase senior notes for cash through open market purchases, privately negotiated transactions, or a tender offer. In some cases, we may redeem some or all of the notes at any time, but may require a redemption premium that will decrease over time. In the event of a change of control, each holder of the notes may require us to repurchase some or all of our notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase. Redemptions and repurchases of debt, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions, and other factors.

## ***Debt Refinancing and Unutilized Financing Costs***

### 2022

In 2022, we incurred approximately \$9.5 million of debt refinancing costs. These costs were incurred as a result of the payoff of our July 2021 Interim Credit Facility with proceeds from the Macquarie Transaction on March 14, 2022, along with the amendment of our Credit Facility on June 29, 2022.

### 2021

With the termination of our January 2021 Interim Credit Facility and other debt activity, we incurred approximately \$7.3 million of debt refinancing costs in 2021.

With proceeds from our 0.993% Senior Unsecured Notes due 2026 offering, on October 22, 2021, we redeemed all of our outstanding €500 million aggregate principal amount of 4.000% senior unsecured notes that were due in 2022, including accrued and unpaid interest. As a result of this redemption, we incurred a charge of approximately \$20 million (including redemption premiums and accelerated amortization of deferred debt issuance costs).

### 2020

With proceeds from our 3.500% Senior Unsecured Notes due 2031 offering in 2020, we redeemed all of our outstanding \$500.0 million aggregate principal amount of 6.375% senior unsecured notes that were due in 2024 and \$300.0 million aggregate principal amount of 5.500% senior unsecured notes that were due in 2024, including accrued and unpaid interest. As a result of these redemptions, we incurred a charge of approximately \$28 million (including redemption premiums and accelerated amortization of deferred debt issuance costs).

## ***Covenants***

Our debt facilities impose certain restrictions on us, including restrictions on our ability to: incur debts; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem, or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate or other assets; and change our business. In addition, the credit agreements governing our Credit Facility limit the amount of dividends we can pay as a percentage of normalized adjusted funds from operations (“NAFFO”), as defined in the agreements, on a rolling four quarter basis. At December 31, 2022, the dividend restriction was 95% of NAFFO. The indentures governing our senior unsecured notes also limit the amount of dividends we can pay based on the sum of 95% of NAFFO, proceeds of equity issuances, and certain other net cash proceeds. Finally, our senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness.

In addition to these restrictions, the Credit Facility contains customary financial and operating covenants, including covenants relating to our total leverage ratio, fixed charge coverage ratio, secured leverage ratio, consolidated adjusted net worth, unsecured leverage ratio, and unsecured interest coverage ratio. The Credit Facility also contains customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations, and failure to comply with our covenants. If an event of default occurs and is continuing under the Credit Facility, the entire outstanding balance may become immediately due and payable. At December 31, 2022, we were in compliance with all such financial and operating covenants.

## **5. Income Taxes**

### *Medical Properties Trust, Inc.*

We have maintained and intend to maintain our election as a REIT under the Code. To qualify as a REIT, we must meet a number of organizational and operational requirements, including a requirement to distribute at

least 90% of our REIT taxable income to our stockholders. As a REIT, we generally will not be subject to U.S. federal income tax if we distribute 100% of our REIT taxable income to our stockholders and satisfy certain other requirements; instead, income tax is paid directly by our stockholders on the dividends distributed to them. If our REIT taxable income exceeds our dividends in a tax year, REIT tax rules allow us to designate dividends from the subsequent tax year in order to avoid current taxation on undistributed income. If we fail to qualify as a REIT in any taxable year, we will be subject to federal income taxes at regular corporate rates. Taxable income from non-REIT activities managed through our TRS entities is subject to applicable U.S. federal, state, and local income taxes. Our international subsidiaries are also subject to income taxes in the jurisdictions in which they operate.

From our TRS entities and our foreign operations, income tax (expense) benefit were as follows (in thousands):

	For the Years Ended December 31,		
	2022	2021	2020
<b>Current income tax (expense) benefit:</b>			
Domestic .....	\$ 1,111	\$ (1,559)	\$ 63
Foreign .....	(27,751)	(18,964)	(10,203)
	(26,640)	(20,523)	(10,140)
<b>Deferred income tax (expense) benefit:</b>			
Domestic .....	(15,628)	6,915	(10,680)
Foreign .....	(13,632)	(60,340)	(10,236)
	(29,260)	(53,425)	(20,916)
<b>Income tax (expense) .....</b>	<b><u>\$(55,900)</u></b>	<b><u>\$(73,948)</u></b>	<b><u>\$(31,056)</u></b>

A reconciliation of income tax (expense) benefit from the statutory income tax rate to the effective tax rate based on income before income taxes for the years ended December 31, 2022, 2021, and 2020 is as follows (in thousands):

	For the Years Ended December 31,		
	2022	2021	2020
Income before income tax .....	\$ 959,719	\$ 730,888	\$463,328
Income tax (expense) at the U.S. statutory federal rate (21% in 2022, 2021, and 2020) .....	(201,541)	(153,486)	(97,299)
Decrease (increase) in income tax resulting from:			
Foreign rate differential .....	1,826	2,742	2,160
State income taxes, net of federal benefit .....	(1,886)	—	970
U.S. earnings not subject to federal income tax .....	165,705	132,266	82,921
Equity investments .....	—	—	380
Change in valuation allowance .....	(11,281)	(10,040)	(8,514)
Statutory tax rate change .....	(941)	(43,924)	(9,471)
Interest disallowance .....	(1,737)	(646)	—
Other items, net .....	(6,045)	(860)	(2,203)
<b>Total income tax (expense) .....</b>	<b><u>\$ (55,900)</u></b>	<b><u>\$ (73,948)</u></b>	<b><u>\$ (31,056)</u></b>

In 2022, we incurred approximately \$5 million of income tax expense from the credit loss recovery on loans made to the Watsonville Community Hospital; whereas, in 2021, we recorded an approximate \$10 million income tax benefit related to the initial loan impairment, as more fully described in Note 3 to Item 8 of this Annual Report on Form 10-K.

During the 2021 second quarter, the United Kingdom enacted an increase in its corporate income tax rates from 19% to 25% effective April 1, 2023, which resulted in a one-time adjustment to our net deferred tax liabilities of approximately \$43 million.

The foreign provision for income taxes is based on foreign profit before income taxes of \$159.6 million, \$164.0 million, and \$62.1 million in 2022, 2021, and 2020, respectively.

The domestic provision for income taxes is based on income (loss) before income taxes of \$10.8 million in 2022, \$(29.7) million in 2021, and \$6.4 million in 2020 from our TRS entities.

At December 31, 2022 and 2021, components of our deferred tax assets and liabilities were as follows (in thousands):

	<u>2022</u>	<u>2021</u>
Deferred tax assets:		
Operating loss and interest deduction carry forwards . . .	\$ 175,922	\$ 197,876
Other . . . . .	<u>15,218</u>	<u>1,815</u>
Total deferred tax assets . . . . .	191,140	199,691
Valuation allowance . . . . .	<u>(71,499)</u>	<u>(61,747)</u>
Total net deferred tax assets . . . . .	<u>\$ 119,641</u>	<u>\$ 137,944</u>
Deferred tax liabilities:		
Property and equipment . . . . .	\$(294,181)	\$(320,546)
Net unbilled revenue . . . . .	(63,324)	(43,366)
Partnership investments . . . . .	(26,268)	(15,963)
Other . . . . .	<u>(27,153)</u>	<u>(3,836)</u>
Total deferred tax liabilities . . . . .	<u>(410,926)</u>	<u>(383,711)</u>
Net deferred tax asset (liability) . . . . .	<u><u>\$(291,285)</u></u>	<u><u>\$ (245,767)</u></u>

At December 31, 2022, we had net NOL and other tax attribute carryforwards as follows (in thousands):

	<u>U.S.</u>	<u>Foreign</u>
Gross NOL carryforwards . . . . .	\$148,900	\$633,682
Tax-effected NOL carryforwards . . . . .	\$ 24,013	\$151,909
Valuation allowance . . . . .	<u>(13,864)</u>	<u>(57,635)</u>
Net deferred tax asset — NOL carryforwards . . . . .	<u>\$ 10,149</u>	<u>\$ 94,274</u>
Expiration periods . . . . .	2024-indefinite	indefinite

#### Valuation Allowance

A valuation allowance has been recorded on certain foreign and domestic net operating loss carryforwards and other net deferred tax assets that may not be realized. As of each reporting date, we consider all new evidence that could impact the future realization of our deferred tax assets. In the evaluation of the need for a valuation allowance on our deferred income tax assets, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, carryback of future period losses to prior periods, projected future taxable income, tax planning strategies, and recent financial performance.

During 2022, a valuation allowance of \$9.8 million has been recorded against a portion of our deferred tax assets to recognize only the components of the deferred tax assets that is more likely than not to be realized. The

valuation allowance was primarily recorded against deferred tax assets for NOLs, non-depreciable basis of real property, and other tax attributes that we believe will not be realized. Valuation allowance activity recorded generally follows the activity of the associated deferred tax asset that is not expected to be recognized. From time-to-time, we may acquire deferred tax assets as part of real estate transactions and will assess the need for a valuation allowance as part of the opening balance sheet. Additionally, valuation allowances will be remeasured for foreign currency translation fluctuations through other comprehensive income.

We have no material uncertain tax position liabilities and related interest or penalties.

#### REIT Status

We have met the annual REIT distribution requirements by payment of at least 90% of our REIT taxable income in 2022, 2021, and 2020. Earnings and profits, which determine the taxability of such distributions, will differ from net income reported for financial reporting purposes due primarily to differences in cost basis, differences in the estimated useful lives used to compute depreciation, and differences between the allocation of our net income and loss for financial reporting purposes and for tax reporting purposes.

A schedule of per share distributions we paid and reported to our stockholders is set forth in the following:

	<u>For the Years Ended December 31,</u>		
	<u>2022</u>	<u>2021</u>	<u>2020</u>
Per share:			
Ordinary dividend (1) . . . . .	\$0.4703	\$0.7646	\$0.6030
Long-term capital gain (2) . . . . .	0.6797	0.1654	—
Return of capital . . . . .	—	0.1800	0.4670
Total . . . . .	<u>\$1.1500</u>	<u>\$1.1100</u>	<u>\$1.0700</u>

- (1) For the years ended December 31, 2022, 2021, and 2020, includes Section 199A dividends of 0.4703, 0.7646, and 0.6030, respectively.
- (2) For the years ended December 31, 2022, 2021, and 2020, includes Unrecaptured Section 1250 gains of 0.2574, 0.0583, and 0.0000, respectively.

#### *MPT Operating Partnership, L.P.*

As a partnership, the allocated share of income of the Operating Partnership is included in the income tax returns of the general and limited partners. Accordingly, no accounting for income taxes is generally required for such income of the Operating Partnership. However, the Operating Partnership has formed TRS entities on behalf of Medical Properties Trust, Inc., which are subject to U.S. federal, state, and local income taxes at regular corporate rates, and its international subsidiaries are subject to income taxes in the jurisdictions in which they operate. See discussion above under Medical Properties Trust, Inc. for more details of income taxes associated with our TRS entities and international operations.

## 6. Earnings Per Share/Unit

### *Medical Properties Trust, Inc.*

Our earnings per share were calculated based on the following (amounts in thousands):

	For the Years Ended December 31,		
	2022	2021	2020
<b>Numerator:</b>			
Net income .....	\$903,819	\$656,940	\$432,272
Non-controlling interests' share in earnings .....	(1,222)	(919)	(822)
Participating securities' share in earnings .....	(1,602)	(2,161)	(2,105)
Net income, less participating securities' share in earnings ..	<u>\$900,995</u>	<u>\$653,860</u>	<u>\$429,345</u>
<b>Denominator:</b>			
Basic weighted-average common shares .....	598,634	588,817	529,239
Dilutive potential common shares .....	203	1,322	1,222
Diluted weighted-average common shares .....	<u>598,837</u>	<u>590,139</u>	<u>530,461</u>

### *MPT Operating Partnership, L.P.*

Our earnings per unit were calculated based on the following (amounts in thousands):

	For the Years Ended December 31,		
	2022	2021	2020
<b>Numerator:</b>			
Net income .....	\$903,819	\$656,940	\$432,272
Non-controlling interests' share in earnings .....	(1,222)	(919)	(822)
Participating securities' share in earnings .....	(1,602)	(2,161)	(2,105)
Net income, less participating securities' share in earnings ..	<u>\$900,995</u>	<u>\$653,860</u>	<u>\$429,345</u>
<b>Denominator:</b>			
Basic weighted-average units .....	598,634	588,817	529,239
Dilutive potential units .....	203	1,322	1,222
Diluted weighted-average units .....	<u>598,837</u>	<u>590,139</u>	<u>530,461</u>

## 7. Stock Awards

### *Stock Awards*

During the second quarter of 2022, we amended the 2019 Equity Incentive Plan (the "Equity Incentive Plan"), which authorizes the issuance of common stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance units, and awards of interests in our Operating Partnership. Our Equity Incentive Plan is administered by the Compensation Committee of the Board of Directors. Among other things, the recent amendment increased the number of shares of common stock registered and reserved for stock awards by 16 million to 28.9 million. As of December 31, 2022, 19.3 million shares remain available for future stock awards. The Equity Incentive Plan contains a limit of 5 million shares as the maximum number of shares of common stock that may be awarded to an individual in any fiscal year. Awards under the Equity Incentive Plan are subject to forfeiture due to termination of employment prior to vesting and/or from not achieving the respective performance/market conditions. In the event of a change in control, outstanding and

unvested options will immediately vest, unless otherwise provided in the participant's award or employment agreement, and restricted stock, restricted stock units, deferred stock units, and other stock-based awards will vest if so provided in the participant's award agreement. The term of the awards is set by the Compensation Committee, though Incentive Stock Options may not have terms of more than ten years. Forfeited awards (along with shares withheld for payroll tax withholding purposes) are returned to the Equity Incentive Plan and are then available to be re-issued as future awards. For each share of common stock issued by Medical Properties Trust, Inc. pursuant to its Equity Incentive Plan, the Operating Partnership issues a corresponding number of Operating Partnership units.

For the past three years, we have only granted restricted stock and restricted stock units pursuant to our Equity Incentive Plan. These stock-based awards have been granted in the form of service-based awards and performance awards based on company-specific performance hurdles. See below for further details on each of these stock-based awards:

#### Service-Based Awards

In 2022, 2021, and 2020, the Compensation Committee granted service-based awards to employees and non-employee directors. Service-based awards vest as the employee/director provides the required service (typically over three years). Dividends are generally paid on these awards prior to vesting.

#### Performance-Based Awards

In 2022, 2021, and 2020, the Compensation Committee granted performance-based awards to employees. Generally, dividends are not paid on performance awards until the award is earned. See below for details of such performance-based award grants:

In 2022, 2021, and 2020, a target number of stock awards were granted to employees that could be earned based on the achievement of specific performance thresholds as set by our Compensation Committee. The performance thresholds were based on a three-year period with the opportunity to earn a portion of the award earlier. More or less shares than the target number of shares are available to be earned based on our performance compared to the set thresholds. At the end of each of the performance periods, any earned shares during such period will vest on January 1 of the following calendar year. The performance thresholds for 2022, 2021, and 2020 awards were based on funds from operations growth, EBITDA, and acquisitions.

Certain performance awards granted were subject to a modifier which increases or decreases the actual shares earned in each performance period. The modifier for the 2022, 2021, and 2020 awards was based on two components: 1) how our total shareholder return ("TSR") compared to the SNL U.S. REIT Healthcare Index ("SNL Index") and 2) how our TSR compared to a threshold set by the Compensation Committee.

The following summarizes stock-based award activity in 2022 and 2021 (which includes awards granted in 2022, 2021, 2020, and any applicable prior years), respectively:

#### **For the Year Ended December 31, 2022:**

	<b>Vesting Based on Service</b>		<b>Vesting Based on Market/Performance Conditions</b>	
	<b>Shares</b>	<b>Weighted-Average Value at Award Date</b>	<b>Shares</b>	<b>Weighted-Average Value at Award Date</b>
Nonvested awards at beginning of the year . . . .	922,954	\$ 20.26	5,477,536	\$ 15.86
Awarded . . . . .	659,393	\$ 21.18	1,828,971	\$ 18.45
Vested . . . . .	(750,854)	\$ 20.25	(2,924,722)	\$ 13.87
Forfeited . . . . .	(21,010)	\$ 20.06	(32,704)	\$ 19.17
Nonvested awards at end of year . . . . .	<u>810,483</u>	\$ 21.02	<u>4,349,081</u>	\$ 18.26

**For the Year Ended December 31, 2021:**

	Vesting Based on Service		Vesting Based on Market/Performance Conditions	
	Shares	Weighted-Average Value at Award Date	Shares	Weighted-Average Value at Award Date
Nonvested awards at beginning of the year . . .	1,057,054	\$ 18.79	5,086,983	\$ 14.41
Awarded . . . . .	651,113	\$ 20.83	1,957,802	\$ 17.94
Vested . . . . .	(781,076)	\$ 18.77	(1,551,482)	\$ 13.73
Forfeited . . . . .	(4,137)	\$ 18.69	(15,767)	\$ 16.72
Nonvested awards at end of year . . . . .	<u>922,954</u>	\$ 20.26	<u>5,477,536</u>	\$ 15.86

The value of stock-based awards is charged to compensation expense over the service periods. For the years ended December 31, 2022, 2021, and 2020, we recorded \$49.4 million, \$52.1 million, and \$47.2 million, respectively, of non-cash compensation expense. The remaining unrecognized cost from stock-based awards at December 31, 2022, is \$47.1 million, which will be recognized over a weighted-average period of 1.2 years. Stock-based awards that vested in 2022, 2021, and 2020, had a value of \$82.6 million, \$49.9 million, and \$58.9 million, respectively.

**8. Commitments and Contingencies***Commitments*

On October 5, 2022, we entered into definitive agreements to sell three Prospect facilities located in Connecticut to Yale for approximately \$457 million. This transaction is expected to close in 2023 subject to certain regulatory approvals and the completion of Yale's acquisition of the hospital operations from Prospect. No assurances can be given that this transaction will be consummated as described or at all.

*Contingencies*

We are a party to various legal proceedings incidental to our business. In the opinion of management, after consultation with legal counsel, the ultimate liability, if any, with respect to those proceedings is not presently expected to materially affect our financial position, results of operations, or cash flows.

**9. Common Stock/Partner's Capital***Medical Properties Trust, Inc.*2022 Activity

On October 9, 2022, the board of directors of the Company authorized a stock repurchase program (the "Stock Repurchase Program") for up to \$500 million of common stock, par value \$0.001 per share. In 2022, we repurchased 1.6 million shares for a total of \$17.9 million. The Stock Repurchase Program expires on October 10, 2023.

2021 Activity

On January 11, 2021, we completed an underwritten public offering of 36.8 million shares of our common stock, resulting in net proceeds of approximately \$711 million, after deducting underwriting discounts and commissions and offering expenses.

In addition, we sold 16.3 million shares of common stock under our at-the-market equity offering program during 2021, resulting in net proceeds of approximately \$340 million.



## 2020 Activity

In 2020, we sold 21.0 million shares of common stock under our at-the-market equity offering program, resulting in net proceeds of approximately \$411 million.

### *MPT Operating Partnership, L.P.*

At December 31, 2022, the Operating Partnership is made up of a general partner, Medical Properties Trust, LLC (“General Partner”) and limited partners, including the Company (which owns 100% of the General Partner) and MPT TRS, Inc. (which is 100% owned by the General Partner). By virtue of its ownership of the General Partner, the Company has a 100% ownership interest in the Operating Partnership.

In regards to distributions, the Operating Partnership shall distribute cash at such times and in such amounts as are determined by the General Partner in its sole and absolute discretion, to common unit holders who are common unit holders on the record date. However, per the Second Amended and Restated Agreement of Limited Partnership of MPT Operating Partnership, L.P. (“Operating Partnership Agreement”), the General Partner shall use its reasonable efforts to cause the Operating Partnership to distribute amounts sufficient to enable the Company to pay stockholder dividends that will allow the Company to (i) meet its distribution requirement for qualification as a REIT and (ii) avoid any U.S. federal income or excise tax liability imposed by the Code, other than to the extent the Company elects to retain and pay income tax on its net capital gain. In accordance with the Operating Partnership Agreement, LTIP units are treated as common units for distribution purposes.

The Operating Partnership’s net income will generally be allocated first to the General Partner to the extent of any cumulative losses and then to the limited partners in accordance with their respective percentage interests in the common units issued by the Operating Partnership. Any losses of the Operating Partnership will generally be allocated first to the limited partners until their capital account is zero and then to the General Partner. In accordance with the Operating Partnership Agreement, LTIP units are treated as common units for purposes of income and loss allocations. Limited partners have the right to require the Operating Partnership to redeem part or all of their common units. It is at the Operating Partnership’s discretion to redeem such common units for cash based on the fair market value of an equivalent number of shares of the Company’s common stock at the time of redemption or, alternatively, redeem the common units for shares of the Company’s common stock on a one-for-one basis, subject to adjustment in the event of stock splits, stock dividends, or similar events. LTIP units must wait two years from the issuance of the LTIP units to be redeemed, and then converted to common units. On December 28, 2020, approximately 232 thousand LTIP units were converted to common units and then redeemed for approximately \$4.9 million of cash. No LTIP units exist at December 31, 2022.

For each share of common stock issued/repurchased by Medical Properties Trust, Inc., the Operating Partnership issues/repurchases a corresponding number of operating partnership units.

## **10. Fair Value of Financial Instruments**

We have various assets and liabilities that are considered financial instruments. We estimate that the carrying value of cash and cash equivalents and accounts payable and accrued expenses approximate their fair values. We estimate the fair value of our interest and rent receivables using Level 2 inputs such as discounting the estimated future cash flows using the current rates at which similar receivables would be made to others with similar credit ratings and for the same remaining maturities. The fair value of our mortgage loans and other loans are estimated by using Level 2 inputs such as discounting the estimated future cash flows using the current rates which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. We determine the fair value of our senior unsecured notes using Level 2 inputs such as quotes from securities dealers and market makers. We estimate the fair value of our revolving credit facility and term loans using Level 2 inputs based on the present value of future payments, discounted at a rate which we consider appropriate for such debt.

Fair value estimates are made at a specific point in time, are subjective in nature, and involve uncertainties and matters of significant judgment. Settlement of such fair value amounts may not be a prudent management decision.

The following table summarizes fair value estimates for our financial instruments (in thousands):

<u>Asset (Liability)</u>	<u>December 31, 2022</u>		<u>December 31, 2021</u>	
	<u>Book Value</u>	<u>Fair Value</u>	<u>Book Value</u>	<u>Fair Value</u>
Interest and rent receivables . . . . .	\$ 167,035	\$ 163,101	\$ 56,229	\$ 56,564
Loans(1) . . . . .	1,405,615 (2)	1,360,113	991,609 (2)	991,954
Debt, net . . . . .	(10,268,412)	(8,697,042)	(11,282,770)	(11,526,388)

- (1) Excludes the acquisition loan and mortgage loan made in October 2021 for our Springstone investment and the acquisition loan made in May 2020 related to our investment in the international joint venture, along with the related subsequent investment in the real estate of three hospitals in Colombia, as these assets are accounted for under the fair value option method, as noted below.
- (2) Includes \$223.8 million and \$70.1 million of mortgage loans, a \$315.9 million and \$335.6 million shareholder loan included in investments in unconsolidated real estate joint ventures, \$640.4 million and \$521.4 million of loans that are part of our investments in unconsolidated operating entities, and \$225.5 million and \$64.5 million of other loans at December 31, 2022 and 2021, respectively.

#### *Items Measured at Fair Value on a Recurring Basis*

Our equity investment and related loan to the international joint venture, our loan investment in the real estate of three hospitals operated by subsidiaries of the international joint venture in Colombia, and our equity investment and related loans in Springstone are measured at fair value on a recurring basis as we elected to account for these investments using the fair value option at the point of initial investment. We elected to account for these investments at fair value due to the size of the investments and because we believe this method was more reflective of current values.

At December 31, 2022 and 2021, the amounts recorded under the fair value option method were as follows (in thousands):

<u>Asset (Liability)</u>	<u>As of December 31, 2022</u>		<u>As of December 31, 2021</u>		<u>Asset Type Classification</u>
	<u>Fair Value</u>	<u>Original Cost</u>	<u>Fair Value</u>	<u>Original Cost</u>	
Mortgage loans . . . . .	\$140,260	\$140,260	\$143,068	\$143,068	Mortgage loans
Equity investment and other loans . . . . .	434,609	441,943	409,638	409,638	Investments in unconsolidated operating entities/Other loans

Our loans to Springstone and the international joint venture and its subsidiaries are recorded at fair value based on Level 2 inputs by discounting the estimated cash flows using the market rates at which similar loans would be made to borrowers with similar credit ratings and the same remaining maturities, while also considering the value of the underlying collateral of each loan. Our equity investment in Springstone and the international joint venture is recorded at fair value based on Level 3 inputs, by using a discounted cash flow model, which requires significant estimates of our investee such as projected revenue and expenses and appropriate consideration of the underlying risk profile of the forecasted assumptions associated with the investee. We classify our valuations of equity investments as Level 3, as we use certain unobservable inputs to the valuation methodology that are significant to the fair value measurement, and the valuations require management judgment due to absence of quoted market prices. For the cash flow models, our observable inputs

include use of a capitalization rate and discount rate (which is based on a weighted-average cost of capital) and our unobservable input includes an adjustment for a marketability discount (“DLOM”). In regards to the underlying projections used in the discounted cash flow model, such projections are provided by the investees. However, we will modify such projections as needed based on our review and analysis of historical results, meetings with key members of management, and our understanding of trends and developments within the healthcare industry.

In 2022, we recorded an unfavorable fair value adjustment of approximately \$7 million to our investments, as shown in “Other (including fair value adjustments on securities)” in our consolidated statements of net income. No fair value adjustment was recorded in 2021.

The DLOM on our Springstone investment was 40% at December 31, 2022. In arriving at the DLOM, we started with a DLOM range based on the results of studies supporting valuation discounts for other transactions or structures without a public market. To select the appropriate DLOM within the range, we then considered many qualitative factors, including the percent of control, the nature of the underlying investee’s business along with our rights as an investor pursuant to the operating agreement, the size of investment, expected holding period, number of shareholders, access to capital marketplace, etc. To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):

<u>Basis Point Change in Marketability Discount</u>	<u>Estimated Increase (Decrease) in Fair Value</u>
+ 100 basis points . . . . .	\$ (43)
- 100 basis points . . . . .	43

#### *Items Measured at Fair Value on a Nonrecurring Basis*

In addition to items that are measured at fair value on a recurring basis, we have assets and liabilities that are measured, from time-to-time, at fair value on a nonrecurring basis, such as for long-lived asset impairment purposes. In these cases, fair value may be based on estimated cash flows discounted at a risk-adjusted rate of interest by using Level 2 inputs as more fully described in Note 2, or for our real estate, including for the impairment analysis on our Prospect Pennsylvania real estate in 2022, we may use a market approach using level 2 inputs, whereby we will divide the expected net operating income (i.e. rent revenue less expenses, if any) of the facility by a market capitalization rate.

## **11. Leases (Lessee)**

We lease the land underlying certain of our facilities (for which we sublease to our tenants), along with corporate offices and equipment. Our leases have remaining lease terms that vary in years, and some of the leases have initial fixed terms (or renewal options available) that extend the leases up to, or just beyond, the depreciable life of the properties that occupy the leased land. Renewal options that we are reasonably certain to exercise are recognized in our right-of-use assets and lease liabilities. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments.

The following is a summary of our lease expense (in thousands):

	Income Statement Classification	For the Years Ended December 31,	
		2022	2021
Operating lease cost(1) . . . . .	(2)	\$12,175	\$10,694
Finance lease cost:			
Amortization of right-of-use assets . .	Real estate depreciation and amortization	51	51
Interest on lease liabilities . . . . .	Interest	128	128
Sublease income . . . . .	Other	(4,485)	(4,466)
Total lease cost . . . . .		<u>\$ 7,869</u>	<u>\$ 6,407</u>

(1) Includes short-term leases.

(2) \$5.7 million and \$6.3 million included in “Property-related”, with the remainder reflected in the “General and administrative” line of our consolidated statements of net income for 2022 and 2021, respectively.

Fixed minimum payments due over the remaining lease term under non-cancelable leases of more than one year and amounts to be received in the future from non-cancelable subleases over their remaining lease term at December 31, 2022 are as follows (amounts in thousands):

	Operating Leases	Finance Leases	Amounts To Be Received From Subleases	Net Payments
2023 . . . . .	\$ 8,742	\$ 129	\$ (4,416)	\$ 4,455
2024 . . . . .	8,880	130	(4,272)	4,738
2025 . . . . .	8,289	131	(4,328)	4,092
2026 . . . . .	7,884	133	(4,021)	3,996
2027 . . . . .	7,873	134	(3,730)	4,277
Thereafter . . . . .	235,940	4,516	(65,320)	175,136 (1)
Total undiscounted minimum lease payments . . .	<u>\$ 277,608</u>	<u>\$ 5,173</u>	<u>\$(86,087)</u>	<u>\$ 196,694</u>
Less: interest . . . . .	<u>(176,016)</u>	<u>(3,235)</u>		
Present value of lease liabilities . . . . .	<u>\$ 101,592</u>	<u>\$ 1,938</u>		

(1) Reflects certain ground leases, in which we are the lessee, that have longer initial fixed terms than our existing sublease to our tenants. However, we would expect to either renew the related sublease, enter into a lease with a new tenant, or early terminate the ground lease to reduce or avoid any significant impact from such ground leases.

Supplemental balance sheet information is as follows (in thousands, except lease terms and discount rate):

	<b>Balance Sheet Classification</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
<b>Right of use assets:</b>			
Operating leases — real estate . . . . .	Land	\$ 63,553	\$ 68,616
Finance leases — real estate . . . . .	Land	1,734	1,785
Total real estate right of use assets . . . . .		\$ 65,287	\$ 70,401
Operating leases — corporate . . . . .	Other assets	26,225	7,458
Total right of use assets . . . . .		<u>\$ 91,512</u>	<u>\$ 77,859</u>
<b>Lease liabilities:</b>			
Operating leases . . . . .	Obligations to tenants and other lease liabilities	\$ 101,592	\$ 85,217
Financing leases . . . . .	Obligations to tenants and other lease liabilities	1,938	1,937
Total lease liabilities . . . . .		<u>\$ 103,530</u>	<u>\$ 87,154</u>
<b>Weighted-average remaining lease term:</b>			
Operating leases . . . . .		33.2	40.6
Finance leases . . . . .		33.9	34.9
<b>Weighted-average discount rate:</b>			
Operating leases . . . . .		6.1%	6.4%
Finance leases . . . . .		6.6%	6.6%

The following is supplemental cash flow information (in thousands):

	<b>For the Years Ended December 31,</b>	
	<b>2022</b>	<b>2021</b>
<b>Cash paid for amounts included in the measurement of lease liabilities:</b>		
Operating cash flows used for operating leases . . . . .	\$ 7,169	\$7,330
Operating cash flows used for finance leases . . . . .	128	126
<b>Non-cash activities — Right-of-use assets obtained in exchange for lease obligations:</b>		
Operating leases . . . . .	23,066	1,120

## 12. Other Assets

The following is a summary of our other assets on our consolidated balance sheets (in thousands):

	<b>As of December 31,</b>	
	<b>2022</b>	<b>2021</b>
Debt issue costs, net(1) . . . . .	\$ 12,036	\$ 5,488
Other corporate assets . . . . .	256,438	231,731
Prepays and other assets . . . . .	304,516	96,261
Total other assets . . . . .	<u>\$572,990</u>	<u>\$333,480</u>

(1) Relates to our revolving credit facility

Other corporate assets include land and land improvements associated with our corporate offices, furniture and fixtures, equipment, corporate vehicles, aircraft, enterprise and other software, deposits, and right-of-use assets associated with corporate leases. Included in prepaids and other assets is prepaid insurance, prepaid taxes, deferred income tax assets (net of valuation allowances, if any), non-tenant receivables, derivative assets, and lease inducements made to tenants, among other items.

Prepaids and other assets are higher in 2022 due to an approximate \$80 million increase in derivative assets (associated with our interest rate swaps) and recovery receivables associated with flood damage of our Norwood facility, among other things.

### **13. Subsequent Events**

On February 7, 2023, a subsidiary of Lifepoint acquired a majority interest in Springstone (the “Lifepoint Transaction”) based on an enterprise value of \$250 million. We received approximately \$205 million in full satisfaction of our initial acquisition loan to Springstone, including accrued interest. We also retained our minority equity interest in the operations of Springstone and will continue to own and lease Springstone’s behavioral hospitals. As part of the Lifepoint Transaction, Lifepoint agreed to extend its current lease with us on eight existing general acute care hospitals by five years to 2041.

On February 15, 2023, we agreed to lease five general acute care facilities located in Utah currently leased to Steward to Catholic Health Initiatives Colorado (“CHIC”), a wholly owned subsidiary of CommonSpirit Health, subsequent to CHIC’s pending acquisition of the Utah hospital business currently operated by Steward. Centura Health will manage the facilities for CHIC. The consummation of this transaction, which is subject to regulatory approval, is expected in 2023. The initial 15 year lease with CHIC for these Utah assets (approximately 5.5% of our total assets at December 31, 2022) will generate an initial cash yield of 7.8%, bump annually by 3%, and include repurchase options at the greater of fair value or our gross investment.

## **ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure**

None.

### **ITEM 9A. Controls and Procedures**

#### **Medical Properties Trust, Inc.**

(a) *Evaluation of Disclosure Controls and Procedures.* Medical Properties Trust, Inc. maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to provide reasonable assurance that information required to be disclosed in its Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that no controls and procedures, no matter how well designed and operated, can provide absolute assurance of achieving the desired control objectives. As required by Rule 13a-15(b) under the Exchange Act, the management of Medical Properties Trust, Inc., with the participation of its Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures. Based on the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures are effective as of the end of the period covered by this report.

(b) *Management's Report on Internal Control over Financial Reporting.*

The management of Medical Properties Trust, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting for Medical Properties Trust, Inc. (as such term is defined in Rule 13a-15(f) of the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Medical Properties Trust, Inc.'s financial statements for external reporting purposes in accordance with GAAP.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management has undertaken an assessment of the effectiveness of the internal control over financial reporting for Medical Properties Trust, Inc. as of December 31, 2022 based upon the framework established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has concluded that, as of December 31, 2022, the internal control over financial reporting for Medical Properties Trust, Inc. was effective.

The effectiveness of the internal control over financial reporting for Medical Properties Trust, Inc. as of December 31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears in this Annual Report on Form 10-K.

(c) *Changes in Internal Controls over Financial Reporting.* There has been no change in the internal control over financial reporting for Medical Properties Trust, Inc. during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

#### **MPT Operating Partnership, L.P.**

(a) *Evaluation of Disclosure Controls and Procedures.* MPT Operating Partnership, L.P. maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed

to provide reasonable assurance that information required to be disclosed in its Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), as appropriate, of Medical Properties Trust, Inc. (the sole general partner of MPT Operating Partnership, L.P.) to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that no controls and procedures, no matter how well designed and operated, can provide absolute assurance of achieving the desired control objectives. As required by Rule 13a-15(b) under the Exchange Act, the management of MPT Operating Partnership, L.P., with the participation of the Chief Executive Officer and Chief Financial Officer of Medical Properties Trust, Inc. (the sole general partner of MPT Operating Partnership, L.P.), carried out an evaluation of the effectiveness of our disclosure controls and procedures. Based on the foregoing, the Chief Executive Officer and Chief Financial Officer of Medical Properties Trust, Inc. (the sole general partner of MPT Operating Partnership, L.P.) concluded that these disclosure controls and procedures are effective as of the end of the period covered by this report.

*(b) Management's Report on Internal Control over Financial Reporting.*

The management of MPT Operating Partnership, L.P. is responsible for establishing and maintaining adequate internal control over financial reporting for MPT Operating Partnership, L.P. (as such term is defined in Rule 13a-15(f) of the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of MPT Operating Partnership, L.P.'s financial statements for external reporting purposes in accordance with GAAP.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management has undertaken an assessment of the effectiveness of the internal control over financial reporting for MPT Operating Partnership, L.P. as of December 31, 2022, based upon the framework established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has concluded that, as of December 31, 2022, the internal control over financial reporting for MPT Operating Partnership, L.P. was effective.

The effectiveness of the internal control over financial reporting for MPT Operating Partnership, L.P. as of December 31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears in this Annual Report on Form 10-K.

*(c) Changes in Internal Controls over Financial Reporting.* There has been no change in the internal control over financial reporting for MPT Operating Partnership, L.P. during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

**ITEM 9B. Other Information**

None.

**ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

None.



## **PART III**

### **ITEM 10. *Directors, Executive Officers and Corporate Governance***

The information required by this Item 10 is incorporated by reference to our definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which will be filed by us with the Commission not later than May 1, 2023.

### **ITEM 11. *Executive Compensation***

The information required by this Item 11 is incorporated by reference to our definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which will be filed by us with the Commission not later than May 1, 2023.

### **ITEM 12. *Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters***

The information required by this Item 12 is incorporated by reference to our definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which will be filed by us with the Commission not later than May 1, 2023.

### **ITEM 13. *Certain Relationships and Related Transactions, and Director Independence***

The information required by this Item 13 is incorporated by reference to our definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which will be filed by us with the Commission not later than May 1, 2023.

### **ITEM 14. *Principal Accountant Fees and Services***

Our independent public accounting firm is PricewaterhouseCoopers LLP, Birmingham, Alabama, PCAOB Auditor ID 238. The information required by this Item 14 is incorporated by reference to our definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which will be filed by us with the Commission not later than May 1, 2023.

## PART IV

### ITEM 15. *Exhibits and Financial Statement Schedules*

#### (a) Financial Statements and Financial Statement Schedules

**Index of Financial Statements of Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. which are included in Part II, Item 8 of this Annual Report on Form 10-K:**

Report of Independent Registered Public Accounting Firm	
Medical Properties Trust, Inc. ....	69
MPT Operating Partnership, L.P. ....	71
Medical Properties Trust, Inc.	
Consolidated Balance Sheets as of December 31, 2022 and 2021 .....	73
Consolidated Statements of Net Income for the Years Ended December 31, 2022, 2021, and 2020 .....	74
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2022, 2021, and 2020 .....	75
Consolidated Statements of Equity for the Years Ended December 31, 2022, 2021, and 2020 .....	76
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021, and 2020 .....	77
MPT Operating Partnership, L.P.	
Consolidated Balance Sheets as of December 31, 2022 and 2021 .....	78
Consolidated Statements of Net Income for the Years Ended December 31, 2022, 2021, and 2020 .....	79
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2022, 2021, and 2020 .....	80
Consolidated Statements of Capital for the Years Ended December 31, 2022, 2021, and 2020 .....	81
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021, and 2020 .....	82
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P.	
Notes to Consolidated Financial Statements .....	83
Financial Statement Schedules	
Schedule II — Valuation and Qualifying Accounts for the Years Ended December 31, 2022, 2021, and 2020 .....	133
Schedule III — Real Estate and Accumulated Depreciation at December 31, 2022 with reconciliations for the years ended December 31, 2022, 2021, and 2020 .....	134
Schedule IV — Mortgage Loans on Real Estate at December 31, 2022 with reconciliations for the years ended December 31, 2022, 2021, and 2020 .....	142

**(b) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>	<b>Form</b>	<b>File Number</b>	<b>Exhibit Number</b>	<b>Filing Date</b>
3.1	Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	S-11/A	333-119957	3.1	January 6, 2005
3.2	Articles of Amendment of Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	10-Q	001-32559	3.1	November 10, 2005
3.3	Articles of Amendment of Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	8-K	001-32559	3.1	January 13, 2009
3.4	Articles of Amendment to Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	8-K	001-32559	3.1	January 31, 2012
3.5	Articles of Amendment to Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	8-K	001-32559	3.1	June 26, 2015
3.6	Articles of Amendment to Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	10-Q	001-32559	3.2	August 10, 2015
3.7	Articles of Amendment to the Second Articles of Amendment and Restatement of Medical Properties Trust, Inc.	8-K	001-32559	3.1	November 8, 2019
3.8	Second Amended and Restated Bylaws of Medical Properties Trust, Inc.	8-K	001-32559	3.1	November 24, 2009
3.9	Amendment to Second Amended and Restated Bylaws of Medical Properties Trust, Inc.	8-K	001-32559	3.2	June 26, 2015
3.10	Amendment to Second Amended and Restated Bylaws of Medical Properties Trust, Inc.	8-K	001-32559	3.1	November 16, 2016
3.11	Amendment to Second Amended and Restated Bylaws of Medical Properties Trust, Inc.	8-K	001-32559	3.1	February 22, 2017
3.12	Amendment to Second Amended and Restated Bylaws of Medical Properties Trust, Inc.	8-K	001-32559	3.1	May 25, 2018
3.13	Amendment to Second Amended and Restated Bylaws of Medical Properties Trust, Inc.	8-K	001-32559	3.1	May 22, 2020
4.1	Form of Common Stock Certificate	S-11/A	333-119957	4.1	January 6, 2005
4.2	Description of Securities of Medical Properties Trust, Inc. Registered under Section 12 of the Securities Exchange Act, as amended	10-K	001-32559	4.2	February 27, 2020
4.3	Indenture, dated as of October 10, 2013, among Medical Properties Trust, Inc., MPT Operating Partnership, L.P., MPT Finance Corporation, the Subsidiary Guarantors and Wilmington Trust, N.A., as Trustee.	8-K	001-32559	4.1	October 16, 2013

<b>Exhibit Number</b>	<b>Description</b>	<b>Form</b>	<b>File Number</b>	<b>Exhibit Number</b>	<b>Filing Date</b>
4.4	Tenth Supplemental Indenture, dated as of July 22, 2016, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, and Wilmington Trust, National Association, as Trustee.	8-K	001-32559	4.2	July 22, 2016
4.5	Eleventh Supplemental Indenture, dated as of March 24, 2017, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, and Wilmington Trust, National Association, as Trustee, Deutsche Bank Trust Company Americas, as Paying Agent, Registrar and Transfer Agent.	8-K	001-32559	4.2	March 27, 2017
4.6	Twelfth Supplemental Indenture, dated as of September 21, 2017, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, and Wilmington Trust, National Association, as trustee.	10-Q	001-32559	4.1	November 9, 2017
4.7	Thirteenth Supplemental Indenture, dated as of July 26, 2019, by and among MPT Operating Partnership, L.P., and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, and Wilmington Trust, National Association, as trustee.	8-K	001-32559	4.2	July 29, 2019
4.8	Fourteenth Supplemental Indenture, dated as of December 5, 2019, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, Wilmington Trust, National Association as trustee, Elavon Financial Services DAC, U.K. Branch as initial paying agent, and Elavon Financial Services DAC, as initial registrar and transfer agent.	8-K	001-32559	4.2	December 11, 2019
4.9	Fifteenth Supplemental Indenture, dated as of December 5, 2019, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, Wilmington Trust, National Association, as trustee, Elavon Financial Services DAC, U.K. Branch, as initial paying agent, and Elavon Financial Services DAC, as initial registrar and transfer agent.	8-K	001-32559	4.4	December 11, 2019

<b>Exhibit Number</b>	<b>Description</b>	<b>Form</b>	<b>File Number</b>	<b>Exhibit Number</b>	<b>Filing Date</b>
4.10	Sixteenth Supplemental Indenture, dated as of December 4, 2020, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc. as parent and guarantor, and Wilmington Trust, National Association, as trustee.	8-K	001-32559	4.2	December 7, 2020
4.11	Seventeenth Supplemental Indenture, dated as of March 24, 2021, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, Wilmington Trust, National Association, as trustee, and Elavon Financial Services DAC, as initial paying agent, registrar and transfer agent	8-K	001-32559	4.2	March 29, 2021
4.12	Eighteenth Supplemental Indenture, dated as of March 24, 2021, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, Wilmington Trust, National Association, as trustee, and Elavon Financial Services DAC, as initial paying agent, registrar and transfer agent	8-K	001-32559	4.4	March 29, 2021
4.13	Nineteenth Supplemental Indenture, dated as of October 6, 2021, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, Wilmington Trust, National Association, as trustee, and Elavon Financial Services DAC, as initial paying agent, registrar and transfer agent	8-K	001-32559	4.2	October 13, 2021
10.1	Second Amended and Restated Agreement of Limited Partnership of MPT Operating Partnership, L.P.	8-K	001-32559	10.1	August 6, 2007
10.2	Medical Properties Trust, Inc. 2013 Equity Incentive Plan***	10-K	001-32559	10.2	March 1, 2019
10.3	Medical Properties Trust, Inc. 2019 Equity Incentive Plan***	DEF 14A	001-32559	A	April 26, 2019
10.4	Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan***	DEF 14A	001-32559	A	April 28, 2022
10.5	Form of Stock Option Award***	8-K	001-32559	10.2	October 18, 2005
10.6	Form of Restricted Stock Award***	8-K	001-32559	10.4	October 18, 2005

<b>Exhibit Number</b>	<b>Description</b>	<b>Form</b>	<b>File Number</b>	<b>Exhibit Number</b>	<b>Filing Date</b>
10.7	Form of Deferred Stock Unit Award***	8-K	001-32559	10.5	October 18, 2005
10.8	Employment Agreement between Medical Properties Trust, Inc. and Edward K. Aldag, Jr., dated September 10, 2003***	S-11/A	333-119957	10.3	January 6, 2005
10.9	First Amendment to Employment Agreement between Medical Properties Trust, Inc. and Edward K. Aldag, Jr., dated March 8, 2004***	S-11/A	333-119957	10.4	January 6, 2005
10.10	Employment Agreement between Medical Properties Trust, Inc. and R. Steven Hamner, dated September 10, 2003***	S-11/A	333-119957	10.6	January 6, 2005
10.11	Employment Agreement between Medical Properties Trust, Inc. and Emmett E. McLean, dated September 10, 2003***	S-11/A	333-119957	10.5	January 6, 2005
10.12	Form of Indemnification Agreement between Medical Properties Trust, Inc. and executive officers and directors***	S-11/A	333-119957	10.55	July 5, 2005
10.13	Form of Medical Properties Trust, Inc. 2007 Multi-Year Incentive Plan Award Agreement (LTIP Units)***	8-K	001-32559	10.2	August 6, 2007
10.14	Form of Medical Properties Trust, Inc. 2007 Multi-Year Incentive Plan Award Agreement (Restricted Shares)***	8-K	001-32559	10.3	August 6, 2007
10.15	Second Amendment to Employment Agreement between Medical Properties Trust, Inc. and Edward K. Aldag, Jr., dated September 29, 2006***	10-K	001-32559	10.58	March 14, 2008
10.16	First Amendment to Employment Agreement between Medical Properties Trust, Inc. and R. Steven Hamner, dated September 29, 2006***	10-K	001-32559	10.59	March 14, 2008
10.17	First Amendment to Employment Agreement between Medical Properties Trust, Inc. and Emmett E. McLean, dated September 29, 2006***	10-K	001-32559	10.61	March 14, 2008
10.18	Second Amendment to Employment Agreement between Medical Properties Trust, Inc. and Emmett E. McLean, dated January 1, 2008***	10-K	001-32559	10.74	March 13, 2009
10.19	Third Amendment to Employment Agreement between Medical Properties Trust, Inc. and Emmett E. McLean, dated January 1, 2009***	10-K	001-32559	10.75	March 13, 2009
10.20	Second Amendment to Employment Agreement between Medical Properties Trust, Inc. and Richard S. Hamner, dated January 1, 2008***	10-K	001-32559	10.76	March 13, 2009

<b>Exhibit Number</b>	<b>Description</b>	<b>Form</b>	<b>File Number</b>	<b>Exhibit Number</b>	<b>Filing Date</b>
10.21	Third Amendment to Employment Agreement between Medical Properties Trust, Inc. and R. Steven Hamner, dated January 1, 2009***	10-K	001-32559	10.77	March 13, 2009
10.22	Third Amendment to Employment Agreement between Medical Properties Trust, Inc. and Edward K. Aldag, Jr., dated January 1, 2008***	10-K	001-32559	10.78	March 13, 2009
10.23	Fourth Amendment to Employment Agreement between Medical Properties Trust, Inc. and Edward K. Aldag, Jr., dated January 1, 2009***	10-K	001-32559	10.79	March 13, 2009
10.24	Amended and Restated Subscription Agreement dated as of June 7, 2018 by and among MPT Operating Partnership, L.P., Primotop Holding, S.a.r.l. and MPT RHM Holdco S.a.r.l.	10-Q	001-32559	10.1	August 9, 2018
10.25	Syndicated Facility Agreement among MPT Operating Partnership, L.P. and Evolution Trustees Limited as Trustee of MPT Australia Realty Trust, as borrowers, Medical Properties Trust, Inc. and certain subsidiaries, as guarantors, the several lenders and other entities from time to time parties thereto, Bank of America, N.A, as administrative agent, and Citizens Bank, N.A., JPMorgan Change Bank, N.A., Suntrust Bank and Wells Fargo Bank, N.A., as co-syndication agents.	10-Q	001-32559	10.1	August 9, 2019
10.26	Real Property Asset Purchase Agreement, dated as of July 10, 2019, by and among Prospect Medical Holdings, Inc., as “Prospect Medical Holdings”, and subsidiaries of Prospect Medical Holdings, as the “Prospect Medical Subsidiaries”, and subsidiaries of MPT Operating Partnership, L.P., as the “MPT Parties”.	10-Q	001-32559	10.2	November 12, 2019
10.27	Form of Lease Agreement between certain subsidiaries of MPT Operating Partnership, L.P., as Lessor, and Circle Health Ltd. and certain of its subsidiaries, as Lessee	10-Q	001-32559	10.1	August 7, 2020
10.28	Amended and Restated Master Lease Agreement between certain subsidiaries of MPT Operating Partnership, L.P. as Lessor and certain subsidiaries of Steward Health Care System LLC, Lessee	10-Q	001-32559	10.1	November 9, 2021

<b>Exhibit Number</b>	<b>Description</b>	<b>Form</b>	<b>File Number</b>	<b>Exhibit Number</b>	<b>Filing Date</b>
10.29	Second Amended and Restated Revolving Credit and Term Loan Agreement, dated as of June 29, 2022, among Medical Properties Trust, Inc., MPT Operating Partnership, L.P., the several lenders from time to time party thereto, Bank of America, N.A., as syndication agent, and JPMorgan Chase Bank, N.A., as administrative agent	8-K	001-32559	1.1	July 6, 2022
21.1*	Subsidiaries of Medical Properties Trust, Inc.				
23.1*	Consent of PricewaterhouseCoopers LLP				
23.2*	Consent of PricewaterhouseCoopers LLP				
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)				
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)				
31.3*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)				
31.4*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)				
32.1**	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Medical Properties Trust, Inc.)				
32.2**	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (MPT Operating Partnership, L.P.)				
Exhibit 101.INS	Inline XBRL Instance Document				
Exhibit 101.SCH	Inline XBRL Taxonomy Extension Schema Document				



Exhibit Number	Description	Form	File Number	Exhibit Number	Filing Date
Exhibit 101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				
Exhibit 101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				
Exhibit 101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				
Exhibit 101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document				
104	Cover page interactive data file (Formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)				

---

\* Filed herewith.

\*\* Furnished herewith.

\*\*\* Management contract or compensatory plan or arrangement.

**ITEM 16. *Form 10-K Summary***

None.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act, the registrants have duly caused this Report to be signed on their behalf by the undersigned, thereunto duly authorized.

MEDICAL PROPERTIES TRUST, INC.

By: /s/ J. Kevin Hanna  
J. Kevin Hanna  
Vice President, Controller, and Chief Accounting Officer

MPT OPERATING PARTNERSHIP, L.P.

By: /s/ J. Kevin Hanna  
J. Kevin Hanna  
Vice President, Controller, and Chief Accounting Officer of the sole member of the general partner of MPT Operating Partnership, L.P.

Date: March 1, 2023

## Power of Attorney

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint J. Kevin Hanna and R. Steven Hamner, and each of them singly, as her or his true and lawful attorneys with full power to them, and each of them singly, to sign for such person and in her or his name in the capacity indicated below, the Annual Report on Form 10-K filed herewith and any and all amendments to said Annual Report on Form 10-K, and generally to do all such things in her or his name and in her or his capacity as officer and director to enable the registrants to comply with the provisions of the Exchange Act, and all requirements of the SEC in connection therewith, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Annual Report on Form 10-K and any and all amendments thereto.

Pursuant to the requirements of the Exchange Act, this report has been signed by the following persons on behalf of the registrants and in the capacities and on the dates indicated.

Signature	Title	Date
<u>/s/ Edward K. Aldag, Jr.</u> Edward K. Aldag, Jr.	Chairman of the Board, President, Chief Executive Officer and Director (Principal Executive Officer)	March 1, 2023
<u>/s/ R. Steven Hamner</u> R. Steven Hamner	Executive Vice President, Chief Financial Officer and Director (Principal Financial Officer)	March 1, 2023
<u>/s/ G. Steven Dawson</u> G. Steven Dawson	Director	March 1, 2023
<u>/s/ Caterina A. Mozingo</u> Caterina A. Mozingo	Director	March 1, 2023

Signature	Title	Date
<hr/> /s/ Emily W. Murphy Emily W. Murphy	Director	March 1, 2023
<hr/> /s/ Elizabeth N. Pitman Elizabeth N. Pitman	Director	March 1, 2023
<hr/> /s/ D. Paul Sparks, Jr. D. Paul Sparks, Jr.	Director	March 1, 2023
<hr/> /s/ Michael G. Stewart Michael G. Stewart	Director	March 1, 2023
<hr/> /s/ C. Reynolds Thompson, III C. Reynolds Thompson, III	Director	March 1, 2023

**Schedule II: Valuation and Qualifying Accounts**  
**Medical Properties Trust, Inc. and MPT Operating Partnership, L.P.**  
**December 31, 2022**

Year Ended December 31,	Balance at Beginning of Year(1)	Additions		Deductions		Balance at End of Year(1)
		Charged Against Operations(1)	Charged to Other Accounts	Net Recoveries/ Write-offs(1)		
			(In thousands)			
2022 .....	\$ 154,161	\$ 294,861 (2)	\$ —	\$ (55,965) (3)	\$ 393,057	
2021 .....	\$ 146,637	\$ 69,131 (4)	\$ 7,340 (5)	\$ (68,947) (6)	\$ 154,161	
2020 .....	\$ 109,803	\$ 58,044 (7)	\$ 22,944 (8)	\$ (44,154) (9)	\$ 146,637	

- (1) Includes real estate impairment reserves, allowance for doubtful accounts, straight-line rent reserves, credit loss reserves, tax valuation allowances, and other reserves.
- (2) Represents a \$170.6 million increase to real estate impairment reserves, \$0.5 million increase in accounts receivable and other reserves, \$114.0 million increase in credit loss reserves on financing-type receivables, and a \$9.8 million increase in valuation allowance to reserve against our net deferred tax assets in 2022.
- (3) Includes a \$2.9 million decrease in real estate impairment reserves related to disposals in 2022, a \$11.7 million decrease in accounts receivable and other reserves, a net credit loss recovery of approximately \$15 million on the Watsonville loans, and a \$26.4 million decrease of credit loss reserves related to financial instruments sold, repaid, or satisfied in 2022.
- (4) Represents a \$41.7 million increase in credit loss reserves on financing-type receivables, \$8 million increase in accounts receivable and other reserves, and an approximately \$20 million increase in valuation allowances to reserve against our net deferred tax assets in 2021.
- (5) Represents \$7.3 million of tax valuation allowances recorded as part of the purchase price allocation of the Priory Transaction as disclosed in Note 3 to Item 8 of this Annual Report on Form 10-K.
- (6) Includes a \$22.4 million decrease in real estate impairment reserves related to disposals in 2021, a \$38.7 million decrease in accounts receivable and other reserves, \$6.0 million decrease of equity investment impairment reserve related to disposals in 2021, and \$1.9 million of credit loss recovery related to loan paydowns in 2021.
- (7) Represents a \$19.0 million increase to real estate impairment reserves, \$23.9 million increase in accounts receivable and other reserves, \$3.3 million increase in credit loss reserves on financing-type receivables, and a \$11.9 million increase in valuation allowances to reserve against our net deferred tax assets in 2020.
- (8) Reflects \$8.4 million of a credit loss reserve recorded on January 1, 2020 to equity as the cumulative effect of a change in accounting principle adjustment upon adoption of ASU No. 2016-13, "Measurement of Credit Losses on Financial Instruments" along with \$14.5 million of tax valuation allowances recorded as part of the purchase price allocation of the Circle Transaction as disclosed in Note 3 to Item 8 of this Annual Report on Form 10-K.
- (9) Includes a \$40.5 million decrease in real estate impairment reserves related to disposals in 2020, \$2.9 million of credit loss recovery related to loan paydowns in 2020, and a \$0.8 million decrease in tax valuation allowances.

# SCHEDULE III — REAL ESTATE INVESTMENTS AND ACCUMULATED DEPRECIATION

## December 31, 2022

Location	Type of Property	Initial Costs			Additions Subsequent to Acquisition			Cost at December 31, 2022(1)			Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Improvements	Carrying Costs	Land	Buildings	Total							
									(Dollar amounts in thousands)						
Aberdeen, UK	Acute care general hospital	\$ 4,036	\$ 95,595	\$ —	\$ —	\$ 4,036	\$ 95,595	\$ 99,631	\$ 7,194	\$ —	1985	January 9, 2020	40		
Algeciras, Spain	Acute care general hospital	505	7,973	—	—	505	7,973	8,478	146	—	1997	April 29, 2022	40		
Alcoona, WI	Acute care general hospital	—	29,062	—	—	—	29,062	29,062	6,055	—	2014	August 31, 2014	40		
Altrincham, UK	Behavioral health facility	13,899	23,895	—	—	13,899	23,895	37,794	61	—	1890, 2014	December 9, 2022	40		
Alvin, TX	Freestanding ER	105	4,087	—	—	105	4,087	4,192	871	—	2014	March 19, 2014	40		
Arnold, UK	Behavioral health facility	453	9,412	—	—	453	9,412	9,865	387	—	2008	June 25, 2021	40		
Ashted, UK	Acute care general hospital	35,840	67,195	—	—	35,840	67,195	103,035	5,852	—	1981	August 16, 2019	40		
Aurora, CO	Freestanding ER	2,845	4,812	—	—	2,845	4,812	7,657	872	—	2015	September 17, 2015	40		
Austin, TX	Freestanding ER	3,665	4,200	—	—	3,665	4,200	7,865	642	—	2017	March 2, 2017	40		
Avondale, AZ	Behavioral health facility	5,383	64,650	—	—	5,383	64,650	70,033	2,050	—	2016	October 19, 2021	40		
Ayr, UK	Behavioral health facility	16,125	46,178	—	—	16,125	46,178	62,303	1,768	—	2004	June 25, 2021	40		
Bad Salzuflen, Germany	Rehabilitation hospital	10,186	25,777	—	—	10,186	25,777	35,963	3,573	—	1974, 2016	November 30, 2017	40		
Bad Salzuflen, Germany	Rehabilitation hospital	6,922	22,669	—	—	6,922	22,669	29,591	2,992	—	1989, 2016	November 30, 2017	40		
Bad Oeynhausen, Germany	Rehabilitation hospital	1,092	2,669	—	—	1,092	2,669	3,761	379	—	1973, 2010	November 30, 2017	40		
Bakersfield, CA	Rehabilitation hospital	2,178	45,253	—	—	2,178	45,253	47,431	930	—	2022	May 15, 2020	40		
Basingstoke, UK	Acute care general hospital	12,264	47,635	—	—	12,264	47,635	59,899	3,609	—	1984	January 9, 2020	40		
Bassenheim, Germany	Rehabilitation hospital	1,095	5,129	—	—	1,095	5,129	6,224	557	—	1887, 1983	February 9, 2019	39		
Bath, UK	Acute care general hospital	1,432	29,685	—	—	1,432	29,685	31,117	6,308	—	2008, 2009	July 1, 2014	40		
Bath, UK	Acute care general hospital	6,827	12,389	—	—	6,827	12,389	19,216	965	—	1992	January 9, 2020	40		
Beckenham, UK	Acute care general hospital	5,184	19,882	—	—	5,184	19,882	25,066	1,501	—	1981	January 9, 2020	40		
Bedford, UK	Acute care general hospital	1,462	7,122	—	—	1,462	7,122	8,584	544	—	1982	January 9, 2020	40		
Bellflower, CA	Behavioral health facility	2,563	—	—	—	2,563	—	2,563	—	—	1972	August 23, 2019	—		
Bennettsville, SC	Acute care general hospital	794	15,773	—	—	794	15,773	16,567	9,999	—	1984	April 1, 2008	42		
Big Spring, TX	Acute care general hospital	1,655	21,254	815	—	1,655	22,069	23,724	2,296	—	1973	April 12, 2019	41		
Birmingham, UK	Acute care general hospital	7,952	40,068	—	—	7,952	40,068	48,020	2,504	—	2017	April 3, 2017	40		
Birmingham, UK	Acute care general hospital	9,360	89,090	—	—	9,360	89,090	98,450	6,751	—	1982	January 9, 2020	40		
Birmingham, UK	Rehabilitation hospital	—	16,477	—	—	—	16,477	16,477	1,030	—	2018	June 29, 2020	40		
Birmingham, UK	Behavioral health facility	391	18,188	—	—	391	18,188	18,579	731	—	1900, 1984, 2016	June 25, 2021	40		
Blackburn, UK	Acute care general hospital	2,526	48,405	—	—	2,526	48,405	50,931	3,652	—	1957	January 9, 2020	40		
Blackburn, UK	Behavioral health facility	19,010	51,573	—	—	19,010	51,573	70,583	2,120	—	1930	June 25, 2021	40		
Blue Springs, MO	Acute care general hospital	4,347	23,494	—	—	4,347	23,494	27,841	4,886	—	1980	February 13, 2015	40		
Boardman, OH	Long term acute care hospital	79	275	—	—	79	275	354	26	—	2008	August 30, 2019	40		
Boise, ID	Long term acute care hospital	1,558	11,027	—	—	1,558	11,027	12,585	1,094	—	2008	February 29, 2012	50		
Bolton, UK	Acute care general hospital	1,504	42,267	—	—	1,504	42,267	43,771	3,181	—	1989	January 9, 2020	40		
Boonton Township, NJ	Behavioral health facility	6,712	17,031	—	—	6,712	17,031	23,743	1,033	—	1952, 1971-1978	September 30, 2015	40		
Bossier City, LA	Long term acute care hospital	900	17,818	944	—	900	18,762	19,662	6,692	—	1982	April 1, 2008	40		
Bowling Green, KY	Rehabilitation hospital	3,486	56,296	3,550	—	3,486	59,846	63,332	5,255	—	1992	August 30, 2019	40		
Braunfels, Germany	Acute care general hospital	2,109	13,138	—	—	2,109	13,138	15,247	2,490	—	1977	June 30, 2015	40		
Bristol, UK	Behavioral health facility	4,466	35,485	—	—	4,466	35,485	39,951	79	—	1790, 2014	December 9, 2022	40		
Bromley, UK	Behavioral health facility	6,856	14,731	—	—	6,856	14,731	21,587	614	—	1714, 1830, 2021	June 25, 2021	40		
Broomfield, CO	Freestanding ER	825	3,895	—	—	825	3,895	4,720	828	—	2014	July 3, 2014	40		
Bundoora, Australia	Acute care general hospital	6,510	60,125	3,935	—	6,510	64,060	70,570	6,090	—	1979	June 7, 2019	37		
Bury, UK	Behavioral health facility	8,076	18,404	—	—	8,076	18,404	26,480	796	—	2003	June 25, 2021	40		
Bussage, UK	Behavioral health facility	8,058	3,562	—	—	8,058	3,562	11,620	149	—	1970	June 25, 2021	40		

Location	Type of Property	Initial Costs		Additions Subsequent to Acquisition		Cost at December 31, 2022(1)				Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Improvements	Carrying Costs	Land	Buildings	Total						
									(Dollar amounts in thousands)					
Cadiz, Spain	Acute care general hospital	290	6,593	—	—	290	6,593	6,883	118	—	—	2000	April 29, 2022	40
Campbelltown, Australia	Acute care general hospital	1,037	51,364	312	—	1,037	51,676	52,713	4,621	—	—	2007	June 7, 2019	40
Canterbury, UK	Acute care general hospital	8,718	26,185	—	—	8,718	26,185	34,903	1,980	—	—	1982	January 9, 2020	40
Carmarthen, UK	Acute care general hospital	864	24,274	—	—	864	24,274	25,138	1,839	—	—	1990	January 9, 2020	40
Carrollton, TX	Behavioral health facility	4,941	52,227	—	—	4,941	52,227	57,168	1,663	—	—	2012	October 19, 2021	40
Casper, WY	Rehabilitation hospital	1,734	—	—	—	1,734	—	—	—	—	—	2012	February 29, 2012	—
Caterham, UK	Acute care general hospital	10,015	19,785	—	—	10,015	19,785	29,800	1,748	—	—	1982	August 16, 2019	40
Chandler, AZ	Freestanding ER	3,567	4,783	—	—	3,567	4,783	8,350	917	—	—	2015	April 24, 2015	40
Chandler, AZ	Freestanding ER	750	3,853	—	—	750	3,853	4,603	698	—	—	2015	October 7, 2015	40
Cheadle, UK	Acute care general hospital	29,362	154,668	—	—	29,362	154,668	184,030	11,673	—	—	1981	January 9, 2020	40
Cheadle, UK	Behavioral health facility	28,297	89,982	—	—	28,297	89,982	118,279	3,652	—	—	1994	July 8, 2020	40
Cheraw, SC	Acute care general hospital	657	19,576	—	—	657	19,576	20,233	12,409	—	—	1982	April 1, 2008	42
Clarksville, TX	Rehabilitation hospital	2,460	25,540	—	—	2,460	25,540	28,000	1,420	—	—	2019	December 17, 2020	39
Cologne, Germany	Acute care general hospital	4,292	14,512	—	—	4,292	14,512	18,804	2,031	—	—	2001	August 7, 2020	40
Colorado Springs, CO	Freestanding ER	600	4,231	—	—	600	4,231	4,831	908	—	—	2014	June 5, 2014	40
Columbus, OH	Behavioral health facility	2,101	44,218	—	—	2,101	44,218	46,319	1,422	—	—	2017	October 19, 2021	40
Commerce City, TX	Freestanding ER	707	4,248	—	—	707	4,248	4,955	858	—	—	2014	December 11, 2014	40
Comroe, TX	Behavioral health facility	3,855	38,892	—	—	3,855	38,892	42,747	1,278	—	—	2018	October 19, 2021	40
Converse, TX	Freestanding ER	750	4,423	—	—	750	4,423	5,173	857	—	—	2015	April 10, 2015	40
Coral Gables, FL	Acute care general hospital	26,215	84,584	—	—	26,215	84,584	110,799	3,104	—	—	1959	August 1, 2021	40
Crown Point, IN	Long term acute care hospital	302	528	—	—	302	528	830	56	—	—	2008	August 30, 2019	40
Croydon, UK	Acute care general hospital	9,437	39,583	—	—	9,437	39,583	49,020	3,007	—	—	1981	January 9, 2020	40
Dahlen, Germany	Rehabilitation hospital	1,303	10,996	—	—	1,303	10,996	12,299	730	—	—	1993, 2006	August 28, 2018	40
Dallas, TX	Long term acute care hospital	1,421	13,536	—	—	1,421	13,536	14,957	5,527	—	—	2006	September 5, 2006	40
Darlington, UK	Acute care general hospital	1,981	33,995	—	—	1,981	33,995	35,976	2,106	—	—	2001	August 7, 2020	40
Darlington, UK	Behavioral health facility	20,165	45,806	—	—	20,165	45,806	65,971	2,012	—	—	1935, 2018, 2020	June 25, 2021	40
Darlington, UK	Behavioral health facility	4,962	25,007	—	—	4,962	25,007	29,969	988	—	—	1960, 1990	June 25, 2021	40
Denver, CO	Freestanding ER	1,257	4,276	—	—	1,257	4,276	5,533	811	—	—	2015	June 8, 2015	40
Denville, NJ	Acute care general hospital	15,709	55,772	—	—	15,709	55,772	71,481	3,308	—	—	1953, 1969-2008	September 30, 2015	40
Detroit, MI	Long term acute care hospital	1,220	8,323	—	—	1,220	8,323	9,543	3,099	—	—	1956	May 22, 2008	40
Diss, UK	Behavioral health facility	2,762	9,849	—	—	2,762	9,849	12,611	453	—	—	1840(2)	June 25, 2021	40
Dorchester, UK	Acute care general hospital	512	29,746	—	—	512	29,746	30,258	2,242	—	—	1981	January 9, 2020	40
Dormagen, Germany	Rehabilitation hospital	1,852	5,477	—	—	1,852	5,477	7,329	631	—	—	1993, 2006	August 28, 2018	40
Dover, NJ	Acute care general hospital	3,865	8,693	—	—	3,865	8,693	12,558	549	—	—	1925, 1927-2008	September 30, 2015	40
Droitwich, UK	Acute care general hospital	72	14,520	—	—	72	14,520	14,592	1,103	—	—	1984	January 9, 2020	40
Dublin, OH	Behavioral health facility	5,118	69,346	—	—	5,118	69,346	74,464	2,185	—	—	2012	October 19, 2021	40
El Paso, TX	Rehabilitation hospital	4,268	21,345	—	—	4,268	21,345	25,613	1,240	—	—	2018	December 17, 2020	38
Englewood, CO	Behavioral health facility	3,369	65,480	—	—	3,369	65,480	68,849	2,081	—	—	2017	October 19, 2021	40
Essex, UK	Behavioral health facility	4,406	41,011	—	—	4,406	41,011	45,417	91	—	—	1790, 1992, 2014	December 9, 2022	40
Euxton, UK	Acute care general hospital	4,382	33,750	—	—	4,382	33,750	38,132	3,026	—	—	1981	August 16, 2019	40
Firestone, TX	Freestanding ER	495	3,963	—	—	495	3,963	4,458	850	—	—	2014	June 6, 2014	40
Flagstaff, AZ	Rehabilitation hospital	3,049	22,464	—	—	3,049	22,464	25,513	2,714	—	—	2016	August 23, 2016	40
Florence, AZ	Acute care general hospital	900	28,462	105	—	900	28,567	29,467	7,674	—	—	2012	February 7, 2012	40
Floridablanca, Colombia	Acute care general hospital	651	20,392	—	—	651	20,392	21,043	214	—	—	1997	July 29, 2022	40
Folsom, CA	Long term acute care hospital	3,291	21,293	—	—	3,291	21,293	24,584	2,106	—	—	2009	August 30, 2019	40
Fort Worth, TX	Behavioral health facility	3,406	34,627	—	—	3,406	34,627	38,033	1,131	—	—	2014	October 19, 2021	40
Fountain, CO	Freestanding ER	1,508	4,131	—	—	1,508	4,131	5,639	869	—	—	2014	July 31, 2014	40
Fresno, CA	Rehabilitation hospital	5,507	70,473	—	—	5,507	70,473	75,980	6,329	—	—	1991	August 30, 2019	40
Frome, UK	Behavioral health facility	2,748	16,652	—	—	2,748	16,652	19,400	705	—	—	1980	June 25, 2021	40

Location	Type of Property	Initial Costs			Additions Subsequent to Acquisition		Cost at December 31, 2022(1)				Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Carrying Costs	Improvements	Carrying Costs	Land	Buildings	Total						
										(Dollar amounts in thousands)					
Frome, UK	Behavioral health facility	10,340	101,166	—	—	—	10,340	101,166	20,506	567	—	1700, 2015, 2017	June 25, 2021	40	
Gardena, CA	Acute care general hospital	14,010	65,282	—	—	—	14,010	65,282	79,292	2,646	—	1966	July 6, 2021	40	
Georgetown, TX	Behavioral health facility	4,569	22,858	—	—	—	4,569	23,920	28,489	741	—	2014	October 19, 2021	40	
Gilbert, AZ	Freestanding ER	1,517	4,661	1,062	—	—	1,517	4,661	6,178	864	—	2015	July 22, 2015	40	
Gilbert, AZ	Behavioral health facility	4,790	45,076	—	—	—	4,790	45,076	49,866	1,408	—	2020	October 19, 2021	40	
Glasgow, UK	Acute care general hospital	6,114	124,874	—	—	—	6,114	124,874	130,988	9,392	—	1983	January 9, 2020	40	
Glasgow, UK	Behavioral health facility	1,355	14,824	—	—	—	1,355	14,824	16,179	603	—	1900, 1980	June 25, 2021	40	
Glen Waverly, Australia	Rehabilitation hospital	29,641	22,296	—	—	—	29,641	22,296	51,937	2,848	—	1972	June 7, 2019	32	
Glendale, AZ	Freestanding ER	1,144	6,087	—	—	—	1,144	6,087	7,231	938	—	2016	October 21, 2016	40	
Glendale, AZ	Freestanding ER	1,193	4,046	—	—	—	1,193	4,046	5,239	767	—	2015	June 5, 2015	40	
Gloucester, UK	Acute care general hospital	5,296	58,249	—	—	—	5,296	58,249	63,545	5,142	—	1990	August 16, 2019	40	
Godalming, UK	Behavioral health facility	8,880	18,014	—	—	—	8,880	18,014	26,894	783	—	1796, 2007	June 25, 2021	40	
Goodyear, AZ	Freestanding ER	1,800	4,713	—	—	—	1,800	4,713	6,513	795	—	2016	April 4, 2016	40	
Great Missenden, UK	Acute care general hospital	11,171	99,814	—	—	—	11,171	99,814	110,985	7,545	—	1981	January 9, 2020	40	
Grefrath, Germany	Rehabilitation hospital	1,164	2,937	—	—	—	1,164	2,937	4,101	346	—	1886, 1983	August 28, 2018	40	
Guildford, UK	Acute care general hospital	6,531	34,573	—	—	—	6,531	34,573	41,104	2,616	—	1989	January 9, 2020	40	
Halsall, UK	Acute care general hospital	1,912	29,573	—	—	—	1,912	29,573	31,485	2,618	—	1986	August 16, 2019	40	
Harrow, UK	Acute care general hospital	36,448	38,358	—	—	—	36,448	38,358	74,806	2,917	—	1980	January 9, 2020	40	
Hartsville, SC	Acute care general hospital	2,050	43,970	—	—	—	2,050	43,970	46,020	9,332	—	1999	August 31, 2015	34	
Hassocks, UK	Behavioral health facility	5,205	27,215	—	—	—	5,205	27,215	32,420	1,255	—	1998	June 25, 2021	40	
Hastings, PA	Acute care general hospital	603	8,834	—	—	—	603	8,834	9,437	1,090	—	1924	December 17, 2019	30	
Hausman, TX	Acute care general hospital	1,500	8,957	—	—	—	1,500	8,957	10,457	2,183	—	2013	March 1, 2013	40	
Heidelberg, Germany	Rehabilitation hospital	6,049	34,547	—	—	—	6,049	34,547	40,596	5,644	—	1885, 1991	June 22, 2016	40	
Helotes, TX	Freestanding ER	1,900	5,115	—	—	—	1,900	5,115	7,015	874	—	2016	March 10, 2016	40	
Helsinki, Finland	Acute care general hospital	3,962	65,927	—	—	—	3,962	65,927	69,889	1,384	—	1992, 2013	March 11, 2022	40	
Hemel Hempstead, UK	Behavioral health facility	11,854	5,983	—	—	—	11,854	5,983	17,837	313	—	1901, 1990	June 25, 2021	40	
Hialeah, FL	Acute care general hospital	18,802	107,783	—	—	—	18,802	107,783	126,585	4,043	—	1950	August 1, 2021	40	
Hialeah, FL	Acute care general hospital	75,339	222,271	—	75,494	—	75,339	297,765	373,104	8,995	—	1969	August 1, 2021	40	
Highland Hills, OH	Behavioral health facility	3,148	43,891	—	—	—	3,148	43,891	47,039	1,412	—	2015	October 19, 2021	40	
Highland Village, TX	Freestanding ER	3,218	1,551	—	—	—	3,218	1,551	4,769	445	—	2015	September 22, 2015	40	
Highlands Ranch, CO	Freestanding ER	4,200	4,779	—	—	—	4,200	4,779	8,979	767	—	2016	July 25, 2016	40	
Hill County, TX	Acute care general hospital	1,120	17,882	503	—	—	1,120	18,385	19,505	14,833	—	1980	September 17, 2010	15	
Hinckley, UK	Behavioral health facility	2,340	15,949	—	—	—	2,340	15,949	18,289	648	—	1892, 2007	June 25, 2021	40	
Hook, UK	Behavioral health facility	5,140	9,790	—	—	—	5,140	9,790	14,930	432	—	1980	June 25, 2021	40	
Hoover, AL	Freestanding ER	—	7,581	—	—	—	—	7,581	7,581	1,697	—	2015	May 1, 2015	34	
Hoover, AL	Freestanding ER	—	1,034	296	—	—	—	1,330	1,330	268	—	2015	May 1, 2015	34	
Hope, AR	Acute care general hospital	1,651	3,359	2,733	—	—	1,651	6,092	7,743	1,146	—	1984-2001	September 29, 2017	41	
Hot Springs, AR	Acute care general hospital	5,622	59,432	21,221	—	—	5,622	80,653	86,275	15,232	—	1985	August 31, 2015	40	
Houston, TX	Acute care general hospital	28,687	104,028	78,415	—	—	28,687	182,443	211,130	12,756	—	1940-1950	September 29, 2017	41	
Houston, TX	Freestanding ER	950	3,996	—	—	—	950	3,996	4,946	624	—	2016	September 26, 2016	40	
Houston, TX	Behavioral health facility	6,063	19,881	2,565	—	—	6,063	22,446	28,509	1,122	—	2020	October 25, 2019	40	
Houston, TX	Acute care general hospital	3,274	27,324	32,499	—	—	3,274	59,823	63,097	19,503	—	1960	August 10, 2007	40	
Huntington Park, CA	Acute care general hospital	3,132	5,002	—	—	—	3,132	5,002	8,134	231	—	1967	July 6, 2021	40	
Huntington Park, CA	Acute care general hospital	3,935	6,103	—	—	—	3,935	6,103	10,038	276	—	1960-1969	July 6, 2021	40	
Idaho Falls, ID	Acute care general hospital	1,822	37,467	15,921	—	—	1,822	53,388	55,210	16,455	—	2002	April 1, 2008	40	
Idaho Falls, ID	Acute care general hospital	1,880	107,608	—	—	—	1,880	107,608	109,488	7,835	—	2020	December 19, 2017	40	
Johnstown, PA	Acute care general hospital	8,877	247,158	—	—	—	8,877	247,158	256,035	25,076	—	1924	December 17, 2019	30	
Kansas City, KS	Acute care general hospital	2,351	13,665	—	—	—	2,351	13,665	16,016	1,059	—	2017	June 10, 2019	50	
Kansas City, MO	Acute care general hospital	10,497	64,419	—	—	—	10,497	64,419	74,916	12,996	—	1978	February 13, 2015	40	



Location	Type of Property	Initial Costs			Additions Subsequent to Acquisition		Cost at December 31, 2022(1)				Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Improvements	Carrying Costs	Land	Buildings	Total	Total						
										(Dollar amounts in thousands)					
Katy, TX	Freestanding ER	1,556	4,174	—	—	1,556	4,174	5,730	652	—	—	2016	October 10, 2016	40	
Katy, TX	Freestanding ER	2,147	3,873	—	—	2,147	3,873	6,020	694	—	—	2015	October 21, 2015	40	
Kingswood, Australia	Acute care general hospital	23,216	75,501	11,829	—	23,216	87,330	110,546	6,888	—	—	2000	June 7, 2019	40	
Kuopio, Finland	Acute care general hospital	1,269	42,401	—	—	1,269	42,401	43,670	920	—	—	2017	March 11, 2022	29	
Lafayette, IN	Rehabilitation hospital	800	14,968	(25)	—	800	14,943	15,743	3,694	—	—	2013	February 1, 2013	40	
Lafayette, IN	Behavioral health facility	2,829	10,795	—	—	2,829	10,795	13,624	421	—	—	2012	October 19, 2021	40	
Lander, WY	Acute care general hospital	761	42,849	—	—	761	42,849	43,610	3,434	—	—	1983	December 17, 2019	40	
Lauderdale Lakes, FL	Acute care general hospital	10,657	150,313	—	—	10,657	150,313	160,970	6,038	—	—	1975	August 1, 2021	40	
Lawton, OK	Acute care general hospital	3,944	63,031	—	—	3,944	63,031	66,975	5,077	—	—	1985	December 17, 2019	40	
Layton, UT	Acute care general hospital	14,360	370,154	5,481	—	14,360	375,635	389,995	22,737	—	—	1976-2010	September 29, 2017	40	
League City, TX	Freestanding ER	1,297	3,901	—	—	1,297	3,901	5,198	731	—	—	2015	June 19, 2015	40	
Leawood, KS	Acute care general hospital	2,513	13,938	—	—	2,513	13,938	16,451	1,073	—	—	2017	June 10, 2019	50	
Leeds, UK	Behavioral health facility	2,163	9,037	—	—	2,163	9,037	11,200	379	—	—	1990	June 25, 2021	40	
Lehi, UT	Acute care general hospital	13,368	29,950	1,676	—	13,368	31,626	44,994	4,738	—	—	2015	September 29, 2017	45	
Lewiston, ID	Acute care general hospital	5,389	75,435	—	—	5,389	75,435	80,824	14,455	—	—	1922	May 1, 2017	40	
Little Elm, TX	Freestanding ER	1,241	3,491	—	—	1,241	3,491	4,732	790	—	—	2013	December 1, 2013	40	
Liverpool, Australia	Acute care general hospital	13,022	40,532	196	—	13,022	40,728	53,750	4,879	—	—	1975	June 7, 2019	30	
London, UK	Acute care general hospital	8,772	57,899	—	—	8,772	57,899	66,671	4,357	—	—	1984	January 9, 2020	40	
London, UK	Behavioral health facility	34,421	49,182	—	—	34,421	49,182	83,603	110	—	—	1811, 2014	December 9, 2022	40	
London, UK	Acute care general hospital	3,117	3,937	—	—	3,117	3,937	7,054	300	—	—	1987	January 9, 2020	40	
London, UK	Behavioral health facility	27,463	14,237	—	—	27,463	14,237	41,700	36	—	—	1790, 1992, 2014	December 9, 2022	40	
London, UK	Acute care general hospital	11,817	77,130	—	—	11,817	77,130	88,947	5,790	—	—	1977	January 9, 2020	40	
London, UK	Behavioral health facility	5,848	14,858	—	—	5,848	14,858	20,706	613	—	—	1900, 1960	June 25, 2021	40	
London, UK	Behavioral health facility	13,107	6,464	—	—	13,107	6,464	19,571	277	—	—	1992	June 25, 2021	40	
Longmont, CO	Freestanding ER	1,773	4,181	—	—	1,773	4,181	5,954	723	—	—	2016	February 10, 2016	40	
Los Angeles, CA	Acute care general hospital	12,562	40,164	—	—	12,562	40,164	52,726	1,556	—	—	1972	July 6, 2021	40	
Lubbock, TX	Rehabilitation hospital	1,376	28,292	3,648	—	1,376	31,940	33,316	5,906	—	—	2008	June 16, 2015	40	
Lynwood, CA	Acute care general hospital	30,116	148,527	—	—	30,116	148,527	178,643	9,018	—	—	1940, 1989-2000	August 13, 2020	40	
Malaga, SP	Acute care general hospital	726	11,364	—	—	726	11,364	12,090	193	—	—	2018	April 29, 2022	40	
Mandeville, LA	Freestanding ER	2,800	5,370	—	—	2,800	5,370	8,170	828	—	—	2016	October 28, 2016	40	
Marrero, LA	Freestanding ER	1,584	5,801	—	—	1,584	5,801	7,385	943	—	—	2016	July 15, 2016	40	
McKinney, TX	Freestanding ER	2,614	4,060	—	—	2,614	4,060	6,674	1,012	—	—	2015	July 31, 2015	30	
McKinney, TX	Behavioral health facility	2,934	—	—	—	2,934	—	2,934	—	—	—	2021	October 19, 2021	—	
McMinnville, OR	Acute care general hospital	5,000	97,900	—	—	5,000	97,900	102,900	16,630	—	—	1996	August 31, 2015	41	
Melbourne, FL	Acute care general hospital	5,642	17,087	21,818	—	5,642	38,905	44,547	4,054	—	—	2002	May 1, 2017	42	
Melton Mowbray, UK	Behavioral health facility	5,411	15,169	—	—	5,411	15,169	20,580	651	—	—	1990	June 25, 2021	40	
Mesa, AZ	Acute care general hospital	6,534	100,042	4,135	—	6,534	104,177	110,711	24,726	—	—	2007	September 26, 2013	40	
Mesa, AZ	Acute care general hospital	2,604	16,400	—	—	2,604	16,400	19,004	283	—	—	2019	April 18, 2022	40	
Meyersdale, PA	Acute care general hospital	390	4,280	—	—	390	4,280	4,670	548	—	—	1960	December 17, 2019	30	
Miami, FL	Acute care general hospital	44,400	107,203	—	—	44,400	107,203	151,603	4,744	—	—	1955	August 1, 2021	40	
Miami, FL	Acute care general hospital	20,430	33,881	10,364	—	20,430	44,245	64,675	593	—	—	1958, 1962, 1988, 2016	April 25, 2022	40	
Milton Keynes, UK	Acute care general hospital	4,979	34,035	—	—	4,979	34,035	39,014	2,570	—	—	1983	January 9, 2020	40	
Monmouth, UK	Behavioral health facility	14,717	10,964	—	—	14,717	10,964	25,681	556	—	—	2017	June 25, 2021	40	
Montclair, NJ	Acute care general hospital	7,900	99,640	577	—	8,477	99,640	108,117	22,329	—	—	1970-2000	April 1, 2014	40	
Mount Pleasant, SC	Long term acute care hospital	597	2,198	—	—	597	2,198	2,795	213	—	—	2012	August 30, 2019	40	
New Braunfels, TX	Rehabilitation hospital	1,853	10,622	—	—	1,853	10,622	12,475	574	—	—	2016	February 29, 2012	40	
New Orleans, LA	Freestanding ER	2,850	6,125	—	—	2,850	6,125	8,975	957	—	—	2011	September 23, 2016	40	
Newark, NJ	Acute care general hospital	32,957	24,553	—	—	32,957	24,553	57,510	1,381	—	—	1919, 1920-2003	May 2, 2016	40	

Location	Type of Property	Initial Costs		Additions Subsequent to Acquisition		Cost at December 31, 2022(1)				Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Improvements	Carrying Costs	Land	Buildings	Total						
									(Dollar amounts in thousands)					
Newburgh, IN	Behavioral health facility	1,215	7,212	—	—	1,215	7,212	8,427	254	—	—	2010	October 19, 2021	40
Norland, MO	Long term acute care hospital	834	17,182	—	—	834	17,182	18,016	5,119	—	—	2007	February 14, 2011	40
Norwalk, CA	Acute care general hospital	2,811	5,940	—	—	2,811	5,940	8,751	278	—	—	1959, 1995	July 6, 2021	40
Norwalk, CA	Acute care general hospital	7,946	30,465	—	—	7,946	30,465	38,411	1,221	—	—	1958-1978	July 6, 2021	40
Norwood, MA	Acute care general hospital	6,373	—	69,916	—	6,373	69,916	76,289	—	—	—	1926-2001	June 27, 2018	46
Nottingham, UK	Acute care general hospital	4,700	43,612	—	—	4,700	43,612	48,312	3,317	—	—	1983	January 9, 2020	40
Nottingham, UK	Behavioral health facility	9,502	8,504	—	—	9,502	8,504	18,006	419	—	—	2000	June 25, 2021	40
Nottingham, UK	Behavioral health facility	9,643	3,081	—	—	9,643	3,081	12,724	129	—	—	1980	June 25, 2021	40
Odessa, TX	Acute care general hospital	6,217	123,518	16,600	—	6,217	140,118	146,335	16,927	—	—	1973-2004	September 29, 2017	41
Ogden, UT	Rehabilitation hospital	1,759	16,414	—	—	1,759	16,414	18,173	3,614	—	—	2014	March 1, 2014	40
Oklahoma City, OK	Behavioral health facility	3,641	3,047	—	—	3,641	3,047	6,688	181	—	—	2017	October 19, 2021	40
Olathe, KS	Behavioral health facility	5,966	55,745	—	—	5,966	55,745	61,711	1,818	—	—	2015	October 19, 2021	40
Olathe, KS	Acute care general hospital	3,485	14,484	—	—	3,485	14,484	17,969	1,127	—	—	2018	June 10, 2019	50
Orpington, UK	Acute care general hospital	9,811	40,540	—	—	9,811	40,540	50,351	3,069	—	—	1987	January 9, 2020	40
Ottumwa, IA	Acute care general hospital	2,377	48,697	—	—	2,377	48,697	51,074	5,434	—	—	1950	December 17, 2019	30
Oulu, Finland	Acute care general hospital	3,076	43,939	—	—	3,076	43,939	47,015	965	—	—	2017	March 11, 2022	40
Overland Park, KS	Acute care general hospital	2,974	14,405	—	—	2,974	14,405	17,379	1,127	—	—	2017	June 10, 2019	50
Overland Park, KS	Acute care general hospital	3,191	14,263	—	—	3,191	14,263	17,454	1,172	—	—	2019	June 10, 2019	50
Overlook, TX	Acute care general hospital	2,452	9,666	7	—	2,452	9,673	12,125	2,383	—	—	2012	February 1, 2013	40
Palestine, TX	Acute care general hospital	1,848	95,257	—	—	1,848	95,257	97,105	7,489	—	—	1988	December 17, 2019	40
Parker, CO	Freestanding ER	1,300	4,448	—	—	1,300	4,448	5,748	797	—	—	2015	November 6, 2015	40
Pasco, WA	Acute care general hospital	2,594	13,195	—	—	2,594	13,195	15,789	1,953	—	—	1920	August 31, 2018	30
Pearland, TX	Freestanding ER	1,075	3,577	—	—	1,075	3,577	4,652	745	—	—	2014	September 8, 2014	40
Perth, Australia	Acute care general hospital	99,659	35,321	2,165	—	99,659	37,486	137,145	4,456	—	—	1965	June 7, 2019	30
Petersburg, VA	Rehabilitation hospital	1,302	9,121	—	—	1,302	9,121	10,423	3,306	—	—	2006	July 1, 2008	40
Phoenix, AZ	Behavioral health facility	2,396	26,521	2,985	—	2,396	29,506	31,902	4,062	—	—	1979	September 29, 2017	42
Phoenix, AZ	Acute care general hospital	12,695	73,773	4,499	—	12,695	78,272	90,967	10,931	—	—	1968-1976	September 29, 2017	43
Phoenix, AZ	Acute care general hospital	5,576	45,782	—	—	5,576	45,782	51,358	6,772	—	—	2017	February 10, 2017	40
Phoenix, AZ	Freestanding ER	1,132	5,052	—	—	1,132	5,052	6,184	726	—	—	2017	April 13, 2017	40
Plano, TX	Freestanding ER	4,204	2,492	—	—	4,204	2,492	6,696	494	—	—	2016	September 30, 2016	40
Poole, UK	Acute care general hospital	2,206	36,429	—	—	2,206	36,429	38,635	3,538	—	—	1996	April 3, 2019	40
Poplar Bluff, MO	Acute care general hospital	2,659	38,694	—	—	2,659	38,694	41,353	14,217	—	—	1980	April 22, 2008	40
Port Arthur, TX	Acute care general hospital	12,972	78,051	6,877	—	12,972	84,928	97,900	18,823	—	—	2005	September 26, 2013	40
Port Huron, MI	Acute care general hospital	2,531	14,252	—	—	2,531	14,252	16,783	3,408	—	—	1953, 1973-1983	December 31, 2015	30
Post Falls, ID	Rehabilitation hospital	417	12,175	1,905	—	767	13,730	14,497	3,099	—	—	2013	December 31, 2013	40
Preston, UK	Behavioral health facility	8,296	24,677	—	—	8,296	24,677	32,973	991	—	—	1850, 2018, 2021	June 25, 2021	40
Princes Risborough, UK	Acute care general hospital	4,425	—	—	—	4,425	—	4,425	—	—	—	N/A	January 9, 2020	40
Raleigh, NC	Behavioral health facility	3,469	27,514	—	—	3,469	27,514	30,983	952	—	—	2018	October 19, 2021	40
Reading, UK	Acute care general hospital	33,024	43,823	—	—	33,024	43,823	76,847	3,816	—	—	1990	August 16, 2019	40
Reading, UK	Acute care general hospital	24,672	79,057	—	—	24,672	79,057	103,729	4,028	—	—	2012	December 18, 2020	40
Renscheid, Germany	Rehabilitation hospital	1,017	2,451	—	—	1,017	2,451	3,468	282	—	—	1951, 1983	August 28, 2018	40
Richmond, TX	Behavioral health facility	5,380	6,155	736	—	5,380	6,891	12,271	254	—	—	2014	October 19, 2021	40
Richmond, VA	Long term acute care hospital	1,299	10,071	—	—	1,299	10,071	11,370	1,087	—	—	1989	August 30, 2019	40
Ringwood, Australia	Acute care general hospital	4,038	18,125	—	—	4,038	18,125	22,163	1,912	—	—	1973	June 7, 2019	35
Riverton, WY	Acute care general hospital	1,163	29,647	—	—	1,163	29,647	30,810	2,756	—	—	1983	December 17, 2019	36
Roaring Springs, PA	Acute care general hospital	1,446	9,549	—	—	1,446	9,549	10,995	1,216	—	—	1924	December 17, 2019	30
Rochdale, MA	Long term acute care hospital	654	3,368	—	—	654	3,368	4,022	329	—	—	1989	August 30, 2019	40
Rochdale, MA	Acute care general hospital	67	344	—	—	67	344	411	34	—	—	1989	August 30, 2019	40
Rochdale, UK	Acute care general hospital	3,395	38,679	—	—	3,395	38,679	42,074	2,927	—	—	1965	January 9, 2020	40

Location	Type of Property	Initial Costs			Additions Subsequent to Acquisition		Cost at December 31, 2022(1)				Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Improvements	Carrying Costs	Land	Buildings	Total	Total						
(Dollar amounts in thousands)															
Rockledge, FL	Acute care general hospital	13,919	23,282	8,338	—	13,919	31,620	45,539	—	5,521	—	1950, 1970	May 1, 2017	42	
Roeland Park, KS	Acute care general hospital	1,569	15,103	—	—	1,569	15,103	16,672	—	1,152	—	2018	June 10, 2019	50	
Romford, UK	Behavioral health facility	5,082	8,319	—	—	5,082	8,319	13,401	—	394	—	1980	June 25, 2021	40	
Rosenberg, TX	Freestanding ER	1,270	4,505	—	—	1,270	4,505	5,775	—	788	—	2016	January 15, 2016	40	
Rowley, UK	Acute care general hospital	2,760	17,370	—	—	2,760	17,370	20,130	—	1,585	—	1986	August 16, 2019	40	
Royston, UK	Behavioral health facility	6,391	19,028	—	—	6,391	19,028	25,419	—	899	—	1906, 1970	June 25, 2021	40	
Salt Lake City, UT	Acute care general hospital	13,590	101,915	15,268	—	13,590	117,183	130,773	—	14,618	—	1906-1987	September 29, 2017	41	
San Antonio, TX	Acute care general hospital	8,053	29,333	7,981	—	8,053	37,314	45,367	—	4,701	—	1978-2002	September 29, 2017	41	
San Antonio, TX	Freestanding ER	3,120	4,801	—	—	3,120	4,801	7,921	—	730	—	2016	December 9, 2016	40	
San Antonio, TX	Freestanding ER	351	3,952	—	—	351	3,952	4,303	—	863	—	2014	January 1, 2014	40	
San Antonio, TX	Acute care general hospital	2,248	5,880	—	—	2,248	5,880	8,128	—	1,494	—	2012	October 2, 2012	40	
San Antonio, TX	Freestanding ER	2,412	4,253	—	—	2,412	4,253	6,665	—	656	—	2016	October 27, 2016	40	
San Bernardino, CA	Acute care general hospital	2,209	37,498	—	—	2,209	37,498	39,707	—	3,415	—	1993	August 30, 2019	40	
Santa Maria de Feira, PT	Acute care general hospital	1,804	17,299	—	—	1,804	17,299	19,103	—	531	—	2015	October 21, 2021	40	
Sebastian, FL	Acute care general hospital	5,733	49,136	56,430	—	5,733	105,566	111,299	—	11,126	—	1974	May 1, 2017	41	
Sherman, TX	Acute care general hospital	6,179	9,066	5,428	—	6,179	14,494	20,673	—	3,091	—	1950-1980	May 1, 2017	41	
Shawnee, KS	Acute care general hospital	3,076	14,945	—	—	3,076	14,945	18,021	—	1,328	—	2018	June 10, 2019	50	
Sheffield, UK	Acute care general hospital	6,277	42,344	—	—	6,277	42,344	48,621	—	3,223	—	2008	January 9, 2020	40	
Sherman, TX	Acute care general hospital	3,363	10,932	—	—	3,363	10,932	14,295	—	3,940	—	1913, 1960-2010	October 31, 2014	40	
Southampton, UK	Behavioral health facility	6,116	17,961	—	—	6,116	17,961	24,077	—	835	—	1820, 1985	June 25, 2021	40	
Spartanburg, SC	Rehabilitation hospital	1,135	15,717	—	—	1,135	15,717	16,852	—	3,685	—	2013	August 1, 2013	40	
St. Albans Park, Australia	Acute care general hospital	2,562	20,786	10,700	—	2,562	31,486	34,048	—	2,420	—	1985	June 7, 2019	40	
Stirling, UK	Acute care general hospital	1,001	18,517	—	—	1,001	18,517	19,518	—	726	—	1992	July 6, 2021	40	
Stockton, CA	Rehabilitation hospital	2,841	—	—	—	2,841	—	2,841	—	—	—	2021	November 23, 2020	40	
Strathpine, Australia	Acute care general hospital	2,755	34,489	—	—	2,755	34,489	37,244	—	3,177	—	1985	June 7, 2019	40	
Sunnybank, Australia	Acute care general hospital	5,982	42,915	—	—	5,982	42,915	48,897	—	4,580	—	1979	June 7, 2019	34	
Surrey, UK	Behavioral health facility	14,280	8,741	—	—	14,280	8,741	23,021	—	25	—	1950, 2014	December 9, 2022	40	
Sussex, NJ	Acute care general hospital	477	2,097	—	—	477	2,097	2,574	—	130	—	1920	September 30, 2015	40	
Swindon, UK	Acute care general hospital	5,056	56,730	—	—	5,056	56,730	61,786	—	4,280	—	1984	January 9, 2020	40	
Tadley, UK	Behavioral health facility	19,853	18,090	—	—	19,853	18,090	37,943	—	891	—	2020	June 25, 2021	40	
Tempe, AZ	Acute care general hospital	6,050	10,986	5,084	—	6,050	16,070	22,120	—	2,410	—	1940	September 29, 2017	41	
TexasKana, TX	Acute care general hospital	14,562	—	—	—	14,562	—	14,562	—	—	—	2017	September 29, 2017	—	
The Woodlands, TX	Freestanding ER	2,005	4,524	—	—	2,005	4,524	6,529	—	764	—	2016	March 28, 2016	40	
Thornton, CO	Freestanding ER	1,350	4,259	—	—	1,350	4,259	5,609	—	887	—	2014	August 29, 2014	40	
Toledo, OH	Rehabilitation hospital	1,150	17,740	—	—	1,150	17,740	18,890	—	2,994	—	2016	April 1, 2016	40	
Tomball, TX	Long term acute care hospital	1,299	23,982	—	—	1,299	23,982	25,281	—	7,195	—	2005	December 21, 2010	40	
Torquay, UK	Acute care general hospital	2,829	33,923	—	—	2,829	33,923	36,752	—	2,915	—	1981	August 16, 2019	40	
Turku, Finland	Acute care general hospital	1,171	57,048	—	—	1,171	57,048	58,219	—	1,206	—	2018	March 11, 2022	40	
Usk, UK	Behavioral health facility	1,641	21,072	—	—	1,641	21,072	22,713	—	838	—	1770, 1850, 1980	June 25, 2021	40	
Valencia, SP	Acute care general hospital	10,791	67,447	—	—	10,791	67,447	78,238	—	2,106	—	2017	December 2, 2021	40	
Viseu, Portugal	Acute care general hospital	2,458	28,010	—	—	2,458	28,010	30,468	—	2,422	—	2016	November 28, 2019	37	
Wantirna, Australia	Acute care general hospital	25,595	202,892	24,129	—	25,595	227,021	252,616	—	18,529	—	1984	June 7, 2019	40	
Warren, OH	Acute care general hospital	5,385	47,588	10,486	—	5,385	58,074	63,459	—	9,460	—	1982	May 1, 2017	41	
Warren, OH	Rehabilitation hospital	2,417	15,857	1,737	—	2,417	17,594	20,011	—	3,150	—	1922-2000	May 1, 2017	46	
Watsonville, CA	Acute care general hospital	16,488	17,800	—	—	16,488	17,800	34,288	—	2,126	—	1983	September 30, 2019	39	
Webster, TX	Long term acute care hospital	663	33,751	—	—	663	33,751	34,414	—	10,126	—	2004	December 21, 2010	40	
West Chester, OH	Behavioral health facility	3,670	61,338	—	—	3,670	61,338	65,008	—	1,976	—	2013	October 19, 2021	40	
West Jordan, UT	Acute care general hospital	16,897	233,256	4,078	—	16,897	237,334	254,231	—	16,101	—	1983	September 29, 2017	40	
West Monroe, LA	Acute care general hospital	11,702	69,433	19,116	—	12,254	87,997	100,251	—	18,622	—	1962	September 26, 2013	40	

Location	Type of Property	Initial Costs		Additions Subsequent to Acquisition		Cost at December 31, 2022(1)				Accumulated Depreciation	Encumbrances	Date of Construction	Date Acquired	Life on which depreciation in latest income statements is computed (Years)
		Land	Buildings	Improvements	Carrying Costs	Land	Buildings	Total						
									(Dollar amounts in thousands)					
West Valley City, UT	Acute care general hospital	5,260	58,314	6,644	—	5,260	64,958	70,218	22,415	—	1980	April 22, 2008	40	
Wichita, KS	Rehabilitation hospital	1,019	18,374	—	—	1,019	18,374	19,393	6,774	—	1992	April 4, 2008	40	
Willenhall, UK	Behavioral health facility	6,917	15,434	—	—	6,917	15,434	22,351	626	—	2000	June 25, 2021	40	
Winchester, UK	Acute care general hospital	6,156	9,754	—	—	6,156	9,754	15,910	754	—	1911	January 9, 2020	40	
Windsor, UK	Acute care general hospital	11,564	99,395	—	—	11,564	99,395	110,959	7,474	—	1955	January 9, 2020	40	
Woking, UK	Behavioral health facility	6,871	4,442	—	—	6,871	4,442	11,313	204	—	1800, 2020	June 25, 2021	40	
Worthing, UK	Acute care general hospital	6,374	28,612	—	—	6,374	28,612	34,986	2,164	—	1994	January 9, 2020	40	
York, UK	Behavioral health facility	20,534	68,118	—	—	20,534	68,118	88,652	2,699	—	1900, 1980	June 25, 2021	40	
Youngstown, OH	Acute care general hospital	4,334	3,565	488	—	4,334	4,053	8,387	2,527	—	1929-2003	May 1, 2017	41	
		\$1,946,737	\$9,772,121	\$581,666	\$—	\$1,948,216	\$10,352,308	\$12,300,524	\$1,008,340					

- (1) The aggregate cost for federal income tax purposes is \$11.0 billion.  
(2) Date of construction is based off of best available information, but note that this facility has had multiple updates since initial construction.

The changes in total real estate assets (excluding construction in progress, intangible lease assets, investment in financing leases, and mortgage loans) are as follows for the years ended (in thousands):

	<u>December 31, 2022</u>	<u>December 31, 2021</u>	<u>December 31, 2020</u>
<b>COST</b>			
Balance at beginning of period . . . . .	\$ 13,628,749	\$ 10,749,707	\$ 7,312,486
Acquisitions . . . . .	622,999	3,023,966	2,912,594
Transfers from construction in progress . . . . .	47,431	—	202,999
Additions . . . . .	150,290	167,164	55,137
Dispositions . . . . .	(1,471,529)	(229,584)	(105,360)
Other . . . . .	(677,416) (3)	(82,504) (3)	371,851 (3)
Balance at end of period . . . . .	<u>\$ 12,300,524</u>	<u>\$ 13,628,749 (4)</u>	<u>\$ 10,749,707</u>

The changes in accumulated depreciation are as follows for the years ended (in thousands):

	<u>December 31, 2022</u>	<u>December 31, 2021</u>	<u>December 31, 2020</u>
<b>ACCUMULATED DEPRECIATION</b>			
Balance at beginning of period . . . . .	\$ 950,369	\$ 728,176	\$ 504,651
Depreciation . . . . .	277,032	262,063	222,580
Depreciation on disposed property . . . . .	(185,519)	(35,551)	(6,653)
Other . . . . .	(33,542)	(4,319)	7,598
Balance at end of period . . . . .	<u>\$ 1,008,340</u>	<u>\$ 950,369 (5)</u>	<u>\$ 728,176</u>

(3) Includes foreign currency fluctuations for all years and \$13.8 million of right-of-use assets in 2020.

(4) Includes \$1.1 billion of land and building cost reflected in real estate held for sale at December 31, 2021. Excludes intangible lease assets that are included in real estate held for sale of \$125.1 million at December 31, 2021.

(5) Includes \$96.5 million of accumulated depreciation reflected in real estate held for sale at December 31, 2021. Excludes accumulated amortization related to intangible lease assets that are included in real estate held for sale of \$17.5 million at December 31, 2021.

**SCHEDULE IV — MORTGAGE LOANS ON REAL ESTATE**  
**MEDICAL PROPERTIES TRUST, INC. AND MPT OPERATING PARTNERSHIP, L.P.**  
**December 31, 2022**

Column A	Column B	Column C	Column D	Column E	Column F	Column G(1)	Column H
Description	Interest Rate	Final Maturity Date	Periodic Payment Terms	Prior Liens	Face Amount of Mortgages	Carrying Amount of Mortgages	Principal Amount of Loans Subject to Delinquent Principal or Interest
	(Dollar amounts in thousands)						
Long-term first mortgage loan:			Payable in monthly installments of interest plus principal payable in full at maturity				
Colombia(4) .....	8.95%	2035		(2)	\$ 117,360	\$ 117,360	(3)
Vibra .....	11.50%	2024		(2)	7,986	7,986	(3)
Prospect .....	7.96%	2034		(2)	151,267	151,267	(3)
Springstone .....	7.00%	2041		(2)	22,900	22,900	(3)
Infracore .....	4.20%	2023		(2)	64,907	64,907	(3)
					<u>\$ 364,420</u>	<u>\$ 364,420</u>	(5)

(1) The aggregate cost for federal income tax purposes is \$364.4 million.

(2) There were no prior liens on loans as of December 31, 2022.

(3) Mortgage loans were not delinquent with respect to principal or interest, other than for two months of interest on the Prospect loan.

(4) Mortgage loans covering three properties.

(5) Excludes allowance for credit loss of \$0.3 million at December 31, 2022.

Changes in mortgage loans (excluding allowance for credit loss) for the years ended December 31, 2022, 2021, and 2020 are summarized as follows:

	Year Ended December 31,		
	2022	2021	2020
	(Dollar amounts in thousands)		
Balance at beginning of year .....	\$ 213,320	\$ 248,335	\$ 1,274,995
Additions during year:			
New mortgage loans and additional advances on existing loans .....	177,924	1,128,695 (6)	193,590
Exchange rate fluctuations .....	(15,824)	(3,640)	9,785
	<u>375,420</u>	<u>1,373,390</u>	<u>1,478,370</u>
Deductions during year:			
Collection of principal .....	(11,000)	(1,160,070) (6)	(1,230,035) (7)
	<u>(11,000)</u>	<u>(1,160,070)</u>	<u>(1,230,035)</u>
Balance at end of year .....	<u>\$ 364,420</u>	<u>\$ 213,320</u>	<u>\$ 248,335</u>

(6) Includes an £800 million mortgage loan advanced to Priory in the first quarter of 2021 that was redeemed as part of the acquisition of the underlying fee simple real estate in the second quarter of 2021 as more fully described in Note 3 to Item 8 of this Annual Report on Form 10-K.

(7) Includes \$835 million of mortgage loans that were used to acquire the underlying fee simple real estate as more fully described in Note 3 to Item 8 of this Annual Report on Form 10-K.



